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ABSTRACT
We searched for genes that are potentially important for the maintenance of Pancreatic
Ductal Adenocarcinoma (PDAC). PDAC is the 4 th leading cause for cancer-related deaths and
exhibits a 5-year survival rate of less than 5%. Since PDAC is a Kras-driven cancer in that
greater than 90% of PDACs contain a Kras mutation, we tested genes that are downstream of
Kras. We used RNAi technology to inhibit approximately 30 genes in the canonical Kras effector
pathways, Mapk, Pi3k, and Ral. These genes were tested in the context of mouse cell lines
derived from a genetically engineered mouse model of PDAC with conditional mutations in
Kras G12D and p53. An individual gene-by-gene approach and a pooled high-throughput screening
strategy were taken to identify important genes. We identified mTOR, and to a lesser extent,
Raptor and Rictor, as genes that are important for the maintenance of PDAC both in vitro and in
vivo.
In addition, we show that inhibition of mTOR and Raptor are synthetic lethal in that
PDAC lines are sensitive to their inhibition, while non-tumorigenic cell lines are not as sensitive.
Moreover, inhibition of mTOR results in downregulation of mTORCl and mTORC2 targets,
while inhibition of Raptor induces downregulation of only mTORC 1 targets. As combination
therapies are likely to be more effective, we looked for a drug that could combine effectively
with mTOR and Raptor. From screening several small molecule drugs that target the Mapk and
Pi3k pathways, we found PDAC lines to be particularly sensitive to AZD6244, while normal cell
lines are significantly less sensitive. The combination or either an mTOR or Raptor hairpin and
AZD6244 was found to be additive in that the effect on viability is significantly greater than that
of each intervention alone. Another approach to combinations is to combine two drugs.
AZD6244 and BEZ235, an inhibitor of Pi3k and mTOR, were tested in combination on both
PDAC and normal cell lines. The combination was synergistic in PDAC lines but not in normal
lines, suggesting that the combination may be effective with low toxicity. In summary, through a
screen, we have identified mTOR, Raptor, and Rictor, as being critical components for the
maintenance of PDAC.
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INTRODUCTION
Clinical Pancreatic Cancer
Epidemiology of Pancreatic Cancer
For pancreatic cancer in 2012, there are an estimated 43,920 new cases and 37,390 deaths
in the United States. Of all cancers, pancreatic cancer has the 12th highest incidence but 4
highest mortality, suggesting that it is a particularly lethal cancer. The number of new cases and
deaths are approximately equally split among men and women. The incidence varies among
different ethnicities. African American males and females have incidences of 16.2 and 12.4 per
100,000 persons per year, while Caucasian males and females have incidences of 12.1 and 9.1
per 100,000 persons per year. Pancreatic cancer is a common and lethal disease in the US.
5-Year
Cancer in 2010 Survival Rate
(1999-2005)
Lung 157,300 16%
Colorectal 51,370 66%
Breast 40,230 90%
Pancreatic 36,800 6%
Prostate 32,050 95%
Figure 1. The Five Most Lethal Cancers. Listed are the five cancers responsible for the most deaths in the
US in 2010. The 5-year survival rate of each cancer is determined in the time period between 1999 and
2005. Adapted from Jemal, Cancer Statistics 2010.
Of the five most common cancers, as measured by the number of deaths in a year,
pancreatic cancer is by far the most lethal with the lowest 5-year survival rate (Figure 1). In 2010
in the US, lung, colorectal, and breast cancer, are responsible for 157,000; 51,000; and 40,000
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deaths, respectively. Pancreatic cancer is responsible for only 36,000 deaths. However,
approximately 94% of patients diagnosed with pancreatic cancer will die 5-years, while only
roughly 84%, 34%, and 10% of patients with lung, colorectal, and breast, respectively, will die.
In conclusion, of the cancers that cause a large number of deaths in the US, pancreatic cancer is
by a large margin, the most deadly.
Worldwide, pancreatic cancer is responsible for an estimated 227,000 deaths per year,
and it ranks 13 th in incidence and 8 th in cancer-related deaths (Anderson KE, 2006). The
incidence of pancreatic cancer has been relatively stable over decades. Most countries have
incidence rates of 8 to 12 per 100,000 persons per year. The incidence varies from country to
country, suggesting a genetic component to the disease. For instance, in India, the incidence is
less than 2 per 100,000 persons per year. Pancreatic cancer is not only a concern in the US but
also worldwide.
As with other cancers, pancreatic cancer tends to affect the elderly population.
Pancreatic cancer is rare in people under the age of 45 unless they have predisposing conditions
such as familial pancreatic cancer or chronic pancreatitis (Tomislav Dragovich). After the age of
50, the frequency and risk of pancreatic cancer increases linearly. The median age of diagnosis is
68 years of age. With an aging population, identifying better therapies for pancreatic cancer will
be critical.
Sub-types of Pancreatic Cancer
Pancreatic cancer can be divided into exocrine tumors, endocrine tumors, and other
tumors. 95% of pancreatic cancers are exocrine tumors. The cell type of origin for exocrine
tumors is unclear, but the tumors resemble exocrine or ductal cells. There are various histological
12
subtypes of exocrine tumors including adenocarcinomas, adenosquamous, mucinous
cystadenocarcinoma, acinar carcinoma, small cell carcinoma, large cell carcinoma, and
pancreatoblastoma.
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of exocrine
pancreatic cancer. In PDAC, there is a lot of stroma, consisting of fibroblasts, inflammatory
cells, and extracellular matrix (Chu et al., 2007). Signaling occurs between the stromal and
cancer cells (paracrine) and amongst the cancer cells (autocrine). The pathways activated include
Tgf-/Smad, Tgf/Met, Matrix Metalloproteinases, Hedgehog, and Wnt (Mahadevan and Von
Hoff, 2007). The current model is that three different precursor lesions can lead to full-blown
PDAC (Figure 2). 90% of the time the precursor lesion is a pancreatic intraepithelial neoplasms
(PanINs). 5-10% of the time, it is an intraductal papillary mucinous neoplasms (IPMNs). Less
than 3% of the time, it is a mucinous cystic neoplasms (MCNs). PanINs are divided into three
stages, PanIN1, PanIN2, and PanIN3 (carcinoma in situ). They begin as PanIN 1 and progress
through PanIN2, PanIN3, and eventually become a PDAC. In summary, PDAC can arise from a
few different precursor lesions with dramatically different histological phenotypes.
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MCN
PanIN-3
Pancreatic Ductal
Adenocarcinoma
Figure 2. Histological Development of Pancreatic Ductal Adenocarcinoma. The pancreas can undergo
three primary paths of development to reach PDAC: Pancreatic intraepithelial neoplasm (PanIN),
intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN). Adapted from
Hezel, 2006 Genes & Development.
5% of pancreatic cancers are endocrine tumors. Endocrine tumors, also known as islet
cell tumors or pancreatic neuroendocrine tumor, are generally less lethal than exocrine tumors.
Endocrine tumors can be further characterized as functional or hormone producing or non-
functional, or non-hormone producing. Functional tumors secrete hormones such as an
insulinoma or glucagonoma. Hormone-producing tumors are notably less malignant than non-
hormone-producing tumors. Some examples of non-hormone-producing tumors include a
gastrinoma or VIPoma (vasoactive intestinal peptide). Endocrine tumors can be sporadic or
inherited, i.e. in an individual with a MEN syndrome (multiple endocrine neoplasia). Most islet
cell tumors are slow growing and benign and can be successfully treated with surgery.
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The various sections of a pancreas (head, body, tail) contain both exocrine and endocrine
cells. Pancreatic tumors most often (70-75%) arise in the head, less frequently in the body (15-
20%), and most rarely in the tail (5-10%).As illustrated, pancreatic cancer can arise not only in
different cell types but in varying physical locations on the pancreas.
Normal Pancreas Physiology
The pancreas consists of endocrine and exocrine functions. The endocrine pancreas
includes the islets of Langerhans, which comprise 1-2% of the mass of the pancreas. The islets of
Langerhans include a cells, P cells, and 6 cells, which secrete glucagon, insulin, and
somatostatin. The primary function of the endocrine pancreas is to provide glucose homeostasis.
The exocrine pancreas comprises 80% of the mass of the pancreas and consists of acini, which
are grape-like clusters of secretory cells. These acini are connected by ducts lined by epithelial
cells. The primary function of the exocrine pancreas is to secrete digestive enzymes. The acinar
and ductal cells secrete the digestive enzymes in response to signals from the stomach and
duodenum. The ducts combine together to form a larger duct that travels to the duodenum. This
allows for the digestive enzymes to travel to the intestinal tract to facilitate digestion. In
summary, endocrine and exocrine cells provide notably different physiological functions.
Diagnosis and Staging of Pancreatic Cancer
Patients who present with pancreatic cancer often present with one of three different
stages of PDAC (Figure 3). 15% to 20% of the time, patients present with the least developed
stage, which is locally resectable (Jemal et al., 2008; Li et al., 2004a). 30% to 35% of the time,
patients present with locally advanced disease, where the tumor has invaded beneath the
basement membrane and into surrounding tissue, but has yet to metastasize to distant organs.
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These patients are not cured by resection due to vascular and stromal invasion. The remaining
45% to 50% of the patients present with disease that has already metastasized to distant sites.
The disease is often diagnosed in its later stages because there are currently no known consistent
signs of pancreatic cancer. Current diagnostic modalities include an abdominal or chest CT scan,
endoscopic ultrasound, a fine needle aspirate or core biopsy, measuring tumor markers such as
CA19-9 or CEA. Work is ongoing to develop screening methods to identify patients earlier on
during disease development (Faca et al., 2008; Greenhalf et al., 2009; Larghi et al., 2009). In
summary, the large majority of patients present with later-stage pancreatic cancer (metastatic,
locally advanced), as opposed to the more benign resectable disease.
%of Patients Median 5-Year
Stage Presenting Overall Survival
w ith Survival Rate
Locally Resectable 15 - 20% 16-22 mos 15 - 20%
Locally Advanced 30 - 35% 8-12 mos < 5%
Metastatic 45 - 50% 4-6 nos < 1 %
Figure 3. The Different Clinical Stages of PDAC. The frequency of patients presenting with each of the
indicated stages of PDAC is noted. The overall survival and 5-year survival rate is also indicated.
Patients who present with different stages of pancreatic cancer have different prognoses
(Figure 3). Those with locally resectable disease show the longest median overall survival (mOS)
at 16 to 22 months, with a 5-yr survival rate of 15% to 20%Patients with locally advanced
disease have a mOS of 8 to 12 months, with a 5-yr rate of less than 5%.Finally, metastatic
patients have a mOS of only 4 to 6 months, with less than 1% surviving for longer than 5 years.
In the absence of therapy, metastatic disease shows a median survival of 3-5 months (Ghaneh et
al., 2007). To summarize, of the 75% to 80% of the patients who present with advanced or
16
metastatic disease, more than 95% will die within 5 years (Benson AB). If the disease is
diagnosed early, the 5-year survival is better but still poor 20% (Heinemann and Boeck, 2008;
Sohn et al., 2000; Winter et al., 2006; Yeo et al., 1995). In conclusion, the prognosis for patients
with developed pancreatic cancer is substantially worse than that for patients with more benign
disease.
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Stage Tumor Nodal Distant Median Survival CharacteristicsGrade Status Metastases (Months)
IA T1 NO MO 24.1 Turror lirnited to the pancreas, 5 2 cm in the longest dimension
IB T2 NO MO 20.6 Tumor limited to the pancreas, 5 2 cm in the longest dimension
llA T3 NO MO 15.4 Turnor extends beyond the pancreas but does not involve the celiac axis or superior mesenteric artery
IB T1, T2, T3 NO MO 12.7 Regional lymph-node metastasis
III T4 NO or N1 MO 10.6 Tumor involves the celiac axis or the superior mesenteric artery (unresectable disease)
IV T1, T2, T3, or T4 NO or Ni M1 4.5 Distant metastasis
00
Figure 4. Detailed Staging of Pancreatic Cancer. The various stages of pancreatic cancer are indicated in
the first column, with the associated characteristics in the other columns.
Clinicians characterize pancreatic cancer in more resolution than the categories described
above (locally resectable, locally advanced, and metastatic) (Figure 4) (Bilimoria et al., 2007).
Instead of having three categories, they use six stages (IA, IB, IIA, IB, III, and IV). Stages IA,
IB, IIA, and IIB correspond to locally resectable disease, while stage III and IV correspond to
locally invasive and metastatic disease, respectively. To properly stage the tumors, clinicians use
multi-phase, multi-detector helical computed tomography in conjunction with intravenous
administration of contrast material (Miura et al., 2006). Each tumor stage has an associated
tumor grade, nodal status, and the presence or absence of metastases. Tumor grade ranges from
T 1 to T4, increasing according to the histological severity of the tumor at the local site. Nodal
status indicates the presence (NI) or absence (NO) of spread to major lymph nodes. MO suggests
the absence of metastases, while Ml indicates the presence of metastases. The median survival
decreases with increasing stage of the cancer. Stage IA, IB, and IIA tumors are those that are
limited to the pancreas and are ranked according to histological grade of the tumor. Stage IIB
tumors have metastasized to regional lymph nodes and can be of any grade (TJ, T2, or T3).
Stage IA through IIB tumors can be successfully resected (Edge and Compton, 2010). Stage III
tumors are either histologically very developed (T4) or have invaded to the celiac axis or the
superior mesenteric artery. Stage III and IV tumors are not resectable. Stage IV tumors are those
that have metastasized. They can be of any grade or lymph node status and would still be
considered Stage IV. This classification is more descriptive and representative of how clinicians
classify pancreatic cancer.
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Clinical Presentation and Symptoms of Pancreatic Cancer
Pancreatic cancer gives rise to a whole host of symptoms. Pancreatic cancer often causes
dull, non-specific upper abdominal pain or back pain localizing around the tumor area. Vague
abdominal discomfort and nausea are common. More rarely, duodenal obstruction or
gastrointestinal bleeding may occur. Other characteristics on physical exam include, temporal
wasting, peripheral lymphadenopathy, hepatomegaly, ascites, pancreatitis, or diabetes mellitus.
Pancreatic cancer can lead to bile duct and gastric outlet obstruction, pancreatic insufficiency,
and pain in the abdomen and lower back. Bile duct obstruction gives rise to jaundice, light stools,
and dark urine. Gastric outlet obstruction leads to nausea and vomiting. Pancreatic insufficiency
leads to weight loss, diarrhea, floating stools, and diabetes. Blood tests may include mild
abnormalities in liver function tests, hyperglycemia, and anemia (Li et al., 2004a; Maitra and
Hruban, 2008). More systemic manifestations that are common upon presentation include
asthenia, anorexia, weight loss, blood clots, fatigue, and depression. Less common systemic
manifestations include venous thrombosis, panniculitis, liver-function abnormalities, gastric-
outlet obstruction, increased abdominal girth, and depression. In summary, not only does
pancreatic cancer lead to death but it likely causes a state of severe discomfort.
Metastasis of pancreatic cancer leads to additional symptoms. Spread to lymph nodes
may induce swelling above the clavicle. Peritoneal metastasis may lead to a distended abdomen
or ascites. Spread to the liver can be detected by elevated liver enzymes and RUQ pain.
Metastases to the lungs can result in dyspnea. Metastases to the bone give rise to bone pain and
fracture (Baumgart and Fischer, 2007). To summarize, metastasis to various organs can give rise
to additional clinical symptoms.
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Risk factors for Pancreatic Cancer
The lifetime risk for an individual to develop pancreatic cancer is, on average, 1.45%.The
greatest incidence of pancreatic cancer is between the ages of 60 and 80. The risk is identical for
men and women. The risk varies across ethnicities. For instance, it is higher for African
Americans than for Caucasians. Smoking is a risk factor, as it is for many other cancer types
including lung. A past smoker will have a 20% higher risk of developing pancreatic cancer as
never smokers. A current smoker will have a 150% higher risk (Fuchs et al., 1996). Another
study estimates that smokers have a 250% to 360% times higher risk of developing pancreatic
cancer than non-smokers (Hassan et al., 2007). Obesity is also a risk factor. A 5 kg/m 2 increase in
BMI increases the risk of developing pancreatic cancer by 12% (Larsson et al., 2007; Michaud et
al., 2001) Having type II diabetes will increase ones risk for pancreatic cancer by 100%
(Everhart and Wright, 1995). A blood type of A, B, or AB, as opposed to 0, also increases the
risk of pancreatic cancer (Genkinger et al., 2009). Other possible contributing factors may
include alcohol and coffee intake, aspirin use, diet, physical activity, H. pylori infection, peptic
ulcer disease, and chronic pancreatitis. Lastly, less conclusive studies have indicated that chronic
cirrhosis and a high-fat and high-cholesterol diet also increase the risk (Genkinger et al., 2009;
Landi, 2009; Lowenfels and Maisonneuve, 2006). In summary, there are large variety of factors
that can increase the risk of developing pancreatic cancer.
A family history of pancreatic cancer can increase one's risk. 5 - 10% of pancreatic
cancer patients have a family history of the disease (Shi et al., 2009). Another estimate suggests
that 2-10% of PDACs are associated with hereditary factors (Habbe et al., 2006). Another
perspective is that individuals with families of four or more members with pancreatic cancer are
57 times more likely to have pancreatic cancer (Tersmette et al., 2001). The responsible genes In
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familial pancreatic cancer include INK4A, LKB1, MLH1, the cationic trypsinogen gene PRSS1,
and the DNA-repair enzymes BRCA 1, BRCA2 and the localizer of BRCA2, PALB2 (Jaffee et
al., 2002; Whitcomb et al., 1996). Inheritance of these genes can promote the accumulation of
mutations and the development of cancer (Couch et al., 2007; Jones et al., 2009; Jones et al.,
2008).
Peutz-Jeghers syndrome is the germ-line condition where the individual has mutations in
LKB1/STKl 1. Lkbl is believed to be involved in regulating cell polarity and metabolism (Baas
et al., 2004; Bardeesy et al., 2002b; Corradetti et al., 2004; Ossipova et al., 2003). Peutz-Jeghers
syndrome patients have a greater than 40-fold increase in risk of developing PDAC (Giardiello et
al., 2000). In contrast, a somatic mutation in LKB l/STK 11 is rare, occurring in only
approximately 5% of sporadic cases (Su et al., 1999).
Another gene that can be responsible for familial PDAC is BRCA2. BRCA2 is involved
in homologous recombination-based DNA repair and is a well-known risk factor for familial
breast and ovarian cancer. BRCA2 alterations are also observed in 17% of familial pancreatic
cancers (Murphy et al., 2002). BRCA2 mutations results in its loss of function, allowing for
more alterations that are potentially tumorigenic (Venkitaraman, 2002). Loss of heterozygosity
of BRCA2 generally happens at a late stage during PDAC development when the lesion has
become dysplastic or has developed into fully-blown PDAC (Goggins et al., 2000). To conclude,
alterations in BRCA2 and LKB 1 are some of the germ-line mutations that confer a predilection
toward PDAC development.
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Genetics of Pancreatic Cancer
Mutations
Pancreatic cancer, like all cancers, arises from the successive accumulation of mutations
(Vogelstein and Kinzler, 2004). In particular, the genes, KRAS, CDKN2A (cyclin-dependent
kinase inhibitor 2A), P53, and SMAD4 (mothers against decapentaplegic) are often mutated.
Virtually all individuals with pancreatic cancer carry one or more of the above mentioned four
genetic alterations (Maitra and Hruban, 2008). More specifically, 90% of tumors have alterations
in KRAS; 95% have alterations in CDKN2A; 75% have a loss of function defect in p53; and
50% lose SMAD4/DPC4. The earliest events in pancreatic cancer progression are the activating
mutation in Kras and telomere shortening (Hruban et al., 2000; van Heek et al., 2002). The
typical sequence of mutations begins with Kras being activated, followed by loss of CDKN2A,
point mutation of p53, and lastly loss of deleted in pancreatic cancer (DPC4/SMAD4) (Feldmann
et al., 2007; Iacobuzio-Donahue, 2011). The sequence of genetic mutations events is supported
by studies in genetically engineered mouse models of pancreatic cancer (Bardeesy et al., 2006;
Guerra et al., 2007; Hingorani et al., 2005). The most common alteration in KRAS is a change of
codon 12 from GGT to GAT, GTT, or more rarely CGT, resulting in glycine changing to
aspartate, valine, or arginine (Klimstra and Longnecker, 1994; Rozenblum et al., 1997).
Activated KRAS signals downstream to the MAPK, P13K, and RalGDS pathways (Campbell et
al., 1998). Much effort has been placed in studying the MAPK pathway in part because it is
frequently overactive in cancer due to KRAS, EGFR, and BRAF mutations. However, in PDAC,
BRAF is rarely altered (Calhoun et al., 2003; Ishimura et al., 2003). Similarly, the P13K pathway
is frequently studied because KRAS and EGFR mutations, as well as loss of PTEN or activating
mutations in P1 10a are observed in cancer (Okami et al., 1998; Samuels and Velculescu, 2004).
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AKT2 is amplified in 10-20% of PDACs, and Pten is frequently loss (Cheng et al., 1996;
Schlieman et al., 2003; Ying et al., 2011). Mutations in other genes that arise at lower
frequencies include Brca2, M113, Tgfbrl/2, and Mkk4 (Jones et al., 2008). In summary,
mutations in KRAS and other tumor suppressor give rise to activated downstream signaling
pathways including MAPK and PI3K.
A tumor suppressor frequently altered in PDAC, CDKN2A, encodes two tumor
suppressors, p161nkaa and p19 . p161nk4a and pl9Arfhave a different first exon and exhibit
alternative splicing of the downstream exons (Sherr, 2001). Ink4a is lost in 80 to 95% of PDACs
by mutation, deletion, or promoter hypermethylation (Hustinx et al., 2005; Rozenblum et al.,
1997). Recent mouse experiments illustrated that both Ink4a and Arf are involved in the
development of pancreatic cancer. In the background of oncogenic Kras, loss of either Ink4a or
Arf promotes tumor growth (Bardeesy et al., 2006). INK4a is the inhibitor of cyclin-dependent
kinase 4. Cyclin-dependent kinase 4 (Cdk4) is involved in the Gl -S cell cycle transition. An
inherited mutation in INK4A, termed Familial Atypical Mole-Malignant Melanoma syndrome,
results in a 13-fold increased risk for pancreatic cancer (Goldstein et al., 1995; Whelan et al.,
1995). Moreover, in human fibroblasts, Ras activation leads to Ink4a activation, which induces
premature senescence (Brookes et al., 2002; Drayton et al., 2003; Serrano et al., 1997; Zhu et al.,
1998). In genetically engineered Kras-mutant mouse pancreatic cancer models, PanINs exhibit
markers of senescence including Ink4a expression. When these PanINs develop into invasive
lesions, Ink4a expression is lost (Collado et al., 2005). In various pancreatic cancer model
system, loss of Ink4a when combined with Kras activation, results in enhanced tumor formation
(Aguirre et al., 2003; Chin et al., 1997; Fisher et al., 2001). In summary, CDKN2A loss
contributes to PDAC formation through loss of Ink4a and Arf function.
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Another tumor suppressor, p53, is altered in greater than 50% of PDACs. The most
common alterations are missense mutations in the DNA-binding domain (Rozenblum et al.,
1997). p5 3 is often found mutated in later stage PanINs that demonstrate histological dysplasia
(Boschman et al., 1994; Maitra et al., 2003). A p53 abnormality allows the cells to bypass
normal DNA damage check points, apoptotic signals, and to become genetically unstable,
thereby further increasing potentially oncogenic mutations. In most cancers, there is a reciprocal
relationship between loss of p53 and Arf (Pomerantz et al., 1998; Rozenblum et al., 1997; Ruas
and Peters, 1998). This is in line with our understanding, as p53 and Arf are believed to act in the
same pathway. In contrast, in pancreatic cancers, simultaneous loss of p53 and Arf is observed in
40% of cases (Heinmoller et al., 2000; Hustinx et al., 2005; Maitra et al., 2003). This suggests
that p53 and Arf have functions that are independent from one another and that inhibit pancreatic
tumorigenesis. In summary, p53, the best studied tumor suppressor, is often mutated during
PDAC development.
The final tumor suppressor that is commonly lost during PDAC progression is SMAD4.
Loss of DPC4 results in upregulation of Tgf-p. In 50% of PDACs, SMAD4 is deleted or mutated
(Hahn et al., 1996). Smad4 is lost in later stage PanIN lesions (Luttges et al., 2001; Maitra et al.,
2003; Wilentz et al., 2000).
The PDAC tumor generally begins as a pancreatic intraepithelial neoplasia (PanIN),
although it can also begin as a mucinous cystic neoplasm (MCN) or an intraductal papillary
mucinous neoplasm (IPMN) (Brugge et al., 2004; Hruban et al., 2008; Takaori, 2007). From this
minimally dysplastic epithelium (PanIN grades 1A and 1B), the tumor progresses to more severe
dysplasia (PanIN grades 2 and 3). It is believed that these PanINs go on to become full-blown
pancreatic cancer. PanIN1 lesions frequently harbor Kras mutations at an estimated frequency of
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15-40%, but less commonly have mutations in p53 or SMAD4 (Lohr et al., 2005). PanIN3
lesions are more likely to express mutated Kras, p53, and Smad4 (Maitra et al., 2003; Wilentz et
al., 2000). As for the other pre-neoplastic lesions, MCNs are mucin-producing cystic lesions that
contain epithelial cells and display an ovarian-type stroma, with epithelial dysplasia and regions
of invasion. IPMNs resemble PanINs at the cellular level, but grow into larger cystic structures.
In summary, mutations accumulate as PanINs develop into PDAC.
In a 2008 study, genomic analysis of 24 human pancreatic tumors demonstrated that there
are, on average, 63 alterations per tumor (Jones et al., 2008). 23,219 transcripts representing
20,611 genes were sequenced across 24 different cancer samples. In these samples, 1,562
somatic mutations in 1,327 genes were detected. The majority of these mutations were point
mutations. The authors organized the genes that were frequently altered into 12 cancer-relevant
core signaling pathways. Each of these pathways is altered in 67-100% of the analyzed tumors,
suggesting that they are important in PDAC development. For each pathway, the mutation is
usually in different genes from tumor to tumor. In summary, there are many mutations in
addition to Kras and the above mentioned tumor suppressors that occur during PDAC
progression.
Pathways Affected
In PDAC, mutations are observed in the Ras and Pi3k/Akt pathways, driving cell growth
and proliferation. These mutations affect signaling in the Egfr, Igf-1r, Hgfr, and Vegfr
pathwaysIn addition, signaling is affected in the developmental pathways: Hedgehog, Notch, and
Wnt. Moreover, during PDAC invasion and neovascularization, matrix metalloproteinases are
activated. Mutations in the tumor suppressors' p53, Ink4a/Arf, and Smad4/Tgf-b allow bypassing
DNA damage control and tumor-induced apoptosis. In summary, the mutations in Kras and other
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oncogenes and tumor suppressors in PDAC result in dysregulation of a variety of different
signaling pathways, allowing for tumorigenesis.
PDACs shows increased levels of Egfr ligands, Tgf-a and Egfr, as well as Egfr
receptors, Egfr and Erbb3 (Barton et al., 1991; Friess et al., 1993; Lemoine et al., 1992; Ory and
Morrison, 2004). This elevated expression is suggestive of an activated autocrine loop.
Moreover, Egfr inhibitors inhibit PDAC cell growth and tumorigenesis in vitro (Li et al., 2004b).
Finally, in orthotopic PDAC tumors, Egfr inhibitors in combination with chemotherapy inhibit
growth (Bruns et al., 2000). Egfr inhibition has been correlated with a decrease in tumor
vasculature via endothelial apoptosis, although the mechanism through which Egfr acts is still
unclear. In summary, Egfr is upregulated in PDACs and its inhibition reduces tumor growth.
PDACs show elevated expression of insulin-like growth factor (Igf) and its receptor, Igf-
IR. The stromal cells surrounding the tumor also show elevated expression of Igf (Bergmann et
al., 1995; Ouban et al., 2003; Stoeltzing et al., 2003). Igf signaling has been shown to promote
cell proliferation and growth-factor independent survival (Nair et al., 2001). Anti-Igf-IR
antibodies or expression of a dominant-negative form of Igf-IR inhibits PDAC xenograft growth
and increases tumor sensitivity to chemotherapy (Maloney et al., 2003; Min et al., 2003). To
conclude, Igf signaling is upregulated in PDAC and its suppression reduces tumor proliferation.
Met, a receptor tyrosine kinase, and Hgf, its ligand, are upregulated in PDACs. More
specifically, Met is upregulated in PanINs and PDACs, while Hgf expression is elevated in
PanINs and the stormal cells of more advanced lesions (Di Renzo et al., 1995; Ebert et al., 1994;
Furukawa et al., 1995; Paciucci et al., 1998). Hgf and Met regulate cell proliferation, motility,
invasion, and proliferation (Corso et al., 2005). Inhibition of this pathway by antibodies or NK4,
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a truncated dominant-negative Hgf fragment, inhibits invasion, growth, and angiogenesis of
PDAC xenografts (Saimura et al., 2002; Tomioka et al., 2001). To summarize, Hgf and Met are
upregulated in PDAC, and targeting it inhibits tumor growth.
Fgf receptors and glypican-1, a membrane heparin sulfate proteoglycan that promotes
Fgf-Fgfr interactions, are upregulated in various primary PDAC samples (Ishiwata et al., 1998;
Kleeff et al., 1998; Kobrin et al., 1993; Kornmann et al., 1997; Kornmann et al., 2002; Ohta et
al., 1995; Yamanaka et al., 1993). Fibroblast growth factor (Fgf) signaling promotes proliferation
and angiogenesis in PDACs (Cross and Claesson-Welsh, 2001). Moreover, in desmoplastic
tumors, bFgf levels are elevated (Kuniyasu et al., 2001). Dominant-negative Fgfr-1 or antisense
glypican-1 can inhibit the growth of PDAC lines in vitro and in xenograft models (Kleeff et al.,
2004; Ogawa et al., 2002; Wagner et al., 1998). In conclusion, Fgf signaling is upregulated in
PDAC and is a suitable target for inhibition.
In 30-100% of human PDAC samples, Stat3 is phosphorylated on Tyr705, while Stat3 is
unphosphorylated in normal pancreas (Scholz et al., 2003; Toyonaga et al., 2003). The Stat
family of transcription factors are activated in various human cancers (Frank, 2007). The Janus-
activated kinase family of tyrosine kinases activates Stat by phosphorylating Stat on the tyrosine
705 residue (Darnell et al., 1994; Shuai et al., 1994; Shuai et al., 1993; Zhong et al., 1994). In
addition, Src has also been shown to phosphorylate Stat (Cao et al., 1996). The Stat3 pathway is
not required for normal development or homeostasis of the pancreas, as Stat3 conditional
knockout mice go on to develop normal pancreas (Lee and Hennighausen, 2005). Not only is
Stat3 correlated to PDAC development, but there is evidence suggesting its functional role. Stat3
is required for acinar-to-ductal metaplasia, an early event in PDAC development (Miyatsuka et
al., 2006). In addition, Stat3 inhibitors and dominant-negative Stat3 constructs have reduced in
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vitro proliferation and xenograft growth for some PDAC cell lines (Jaganathan et al., 2010;
Scholz et al., 2003; Toyonaga et al., 2003; Wei et al., 2003). In a recent study, a subset of PDAC
cell lines that demonstrated an activated Gp 1 30-Stat3 pathway showed sensitivity to Jak2
inhibitors. Furthermore, conditional inactivation of Stat3 in a genetically engineered Kras-driven
mouse model of PDAC resulted in reduced tumor formation. In conclusion, Stat3 may be a
potential therapeutic target in PDAC.
Vegf signaling is upregulated in PDAC. Vegf promotes endothelial cell proliferation by
binding to and signaling through Vegfr-1 and Vegfr-2 (Ferrara et al., 2003). Inhibition of Vegf
signaling by soluble Vegf receptors (which bind up free-floating Vegf ligand), anti-Vegf
antibodies, or ribozymes inhibits growth of PDAC xenografts (Fukasawa and Korc, 2004;
Hoshida et al., 2002; Hotz et al., 2003; Korc et al., 1992; Tokunaga et al., 2002; von Marschall et
al., 2000). Vegf-C is a regulator of lymphoangiogenesis and is overexpresssed in PDAC. It is
believed to contribute to PDAC lymph node metastasis (Kurahara et al., 2004; Tang et al., 2001).
Additional work will be required to validate its importance in lymph node spread. In summary,
inhibition of Vegf signaling is a potential therapeutic approach for PDAC.
Signaling pathways involved in the development of the pancreas, such as hedgehog and
notch, are often reactivated in PDAC. The hedgehog signaling pathway controls developmental
growth and patterning of many organs including the pancreas (Ingham and McMahon, 2001).
The hedgehog family of ligands consist of Sonic, Indian, and Desert hedgehog (Shh, Jhh, and
Dhh). These ligands bind to patched (Ptc), a transmembrane protein and tumor suppressor.
Hedgehog ligands will release Smoothed (Smo) from inhibition by Ptc. Smo then activates the
Gli family of transcriptional regulators. Mutations in this pathway such as overexpression of Hh
ligands, loss of Ptc, activation of Smo, or overexpression of Gli have been observed in a variety
29
of cancers (Hebrok et al., 1998; Pasca di Magliano and Hebrok, 2003; Taipale and Beachy,
2001). Shh is not normally expressed in the adult pancreas but is expressed at progressively
higher levels as we move from PanINs to later-stage lesions and carcinomas (Berman et al.,
2003; Thayer et al., 2003). In PDAC, tumor cells secrete Hh ligands that bind to the Ptc receptor
on neighboring stromal and mesenchymal cells, thereby hedgehog signaling in surrounding cells.
Autocrine hedgehog signaling in tumor cells is less relevant to tumor formation, as activation of
an oncogenic form of Smo in pancreatic epithelial cells had no effect (Tian et al., 2009).
Moreover, genetic inactivation of Smo in pancreatic epithelial cells also had no effect on PDAC
development (Nolan-Stevaux et al., 2009). On the other hand, pharmacological inhibition of
Smo, which affects both tumor and stromal cells, inhibits tumor development in GEMMs
(Feldmann et al., 2008; Olive et al., 2009). In conclusion, inhibition of Smo in the cells
surrounding the PDAC may be a suitable therapeutic strategy.
Another pancreatic developmental pathway that is reactivated in PDAC is Notch. Notch
is generally involved in regulating cell proliferation, death, fate, and differentiation during
development. The notch pathway consists of notch ligands (Delta-like and Jagged) binding to
notch receptors (Notch 1-4), which induces proteolysis of Notch and the subsequent Notch
intracellular domain (NICD) moving into the nucleus and inducing transcriptional activation of
target genes. The Notch pathway is upregulated in various cancers including pancreatic cancer
(Ranganathan et al., 2011). Normally Notch ligands and Notch are not expressed at detectable
levels in the adult pancreas. In PanINs and PDAC, Notch ligands and receptors, along with
transcriptional targets such as HES-1, are elevated in expression (Miyamoto et al., 2003). Its
aberrant regulation is observed in various cancers (Kadesch, 2004; Lai, 2004; Radtke and Raj,
2003; Sjolund et al., 2005). However, activation of Notch in pancreatic progenitor cells in vivo is
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insufficient to induce PDAC development (Murtaugh et al., 2003). In various cell-based systems,
activated Ras cooperates with Notch to transform cells (Sundaram, 2005). In a Kras G12D mouse
model of pancreatic cancer, expression of an active form of Notch1 (NIC) enhanced PanIN
formation (De La et al., 2008). Combining Notch activation with Ras mutation may enable
PDAC development. On the other side, loss of Notch2 inhibited PanIN formation and delayed
tumor formation (Mazur et al., 2010). In contrast, NotchI deficiency surprisingly increased
PanIN formation (Hanlon et al., 2010). This suggests that targeting the proper Notch components
will be important for finding an effective therapy. Inhibition of the Notch pathway with y-
secretase inhibitors suppressed PDAC development in Pdxl -Cre, KrasG12 D, p53fl0*+ mice (Plentz
et al., 2009). Unfortunately, y-secretase inhibitors have various disadvantages including
inhibiting a variety of Notch receptors as well as other signaling pathways, resulting in notable
toxicity. Developing therapies that selectively target components of the Notch pathway, such as
Notch 1 may be a suitable strategy for PDAC.
Telomere shortening and dysfunctionln low-grade PanINs, shortened telomeres and
anaphase bridging have been detected, suggesting that loss of telomere function is an early event
in the development of PDACs (van Heek et al., 2002). In addition, pancreatic cancer cell lines
(which are in the late stages of PDAC development) tend to demonstrate anaphase bridging and
an absence of telomeres (Gisselsson et al., 2001). It is believed that reactivation of telomerase is
needed for pancreatic cancer to reach its later stages, but the mechanism is unclear.
Understanding telomerase activity will expand our knowledge of PDAC progression.
Inflammation
Inflammation of the pancreas (chronic pancreatitis and hereditary pancreatitis) increases
the risk of PDAC development (Whitcomb et al., 1996). In an acinar-cell driven KrasG12D
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GEMM, cerulean treatment to induce pancreatic inflammation accelerated PDAC development
(Guerra et al., 2007). Other studies with acinar-driven PDAC models have shown an acceleration
of PanIN development in the presence of injury (Habbe et al., 2008; Morris et al., 2010).
Moreover, inducing inflammation accelerates the progression of PanINs to PDACS (Carriere et
al., 2009; Morris et al., 2010). In endocrine cell driven GEMMs, inflammation is also a
contributor to PDAC development (Gidekel Friedlander et al., 2009). In contrast, for ductal cell-
driven GEMMs, inflammation has not had a notable effect. In summary, in PDAC GEMMs that
originate from certain cell types, inflammation promotes PDAC formation.
Cox-2, a mediator of inflammatory signaling, is upregulated in PDAC. Cox-2 is
detectable in 90% of human PDACs, while it is undetectable in normal pancreatic tissue (Tucker
et al., 1999). In human and mouse PanINs, Cox-2 levels correlate with the histological severity
of the disease. Inhibition of Cox-2 with reduced proliferation of various pancreatic cancer cell
lines (Albazaz et al., 2005; Hingorani et al., 2003). Treatment with nimesulide, a non-steroidal
anti-inflammatory drug that inhibits Cox-2, in a Kras-driven GEMM reduced PanIN formation
(Funahashi et al., 2007). Another Cox-2 inhibitor, celecoxib, was given in combination with
gemcitabine and a Muc1-based vaccine in a Kras-driven GEMM, resulting in complete
prevention of invasive disease (Mukherjee et al., 2009). Unfortunately, this combination later did
not show a statistically significant effect in clinical trials. In summary, Cox-2 is upregulated in
PDAC and may be a potential therapeutic target.
Stat3 is required for PDAC initiation and progression (Fukuda et al., 2011; Lesina et al.,
2011). Stat3 regulates not only proliferation and apoptosis, but also inflammation through the
production of cytokines and chemokines such as 11-6. Inhibition of Stat3 and Egfr by
triterpernoids and rexinoids in single and in combination led to improved survival of Pdx1 -Cre,
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Kras G12, p53 o GEMMs (Liby et al., 2010). In summary, inhibition of Stat3 may be a suitable
strategy for PDAC.
Directly regulating the immune system is a potential therapeutic strategy for PDAC. In
cancer, leukocyte infiltration can have tumor suppressive or tumor promotive functions. In
PDAC, leukocyte infiltration typically is immunosuppressive. Using this knowledge, a clinical
trial was designed that combined gemcitabine with an activating CD40 antibody (Beatty et al.,
2011). The CD40 antibody induced tumor regression, but only in tumors that had macrophage
but not T cell infiltration. This interesting finding was further pursued in GEMMs, and a similar
result was identified where macrophage-containing tumors demonstrated regression. In
summary, the CD40 antibody may be a viable therapeutic approach for patients with substantial
macrophage infiltration in their PDACs.
Besides inflammatory cells, another important component of PDAC is the stromal cells.
A characteristic of pancreatic cancer is the formation of a dense stroma, which is known as the
desmoplastic reaction (Chu et al., 2007; Mahadevan and Von Hoff, 2007). This desmoplastic
stroma is produced by stellate cells, also known as myofibroblasts. Upon growth signals such as
Tgfp, Pdgf, and Fgf, these cells secrete collagen and other extracellular matrix components. The
high stromal cell content may also explain the poor vascularization of these tumors. A study in a
genetically engineered mouse model of pancreatic cancer demonstrates that targeting the
hedgehog pathway in stromal cells can increase the vascularization of the tumor. This increase
vascularization in combination with chemotherapy allows for better delivery to the tumor and
anti-tumor efficacy (Olive et al., 2009). To conclude, targeting the stroma in conjunction with the
tumor may be an effective strategy for treating PDAC.
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Cancer Stem Cells
A subset of cells in the PDAC tumor (1-5%) has been identified as cancer stem cells
(CSCs). It is believed that cancers arise from the CSCs. As the tumor develops, these CSCs
persist indefinitely as they undergo asymmetric division to give rise to additional CSCs and
differentiated progeny cells. CSCs are also more resistant to chemotherapy and radiation therapy,
making complete eradication of the tumor difficult (Hermann et al., 2007; Jimeno et al., 2009).
Identifying drugs that are particularly effective against CSCs may be an effective strategy.
CSCs were identified in PDAC in 2007. In a xenograft model of human PDAC in
immunocompromised mice, a 0.2 - 0.8% subset of the cells had a 100-fold greater tumorigenic
potential when compared to the other tumor cells (Li et al., 2007). This subset of cells was
defined by cell surface markers as being CD44+/CD24+/ESA+ and was able to self-renew and
generate differentiated progeny, a defining factor of a cancer stem cell. Moreover, this subset
was identified in 10 different primary human PDAC xenografts, suggesting that it was not an
anomaly of one particular tumor. These putative CSCs demonstrated activation of the Hedgehog
developmental pathway (Lee et al., 2008). The Hedgehog pathway is not normally expressed in
the pancreas except during its development. This finding is in line with the concept that CSCs
are a more undifferentiated, parental cell type, than the tumor itself. Consequently,
developmental signaling pathways are reactivated in CSCs. In summary, CD44+/CD24+/ESA+
cells may be the cancer stem cells in PDAC.
In another study in 2007, CD 133+ cells were identified as CSCs in 11 primary human
pancreatic cancer and cancer cell line samples (Hermann et al., 2007). The overlap between
CD44+/CD24+/ESA+ and CD133+ cells is such that 10-40% of CD44+/CD24+/ESA+ cells are
also CD133+.This relatively low overlap suggests that differing subsets of the tumor population
34
are more tumorigenic than others. Depending on the cell surface markers tested, a study may
identify different groups of cells as being CSCs.
GEMMs were used to identify the pancreatic cell type that could give rise to PDACs.
Activating Kras G12D in Nestin-expressing pancreatic progenitor cells or in adult acinar cells were
both able to give rise to PanIN formation (Habbe et al., 2008; Heid et al., 2011). Moreover,
activating Kras G12D expression along with tumor suppressor loss in adult pancreatic endocrine or
exocrine cells were both able to result in PDAC development (Gidekel Friedlander et al., 2009).
In summary, studies in GEMMs suggest that the development of PDAC can arise from various
pancreatic cellular compartments in both the progenitor and mature states. Further studies will be
needed to identify the compartment from which human PDAC develops.
Metastasis
It is believed that metastasis is a highly inefficient process, as only a small fraction of
cells from the primary tumor enter the bloodstream, and only 0.0 1% of the cells in circulation
end up forming metastases (Gupta et al., 2005). Interestingly, the wild-type copy of Kras likely
suppresses PDAC metastasis. The wild-type Kras allele is often lost during PDAC metastasis
(Qiu et al., 2011). The Kras and Ink4a/Arf mutant mouse model develops metastases (Mazur and
Siveke, 2011). Deletion of Ink4a/Arf upregulates signaling the Notch and Nf-xB pathway, which
is believed to promote metastasis. The Kras and p53 point mutant mouse model also develops
metastases. In the p53 point mutant model, upregulation of Integrin and Egfr promotes
metastasis (Muller et al., 2009). Smad4 deletion in a Kras mutant background also gives rise to
metastatic PDAC (Iacobuzio-Donahue et al., 2009). Pancreatic stromal cells, or more specifically
tumor fibroblasts and pancreatic stellate cells, have been shown to co-migrate with PDAC cells
in a transplant mouse model system, suggesting that stromal cells contribute to the metastatic
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process (Xu et al., 2010). In addition, the low levels of vasculature in PDAC could also
contribute to metastasis (Mazur and Siveke, 2011). In summary, metastasis, despite being
inefficient, frequently occurs in PDAC and is modeled by the current GEMMs.
A study in 2010 suggests that a single tumor forms several years prior to metastatic
disease (Yachida et al., 2010). The study analyzed the DNA sequence of human pancreatic
primary tumors and their metastases to understand the timeline of tumor evolution (Figure 5).
They show that the time from tumor initiation to the development of the parental cell that would
give rise to metastasis is greater than 10 years. This suggests that for more than a decade, the
cells dividing in the primary tumor are benign in that they, on average, will not form the lethal,
metastatic cell. The time for the parental clone to form metastases is about 5-6 years. The time
for the metastasis to grow to the point that it kills the patient is only approximately 3 years. In
conclusion, there is notable time for intervention between the point of tumor initiation and the
formation of the parental clone to the metastasis. If the primary tumor can be detected in that
time period and removed, the patient's life can be extrended.
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Non-metastatic primary tumour Metastatic subclones
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initiation clone seeds death
Figure 5. Timeline of the Development of Human PDAC. The progression of human PDAC from the
intiation of the tumor to its metastasis and eventual patient death. Adapted from Yachida, Nature 2010.
Another study in 2010 analyzed the DNA sequence of various pancreatic tumors and
their metastases and identified certain genomic alterations likely responsible for the metastasis of
PDAC (Campbell et al., 2010). Sequencing revealed that various kinds of chromosomal
rearrangements occur in the primary tumor and metastasis. While most kinds of chromosomal
rearrangements are observed in either the primary or the metastatic lesion, fold-back inversions
are observed in both the primary and its corresponding metastatic tumor. Therefore, fold-back
inversions may be a driver of PDAC metastasis. The mechanism for these genomic alterations is
still unknown. Further studies will be necessary to demonstrate the functionality of fold-back
inversions.
A computational study in 2012 analyzed the rate of growth of PDAC cells in 228
patients (Haeno et al., 2012). They identified that pancreatic cancer growth is initially
exponential. Moreover, at the time of diagnosis, most patients harbor metastases. Finally, they
show that treating tumors with therapies that reduce the growth rate may be more effective than
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Metastases
surgical resection. In conclusion, earlier diagnosis followed by systemic therapy may be as
effective a strategy as that of surgical resection.
Another study in 2012 established a mouse model with tagged cancer cells to better
understand PDAC metastasis (Rhim et al., 2012). Invasion of cancer cells into the bloodstream
occurred even before frank malignancy could be detected by histological analysis. Circulating
cells demonstrated a mesenchymal phenotype and stem cell properties. These cells eventually
seeded the liver. At the primary tumor, EMT and invasion were most common at sites of
inflammation. Moreover, induction of pancreatitis promoted invasion of cells into the circulation.
On the other hand, immunosuppression reduced the amount of cells in circulation. In summary,
cells in PDAC invade into the circulation early on and are promoted by inflammatory signals.
Mouse Models of Pancreatic Cancer
Genetically engineered mouse models create a system in which to dissect the biology of
pancreatic cancer. In addition, they provide a platform to screen and test therapeutic targets and
compounds. Advances in gene targeting have enabled temporal and spatial control over the
activation of various oncogenes and tumor suppressors, with the goal of mimicking the natural
development of human cancer.
The first attempts to genetically model pancreatic cancer involved targeting oncogenic
transgenes to the acinar cells of the pancreas. Transgenic mice expressing SV40 large T antigen
or mutant H-Ras develop acinar cell carcinoma. Another mouse mode with H-Ras, driven by the
Elastase (Ela) promoter, which is expressed in acinar cells, develops acinar cell carcinoma
(Glasner et al., 1992; Ornitz et al., 1987; Quaife et al., 1987). Similarly, Ela-c-Myc mice go on to
develop mixed acinar-ductal carcinomas (Sandgren et al., 1993; Sandgren et al., 1991).
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Combining Ela-Tgf-a with p53 deficiency led to mixed acinar-ductal or cystic acinar tumors
(Wagner et al., 1998). Metallothionein-Tgf-a transgenic mice, in the background of p53 or
Ink4a/Arf deficiency developed benign ductal lesions that resembled serous cystadenomas
(Bardeesy et al., 2002a). More recently, acinar cells have been targeted using the conditional
RCAS-TVS system in combination with an elastase-driven oncogene. The RCAS-TVS system
allows for temporal control over genetic alterations. The Ela-c-Myc in the background of
Ink4a/Arf deficiency resulted in only islet cell tumors. The Ela-PyMT in the background of
Ink4a/Arf deficiency developed pancreatic tumors of mixed acinar and ductal features. An
elastase-driven Kras model gives rise to acinar and ductal lesions that resemble PanINs
(Brembeck et al., 2003; Grippo et al., 2003). Expression of transgenic mutant Kras under acinar
and ductal promoters lead to lesions similar to PanINs, mixed acinar and ductal carcinomas, or
periductal inflammation (Brembeck et al., 2003; Grippo et al., 2003). In summary, these acinar
cell models driven by an oncogenic transgene and sometimes lacking a tumor suppressor, gave
rise to many mixed acinar-ductal tumors as opposed to PDACs.
Models of PDAC
A knock-in model of Kras mutant cancer has been developed using recombinase
technology. Bacteriophage P1-derived Cre recombinase recognizes loxP sites (specific sequence
of short repeat) and induces recombination of the sites. Therefore, controlled spatial and
temporal presence of Cre recombinase can allow for the removal or expression of targeted genes.
Lox-STOP-Lox-KrasG12D is a conditional allele of Kras, where the Kras gene is preceded by a
stop cassette. Upon expression of Cre in the nucleus of the cell, the Lox-STOP-Lox cassette is
recombined and removed, allowing for expresseion of KrasGI2D
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To direct mutant Kras expression to the pancreas, the two most commonly used pancreas-
specific promoters used to drive Cre are Pdx 1 and Ptfl. Pdx 1 and Ptfl are expressed during early
development of the pancreas. More specifically, Pdx1 is expressed in the pancreatic progenitor
cell at day 9.5. One of the caveats to these models is that the Pdx1 transcription factor is not only
expressed in the pancreas but also in the developing foregut and epidermis. Similarly, Ptfl is
expressed in the parts of the nervous system including the brain, spine, and retina. Consequently,
Kras may be activated outside the pancreas, giving rise to undesired tumors.
Cre-induced activation of LSL-KraG12D induces prolific PanIN development in the first
few weeks (Aguirre et al., 2003; Hingorani et al., 2003). The PanINs progressed like in the
human disease through various histological stages and eventually became full-blown PDAC with
low penetrance and long latency (Hingorani et al., 2003). A similar model also gave rise to
PanINs: KrasG12v-IRES-LacZ in combination with Cdk4R24C (resistant to Ink4a inhibition and
thus partially mimics Ink4a deficiency). In the model, all the acinar and ductal cells theoretically
express Kras, but not all the cells go on to form tumors, suggesting that mutant Kras by itself is
insufficient to induce development of full-blown PDAC. In summary, activation of mutant Kras
in the pancreas is sufficient to generate histologically-representative PDAC in mouse models.
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Promoter Tumor Metastasis #of
Driving Oncogenes Tumor Suppressors Onset fequency) Median survival (mos) T or Comments Reference
Cre (mos) Tumors
Pdx1 LSL-KrasG12D 14.3 Yes (67%) > 15 3 Long latency, spectrum of PanINs, Pdx1 expression in other organs Bardeesy, PNAS 2006
Ptf1a LSL-KrasG12D > 12 Yes (NR) > 12 NR Long latency, spectrum of PaniNs Mazur, Gut 2011
LSL-KrasG12D
Ptf1a Ba-Tgfa 5.0 Yes (50%) 7.0 NR PanIN and IMPN (pancreatobiliary subtype)-derived PDAC Mazur, Gut 2011
Fdx1 LSL-KraSG1 2D p53"*** 5.5 Yes (33%) NR 3 Bardeesy, PNAS 2006
Pdx1 LSL-KrasG1 2D p53flo"* p16*'- 3.8 Yes (25%) NR 16 Bardeesy, PNAS 2006
Fx1 LSL-KrasG1 2D p53"*-** p16-- 3.3 Yes (25%) NR 4 Bardeesy, PNAS 2006
Pdx1 LSL-KrasG12D p5 3 R172H/+ 2.5 Yes (63%) 5.0 NR Accelerated developrnent of metastatic w ell-differentiated PDAC Mazur, Gut 2011
Ptf1a LSL-KrasG12D p5 3R270H/+ Brca2Tr/DU 2.0 Yes (NR) 2.5 NR Model of familial PDAC Mazur, Gut 2011
Pdx1 LSL-KrasG12D p53Oxox p16'- 1.8 Yes (20%) 2.0 5 High penetrance and short latency Mazur, Gut 2011
Pdx1 LSL-KrasG12D p53"0x""x 1.6 No 3.0 3 Well-differentiated PDAC w ith short latency Mazur, Gut 2011
Pdx1 LSL-KrasG12D pI 6fWox+ PgfloW+ 8.5 Yes (69%) 10 12 Longer latency than Ink4a/Arf-null rnice, but gross metastasis Mazur, Gut 2011
Pdx1 LSL-KraSG12D o16f)nox P gnflo/fox 2.1 Yes (11%) 2.0 27 PDAC w ith short latency and high penetrance, rnicrometastasis only Mazur, Gut 2011
Pdx1 LSL-KraSG12 D p16- 4.5 Yes (33%) NR 3 Bardeesy, PNAS 2006
Pdx1 LSL-KraSG12D p19-1- NR Yes (33%) 5.0 NR PDAC w ith short latency Mazur, Gut 2011
Ptf1a LSL-KrasG12D Notchflo**"ox > 6 Yes (13%) 12 NR Similar or slightly accelerated PDAC development as Ptf1a+cm, KrasG12D Mazur, Gut 2011
Ptf1a LSL-KrasG12D Notch2o**""x > 9 Yes (50%) > 15 NR MCNs, only PanIN1, sarcomatoid PDAC w ith long latency Mazur, Gut 2011
Pdx1 LSL-KraSG12D Smad4""""ox 4.0 Yes (37%) 9.0 NR Mvbdel of IPItl-to-PDAC progression Mazur, Gut 2011
Ptf1a LSL-KrasG1 2D Smad4flowflox 3.5 Yes (18%) 8.0 NR MCNs resembling human disease Mazur, Gut 2011
Ba-tTA
TRE-Cre LSL-KrasG12V 12 No 18 NR PDAC developrnent after chronic pancreatitis Mazur, Gut 2011
Ptf1a LSL-KraSG12D Tgff0leox/flox NR Yes (NR) 2.0 NR Aggressive undifferentiated PDAC Mazur, Gut 2011
Figure 6. Table of Genetically Engineered Mouse Models that develop Pancreatic Ductal
Adenocarcinoma. Various knock-in and transgenic mouse models of PDAC are depicted in this table.
Adapted from Mazur, Gut 2011 and Bardeesy, PNAS 2006.
Many mouse models of PDAC have been developed (Figure 6). These models all have
the knock-in LSL Kras allele, with either a G12D or G12V mutation. Some also contain floxed
(flanked by lox sites) or null alleles of tumor suppressors such as p53, p16, and p19. The
construct used to focus expression of these alleles to the pancreas is either Pdx1 or Ptfl a. In the
rare case, a combination of Ela-tTA and TRE-Cre (TRE is a tet-responsive element) is used. This
combination allows for expression of the tet-transactivator (tTA) in elastase-expressing cells.
Upon administration of doxycycline (dox), dox binds to tTA, promoting it to bind to the TRE
and drive transcription of downstream genes. This set-up allows for temporal control over
expression of Cre in Elastase-expressing cells. If a simple Ela-Cre construct were used, there
would be no temporal control, as Cre would be expressed in all cells that expressed elastase at
some point in their development. In summary, a variety of PDAC mouse models were developed
with the Pdx1 or Ptfl a promoter driving Cre to activate Kras and remove tumor suppressors.
The tumor characteristics of these mouse models vary with regard to tumor onset,
survival, and metastasis (Figure 6). The time to tumor onset is slowest for Kras-only tumors,
while they are more rapid for tumors that also involve tumor suppressor alterations. The time-
frame for tumor onset was as rapid as 1.6 months and as slow as 14.3 months. The median time
until death was as short as 2 months and as long as 18 months. Kras-only mice generally take
longer than a year for PDAC development. The time for tumor-onset correlates relatively well
with the survival of the mice, with the latter being longer than the former. The vast majority of
the mouse models metastasize, with frequencies ranging from 11% to 69%.Even the Kras-only
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models metastasize with a frequency of 67%, suggesting that additional genetic alterations are
acquired to allow for metastasis. The most metastatic model is the p1 6/p 19 conditional
heterozygote at a frequency of 69%.In comparison, the p1 6/p19 conditional homozygote only
had a metastasis frequency of 11 %.This suggests that the heterozygote model allows for more
gradual tumor development, which may enable additional genetic lesions to accumulate,
resulting in metastasis. In summary, the mouse models with different genetic alterations
demonstrate variety in tumor development, not unlike the human disease.
The different mouse models also gave rise to various histological phenotypes and
numbers of tumors. The number of tumors in each mouse model ranged from 3 to 27 tumors.
The p16 and p19 mutant mice also show a significant increase in the number of tumors as
compared to the other models. The p16/p19 heterozygote gave rise to 12 tumors, while the
p1 6/p 19 homozygote developed 27 tumors. The various mouse models took different paths to get
to PDAC, including the expected pre-neoplastic lesions: PanINs, IPMNs, and MCNs. In
summary, different genotypes developed PDAC with diverse histologies and ended up with
varying numbers of tumors.
Ink4a (p16) plays a critical role in PDAC tumorigenesis. Ink4a is lost in 80-95% of
sporadic PDACs (Schutte et al., 1997). Individuals with germ-line Ink4a mutations have an
increased risk for PDAC (Goldstein et al., 1995; Whelan et al., 1995). However, Ink4a loss by
itself in the pancreas is insufficient to result in PDAC. Ink4a loss tends to precede p53 and
Smad4 alterations, as PanIN- 1 and PanIN-2 lesions frequently show Ink4a loss but rarely p53
mutations. Mutations exclusively targeting Ink4a without affecting Arf have been identified in
PDAC, suggesting that loss of Ink4a promotes PDAC development. Ink4a is a G1 cyclin-
dependent kinase (Cdk) inhibitor that binds to Cdk4 and Cdk6, preventing their association with
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D-type cyclins (Sharpless, 2005). In the absence of Ink4a, Cdk4 or Cdk6 associates with cyclin
D, thereby activating the Cdk. The active Cdk phosphorylates and inactivates Rb, allowing for S-
phase entry and cell cycle progression. The presence of Ink4a puts a halt to S-phase entry and
cell division. It is hypothesized that Ink4a is activated by upstream oncogenic signals in tumor
cells, thereby inducing oncogene-related senescence (Michaloglou et al., 2005; Serrano et al.,
1997). In one study of genetically engineered mice, mice that are KraSG12D showed an average
tumor latency of 57 weeks or 14.3 months (Bardeesy et al., 2006). Combining KrasG12D with
Ink4a deficiency reduced the latency to 18 weeks or 4.5 months. To conclude, Ink4a is a critical
tumor suppressor in PDAC.
The other component of Cdkn2a is Arf, which inhibits the Mdm2-mediated degradation
of p53 (Pomerantz et al., 1998; Zhang et al., 1998). Homozygous deletion of Arf and Ink4a are
observed in approximately 40% of PDACs. This is not surprising considering their overlapping
gene sequences. While Ink4a mutations that spare Arf function have been observed, Arf
mutations that spare Ink4a have not been observed (Hustinx et al., 2005; Rozenblum et al.,
1997). Since any mutation that results in Arf loss also results in Ink4a loss, there is question as to
the functional significance of Arf loss. A potential functional consequence of Arf-loss is reduced
levels of p53, thereby facilitating cell proliferation (Lowe and Sherr, 2003). In addition, Arf has
p53-independent functions such as the inhibition of ribosomal RNA processing (Itahana et al.,
2003; Sugimoto et al., 2003). To determine the potential tumor suppressive function of Arf,
GEMMs were used. In a GEMM with KrasG12D and p16/p19flOXI+, the average latency was 34
weeks or 8.5 months (Bardeesy et al., 2006). Those that were p16/p19 ox/flox showed a latency of
8.5 weeks or 2.1 months (Aguirre et al., 2003). Both the p1 6/p 19 heterozygous and homozygous
models develop PDACs that resemble the human disease histologically with a high grade tumor
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and proliferating stroma. The latency for the p1 6/pI 9 floox/flo' mice is notably shorter than that for
p16/ mice (18.3 weeks), suggesting that both p16 and p19 play a role in tumor formation. As
illustrated, some studies suggest that Arf plays a functional role in PDAC tumorigenesis, but
additional studies will be necessary.
p53 is mutated in 50-75% of PDACs (Rozenblum et al., 1997). p5 3 loss alone in the
pancreas is insufficient to give rise to PDAC. The p53 mutation is typically observed in
advanced PanINs that also have activated Kras and loss of Ink4a. In human PDAC, the large
majority of p53 alterations are point mutations. The point mutation results in a loss-of-function,
but results in a different phenotype than a genetic deletion of p53. Mouse model studies have
shown that homozygous loss of p53 does not give rise to metastasis, while a single allele of point
mutant of p53 does.
Combined p53 and Arf loss is observed in 38% of PDACs (Hustinx et al., 2005; Maitra
et al., 2003; Rozenblum et al., 1997). This suggests that there are non-redundant functions of p53
and Arf or that Arf loss is simply a bystander effect of Ink4a deletion. Kras G12D, in combination
with a conditional null allele or point mutant allele (R273H) of p53, gives rise to full-blown
PDAC (Bardeesy et al., 2006; Hingorani et al., 2005). In one study, mice that are Kras G12D
showed an average tumor latency of 57 weeks or 14.3 months (Bardeesy et al., 2006).
Combining Kras G12D with heterozygous p53 flOX/+ reduces the latency to 22 weeks or 5.5 months.
Combining KrasG12D with p53 flox+ and pl6*' gives a latency of 14.7 weeks or 3.7 months. This
suggests that p16 has a functional effect on tumor formation, as tumors form more rapidly than
mice that are only p53" **.KraSG12D with p5 3 flo' or p16-/- alone give a latency of 6.2 weeks
and 18 weeks, respectively. KrasG12 D combined with both p53 fox/fox and p16-/- gives a latency of
7.2 weeks or 1.8 months. In the homozygous situation, the additional loss of p16 in the context
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of p53 loss does not further enhance tumor formation. In conclusion, when there is a
heterozygous mutation in p16 or p53, a loss of one allele in the other tumor suppressor facilitates
tumor development.
It appears that either p53 or Arf is lost in full-blown PDAC. In models with KrasG12D and
either p5 3fl*x/+ or p53 R273H, all the PDAC lesions have lost the wild-type p53 allele. In contrast,
GEMMs with Kras and p1 6/Arf alterations develop PDAC lesions where no lesion exhibits p53
loss. Therefore, either p16 or Arf loss is capable of substituting for p53 loss. GEMMs with
KrasG12D and p53f l* orp16*' (with an intact Arf) show loss of the wild-type p53 and p16 in
most tumors (Bardeesy et al., 2006). This suggests that the tumor suppressive function of p53
and Ink4a are not redundant. Rather, complete loss of function of both genes is beneficial for
tumor growth. Finally, either p53 or Arf loss is necessary in a developed PDAC lesion.
GEMMs with other genetic lesions gave rise to various types of pancreatic cancer. Mice
with a Smad4 deficiency developed cystic lesions that resembled human IPMN and MCN. These
preneoplastic lesions are less commonly observed in human PDAC than are PanINs. The Egfr
signaling pathway is upregulated in human PDAC. In approximately 90% of PDACs, the family
of four Egfr receptors and their corresponding ligands, Egfr and Tgf-a, are overexpressed.
Enhancing Egfr signaling, by overexpressing Tgf-a in acinar cells, in the background of a Kras
mutation increases PDAC formation in a GEMM. In summary, various mutations found in
human PDAC, when engineered into GEMMs, can give rise to pancreatic cancer.
Since metastasis is a critical component of PDAC, efforts have been made to model
metastasis in GEMMs. Macro metastases are only found in mice with heterozygous mutations in
tumor suppressors. Mice with homozygous deletions are believed to rapidly develop multiple
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tumors that result in premature death. In contrast, mice with heterozygous mutations have time
for their tumors to grow and eventually metastasize. From this perspective, the heterozygous
models are more realistic because, in humans, usually only one tumor develops and metastases
eventually are responsible for the patient's death.
Models for Early Detection
Positron emission tomography (PET) is a common imaging technique used in clinical
oncology for the detection of tumors. 18F-fluorodeoxyglucose (FDG)-PET has been examined in
mouse models of PDAC (Herrmann et al., 2008). In Pdx1-Cre, KrasG12D and Pdxl-Cre, KrasG12D
p53 R172H models, levels of FDG uptake correlated with the severity of the lesion, with little
uptake in PanINs and strong uptake in PDACs (Fendrich et al., 2011). These results suggest that
FDG-PET may be a viable approach in diagnosing human PDACs.
Another approach for early diagnosis is endoscopic confocal laser microscopy. A
cathepsin-activated near-infrared probe was used along with flexible confocal laser microscopy
to detect PanINs in a GEMM (Eser et al., 2011). Yet another approach is to use an ultrasound to
detect relatively small PDACs. Small-animal ultrasound was used to detect PDACs as small as
1mm developing in a GEMM (Olive and Tuveson, 2006). The last approach being taken is to test
for a protein biomarker that is present in the bloodstream during early PDAC development. In a
KrasG12 D, Ink4a/Arfoxox GEMM, proteomics were used to identify a panel of proteins that
correlated with early PDAC progression (Faca et al., 2008). Yet another method for early
detection is to look for protein biomarkers in the circulation. GEMMs may be particularly useful
for identifying a protein or protein panel because they allow for less intra-cohort variation. Since
each mouse has the same genetic make-up and highly similar environmental upbringing, the
differences between those with PDAC and those without can be better isolated without
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background noise. In summary, there are a variety of methods being developed that allow for
early detection of PDAC.
Treatments for Pancreatic Cancer
Treatments for Resectable or Locally Advanced Pancreatic Cancer
There are a variety of treatments for the 50% to 55% of pancreatic cancer patients who
are diagnosed with resectable or locally advanced disease. For resectable disease, depending on
the location of the tumor, possible procedures include cephalic pancreatoduodenectomy (the
Whipple procedure), distal pancreatectomy, or total pancreatectomy. During the surgery, at least
12 to 15 local lymph nodes will be resected (Shaib et al., 2007). In addition to the
pancreatectomy, percutaneous or endoscopic stent replacement is often necessary as 70% of
patients with resectable disease present with biliary obstruction. Large clinical trials have shown
that postoperative administration of fluorouracil, leucovorin, or gemcitabine improves
progression-free and overall survival (Neoptolemos et al., 2004; Oettle et al., 2007; Regine et al.,
2008)'. Moreover, some trials have shown a trend towards increased overall survival when
radiation therapy is combined with surgery (Herman et al., 2008). Adjuvant treatment with
chemotherapy and radiation has demonstrated improvements in PFS and OS (Crane et al., 2004;
Kalser and Ellenberg, 1985; Klinkenbijl et al., 1999; Oettle et al., 2007). The standard post-
operative care in the US is radiation plus systemic chemotherapy, while that outside the US is
gemcitabine or 5-FU chemotherapy without radiation. An emerging strategy is pre-operative or
neoadjuvant treatment with chemotherapy or radiation therapy (Evans et al., 2008; Katz et al.,
2008). Phase 2 trials suggest that this approach is at least as effective as postoperative treatment.
In summary, surgical treatment is often paired with adjuvant therapy for resectable disease.
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For patients with locally advanced pancreatic cancer, the management is mostly
palliative, as greater than 95% of patients will be dead within 5 years. 30% of patients with
pancreatic cancer are diagnosed with advanced locoregional disease. The median overall survival
ranges from 9 to 10 months. As for resectable disease, adjuvant chemoradiation is the standard
treatment, as it is notably more effective than radiation therapy alone (Huguet et al., 2007;
Sultana et al., 2007). A small randomized trial with 16 patients demonstrated that
chemoradiotherapy (fractionation radiotherapy with 5-FU) led to a mOS of 13.2 months as
compared to 6.4 months for the best supportive care (Shinchi et al., 2002). In summary,
treatment for locally advanced disease is similar to that for metastatic disease in that systemic
therapies are an important component.
Approved Treatments for Metastatic Disease
The majority of patients with pancreatic cancer present with metastatic disease. Even for
those patients who do not present with metastases, their disease often eventually becomes
metastatic. 80% of patients receive Gemzar/gemcitabine as front-line therapy. Gemcitibine was
launched in the US and EU in 1995 for the treatment of locally advanced and metastatic
pancreatic adenocarcinoma. Over time other indications have been added to the label, including
metastatic breast cancer, non-small cell lung cancer, and advanced ovarian cancer for both the
US and EU. In the EU, Gemzar is also approved for the treatment of bladder cancer. The pivotal
trial for gemcitabine demonstrated that gemcitabine had efficacy above 5-FU. 126 patients with
locally advanced or metastatic disease were assigned to gemcitabine or 5-FU, administered as a
bi-weekly intravenous infusion (Burris et al., 1997). 24% of patients treated with gemcitabine
showed a clinical response, while only 5% treated with 5-FU showed a response. Moreover, the
mOS for the gemcitabine group was at 5.7 months, as compared to 4.4 months for the 5-FU
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group. The 1--year survival rate for the gemcitabine group is 18%, as compared to 2% for the 5-
FU group. More recently, in a phase 3 trial, gemcitabine has been given at a fixed-dose rate
(higher dose) and compared to the standard dosing protocol. The mOS was not significantly
better for the higher-dose group at 6.2 months, as compared to 4.9 months for the standard-dose
group (Poplin et al., 2009). However, the higher-dose gemcitabine gave rise to more side effects
as expected. In summary, the standard-of-care for metastatic PDAC has been gemcitabine for the
past 15+ years.
While the most common first-line therapy for PDAC is gemcitabine, there are actually
multiple first-line and second-line therapies (Figure 7). However, patients eventually relapse, at
which point other first-line therapies (addition of another chemotherapeutic) or second-line
therapies may be attempted. Various 1" and 2"d line therapies are listed in Figure 7. While none
of the combinations have demonstrated superiority when compared to gemcitabine alone in a
large-scale phase 3 clinical trial, their effectiveness is comparable to gemcitabine alone. Once the
disease progresses after gemcitabine therapy, most patients are too sick to receive second-line
therapy. However, for those who initially presented with minimally symptomatic disease,
second-line chemotherapy can be taken. 20% of patients who have progressed on gemcitabine
are given additional therapies. There is currently no standard second-line therapy for patients
who have progressed on gemcitabine. The most commonly used second-line therapies are 5-FU,
capecitabine, and oxaliplatin (Cantore et al., 2004; Demols et al., 2006; Tsavaris et al., 2005).
Since these other chemotherapeutics are already approved for other cancer indications, their off-
label use for PDAC is possible. In summary, while gemcitabine is the primary treatment for
metastatic PDAC, there are other chemotherapies that can be combined with gemcitabine or used
independently.
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Drug Stage of Serious Toxic Effects
Combination Therapy Occurring in > 10% of Patients
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Gemcitabine 1"s Line triphosphate moiety, dFdCtriphosphate, by 16%deoxycytidine kinase is incorporated into thereplcatin. - Thrombocytopenia - 10%
nascent DNA and blocks DNA replication. evated AST Level - 10%
- Prolonged exposure to gemcitabine - Neutropenia - 49%Higher Dose 1"t Line increases accumulation of dFdC - Thrombocytopenia - 37%
Gemcitabine triphosphate - Anemia - 23%
- Nausea and vormiting - 21%
Gemcitabine - Oxaliplatin is a diarminocyclohexano - Neutropenia - 20%
+ 1s' Line platinum analogue that binds and alkylates * Peripheral Sensory Neuropathy - 19%
Oxaliplatin DNA - Thrombocytopenia - 14%
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Gemcitabine - Nausea and vormiting - 22%
+ 1sI Line - Cisplatin is a DNA-binding alkylating agent * Anemia - 13%
Cisplatin - Pain - 12%
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+ 1"s Line fluorouracil and inhibits thynidilate - Neutropenia - 23%
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Figure 7. Safety Profile of 1"t and 2nd line Therapies Used for PDAC. In the "Serious Toxic Effects"
column is the frequency of serious adverse events (SAEs) that arise upon taking the indicated drug
combination. In the "Mechanism of Action" column, the mechanism of action of the listed drug is
described. Adapted from Hidalgo, NEJM 2010.
When selecting treatment options, the other factor considered in addition to efficacy is
safety (Figure 7). Figure 7 lists the serious and common (greater than 10%) adverse events
(SAEs) that arise from the various treatment plans. SAEs are a significant problem because
quality of life can be notably affected by toxicities. Since PDAC patients often only have several
months of life remaining, it is particularly important to make the best of the remaining time.
Clinicians take toxicity into account when selecting a regimen. A regimen that provides better
safety but slightly worse efficacy may be preferable to the most efficacious but more toxic drug.
The standard treatment, gemcitabine, is relatively toxic with neutropenia and elevated alkaline
phosphatase occurring in 26% and 16% of patients, respectively. As expected, an increased dose
of gemcitabine results in an elevated frequency of toxicity with neutropenia and
thrombocytopenia occurring at 49% and 37%, respectively. In summary, the drug regimen is
decided upon based on not only its efficacy but also its side effects.
In several first-line and second-line therapies, only erlotinib is a targeted agent (Figure
7). Erlotinib, an Egfr inhibitor, in combination with gemcitabine, has shown a small, but
statistically significant improvement in survival (Genkinger et al., 2009). Egfr overexpression
has been found to correlate with poor prognosis and disease progression (Ueda et al., 2004). In a
569 patient phase 3 trial, individuals receiving erlotinib and gemcitabine had a mOS of 6.2
months, while those receiving gemcitabine alone had one of 5.9 months, with a HR of 0.82 (95%
CI 0.69 - 0.99, p = 0.04) (Moore et al., 2007). The respective 1-year survival rates were 23% and
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17%, p = 0.02. Surprisingly, there was not a correlation between Egfr expression (as determined
immunohistochemistry or fluorescence in situ hybiridzation) and response to therapy. In a 766
patient phase 3 trial of another Egfr inhibitor, Cetuximab, a mAb, surprisingly did not show
benefit when combined with gemcitabine. In conclusion, erlotinib extends life slightly by 0.3
months on a baseline of 5.9 months.
Erlotinib, in combination with gemcitabine, gives rise to more side effects than
gemcitabine alone. The side effects consist mostly of grade 1-2 diarrhea and skin rash. Patients
who received erlotinib and demonstrated a drug-induced skin rash of grade 2 or greater
demonstrated better survival. More specifically, patients who had a skin rash of grade 0, 1, or 2,
demonstrated mOS of 5.3, 5.8, and 10.5 months, and a 1-yr survival rate of 16%, 9%, and
43%.However, the patients with skin rashes were also younger and had better performance
status, thereby confounding the analysis (Stathis and Moore, 2010). In summary, the side effects
of erlotinib are less severe than that of chemotherapy. In conclusion, for the additional efficacy,
erlotinib also contributes some toxicity.
Another disadvantage besides increased toxicity is that erlotinib is less effective in Kras-
mutant tumors. In the 79% of patients who had Kras mutant tumors, the hazard ratio for erlotinib
was 1.07. Whereas in the 21% of patients who had Kras wild-type tumors, the hazard ratio was
0.66. While the difference in hazard ratio was not statistically significant due to the small
number of Kras wild-type patients, there is a clear trend toward erlotinib efficacy in Kras wild-
type tumors. Moreover, studies in colorectal and other cancer types have also suggested that Kras
mutant tumors are less likely to show a benefit from Egfr inhibitors (Siena et al., 2009). Further
studies will be needed to confirm the relation between Kras mutation status and erlotinib-
sensitivity. Yet another drawback of erlotinib is the higher cost for targeted agents than for more
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traditional chemotherapy. To summarize, erlotinib is somewhat effective against non-Kras
mutant PDACs but has some toxicity and is costly.
A recent study demonstrated that the combination of oxaliplatin, irinotecan, fluorouracil,
and leucovorin (FOLFIRINOX) is more efficacious but also more toxic than gemcitabine for
PDAC (Conroy et al., 2011). 342 patients were assigned either FOLFIRINOX or gemcitabine.
The median overall survival (mOS) in the FOLFIRINOX group was 11.1 months, while the mOS
in the gemcitabine group was 6.8 months (p-value < 0.001). The objective response rate in the
FOLFIRINOX group was 32%, while that in the gemcitabine group was 9.4% (p-value < 0.001).
The hazard ratio was 0.57 with a 95% CI of 0.45 - 0.73. Clearly, FOLFIRINOX is more
effective than gemcitabine by standard metrics of anti-tumor efficacy. Unfortunately,
FOLFIRINOX is also more toxic, as illustrated by its higher frequency of various SAEs
including neutropenia, fatigue, vomiting, diarrhea, and more (Figure 8). In summary,
FOLFIRINOX may be a suitable 1 't line therapy for patients that are willing and able to endure
more toxicity.
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Frequency of
Grade 3/4 Events
Side Effect Gemcitabine FOLFIRINOX P-Value
Neutropenia 21.0% 45.7% < 0.001
Febrile Neutropenia 1.2% 5.4% 0.03
Thrornbocytopenia 3.6% 9.1% 0.04
Aneria 6.0% 7.8% NS
Fatigue 17.8% 23.6% NS
Voriting 8.3% 14.5% NS
Diarrhea 1.8% 12.7% < 0.001
Sensory Neuropathy 0.0% 9.0% < 0.001
Bevated Alanine
Aminotransf erase 20.8% 7.3% <0.001
Thromboernbolism 4.1% 6.6% NS
Figure 8. Frequency of Serious Adverse Events (SAEs) from Gemctiabine and FOLFIRINOX Treatments
in PDAC Patients. The frequency of SAEs (Grade 3/4 Events) is indicated in each column for
gemcitabine and for FOLFIRINOX. The p-value assesses the significance of whether the frequency of
that particular SAE is different between gemcitabine and FOLFIRINOX therapy. Adapted from Conroy,
NEJM 2011.
There have been many phase 3 trials for pancreatic cancer that have combined
gemcitabine with another chemotherapeutic such as platinum compounds, topoisomerase
inhibitors, fluorouracil, or antifolates, including cisplatin, oxaliplatin, 5-FU, capecitabine,
irinotecan, exatecan, and pemetrexed. While none of these studies have individually shown a
statistically significant increase in overall survival, metaanalyses and sub-set analyses have
demonstrated a benefit for patients with good performance status. A metaanalysis of 4,000
patients across 15 studies demonstrated that there is a benefit, for patients with good
performance status, when gemcitabine is combined with platinum analogs or fluoropyrimidines,
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giving a hazard ratio (HR) of 0.91, p = 0.004 (Heinemann et al., 2008). A metaanalysis of 10,000
patients across 51 trials demonstrated that gemcitabine in combination with a platinum-based
agent or capecitabine demonstrated a statistically-significant benefit: HR of 0.85 and 0.83,
respectively (Sultana et al., 2007). Even in an individual study, healthy patients, as defined by a
Karnofsky score of 90-100, when given gemcitabine with capecitabine, demonstrated a
statistically significant improvement in mOS of 10.1 months versus 7.4 months for gemcitabine
alone. To conclude, patients with a good performance status can withstand and benefit from
combination gemcitabine therapy (Cunningham et al., 2009; Heinemann et al., 2008).
Failed therapies for metastatic disease
Many efforts have been made to enhance the efficacy of gemcitabine by combining it
with other chemotherapies (Figure 9). Several combinations with gemcitabine demonstrated
efficacy in the pre-clinical, phase I, and phase II stages. This lead to several phase III
combination studies. All but one of the trials (Gemcitabine ± Pemetrexed) show a slight increase
in overall survival when the gemcitabine combination is used. Despite having a couple to several
hundred patients in each trial, the survival difference was not large enough for a statistically
significant difference. The additional toxicity that may arise from the additional
chemotherapeutic may make the combination therapy an undesirable treatment. In summary,
many chemotherapeutic combinations with gemcitabine only slightly prolong survival, if at all,
compared to gemcitabine alone.
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OS (mos) p-Treatment Corn parison Gem. vs Com b. Value Reference
Gemcitabine ±Cisplatin 6.0 vs 7.5 0.15 Heinemann, 2006
Gemcitabine ± Cisplatin 5.0 vs 7.5 0.43 Colucci, 2002
Gemcitabine ± Oxaliplatin 7.1 vs 9.0 0.13 Louvet, 2005
Gemcitabine ± Oxaliplatin 4.9 vs 5.7 0.22 Poplin, 2009
Gemcitabine ± 5-FU 5.7 vs 6.5 0.09 Berlin, 2002
Gemcitabine ± Capecitabine 7.2 vs 8.4 0.23 Hermann, 2007
Gemcitabine ± Irinotecan 6.3 vs 6.6 0.79 Roche Lima, 2004
Gemcitabine ± Irinotecan 6.4 vs 6.5 0.97 Stathopoulos, 2006
Gemcitabine ± Exatecan 6.2 vs 6.7 0.52 Abou-Alfa, 2006
Gemcitabine ± Pemetrexed 6.3 vs 6.2 0.85 Oettle, 2005
Figure 9. Gemcitabine combinations that failed in PDAC Phase 3 Clinical Trials. Various drugs were
tested in combination with gemcitabine. The overall survival (OS) in the two treatment groups
(gemcitabine and the gemcitabine combination) is indicated. In addition, the p-value testing for a
difference between the OS of gemcitabine and the gemcitabine combination group is indicated. Adapted
from Stathis, Nat Rev Clin Onc 2010.
Marimastat is a matrix metalloproteinase (MMP) inhibitor that was studied in pancreatic
cancer. MMPs are proteolytic enzymes involved in the degradation of extracellular matrix.
Elevated levels of MMPs has been demonstrated in PDAC and has been shown to aid tumor
vascularization, invasion, and metastasis. In a 414 patient phase 3 trial comparing marimastat to
gemcitabine, patients exhibited similar 1-year survival rates when compared to gemcitabine
alone (Bramhall et al., 2001). However, in a 313 patient phase 3 trial combining marimastat with
gemcitabine, marimastat did not provide any additional benefit in overall survival (Bramhall et
al., 2002). Another MMP inhibitor, BAY 12-9566, which specifically inhibits MMP-2, MMP-3,
MMP-9, and MMP-13, was tested in a P3 trial against gemcitabine. BAY 12-9566 performed
significantly worse, as patients treated with BAY 12-9566 showed a mOS of 3.7 months, as
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compared to 6.6 months for gemcitabine (Moore et al., 2003). To conclude, MMP inhibitors
have not been effective alone or in combination for treating PDAC.
Inhibiting angiogenesis is an approach taken for pancreatic cancer, as it has been for
many other cancers. Overexpression of Vegf and its receptors, Vegfr-1, Vegfr-2, and Vegfr-3,
have been correlated with poor prognosis and metastasis (Seo et al., 2000). Bevazicumab is an
anti-VEGF mAb. In a 602 patient phase 3 trial that combined bevacizumab with gemcitabine,
bevacizumab failed to improve survival. Moreover, in a 607 patient phase 3 trial that combined
bevacizumab with gemcitabine and erlotinib, the addition of bevacizumab did not provide a
statistically significant improvement in overall survival. Axitinib took another approach to
inhibiting Vegf signaling as an oral inhibitor of Vegfr- 1, Vegfr-2, and Vegfr-3. A phase 3 trial
adding axitinib in combination with gemcitabine failed to show a survival improvement during
an interim analysis, prompting the discontinuation of the study (Spano et al., 2008). In summary,
inhibition of Vegf may have shown promising results in pre-clinical and early clinical trials, but
larger-scale trials fail to show efficacy.
Drugs in pre-clinical trials for metastatic disease
Pre-clinical trials of drugs in PDAC show promising results. Various combinations of
targeted agents against the Mapk and Pi3k pathway show incremental, additive, and synergistic
effects (definitions are described in the Figure 10 legend). These benefits are seen in cell culture,
xenograft, and orthotopic models. Many of these pre-clinical drugs have been tested in phase 3
trials and have shown poor results, including rapamycin and temsirolimus. Others are currently
in clinical trials, including NVP-BEZ235, AZD6244, and MRK003. Although much success has
been observed in pre-clinical studies, and even in early-phase trials, success in large-scale phase
3 trials is rare.
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NVP-BEZ235
mTOR/Pi3k Gemcitabine BEZ235 + Aw asthi
Chemotherapy EMAP (Endothelial 4 PDAC lines Gemcitabine J Cell Biochem,
Endothelial Monocyte Activating is additive 2011
Monocytes Polypeptide II)
BxPC3-3 (w t Kras)
Erlotinib Hs 700T (w t Kras) Erlotinib + RDEA119 &
Mek or Mek RDEA119 or MIAPaCa-2 (mut Erlotinib +in Can Res, 2011AZD6244 Kras) are synergistic
PANC-1 (mut Kras)
Mek RDEA 119 3 early passage Rapamycin + ChangMek RDEAII9primaries RDEA19Chn
mTORC1 Rapamycin pimre 21,2 is tl BMC Cancer, 2010OCIP1 9, 21, 23 is incremental
Garrido-Laguna
mTORC1 Temsirolimus 17 fresh xenografts Br J Cancer, 2010
BxPC-3 Rapamycin +
Mek AZD6244 BxPC-3 MIA PaCa- AZD6244 Chang
mTORC1 Rapanycin MIA PaCa-2 2 is incremental Can Biol Ther, 2009
R3k/mTOR NVP-BEZ235 5 early passage Caolines Br J Cancer, 2009
mTORC1 Rapamrycin . Rapamycin + Erlotinib Buck
Egfr Erlotinib 5 lines is synergistic Mol Can Ther, 2006
MRKO03 +
y-secretase MRK003 PDA C Cook
Chemotherapy Gemcitabine inctais JBM, 2012
has a greater effect than each drug individually. "Additive" is when the effect of the combination of drugs
is equal to the sum of the effect of each individual drug. "Synergistic" is when the combination of the two
drugs is greater than the sum of the effect of each individual drug.
Drugs in clinical trials for metastatic disease
Despite the many failed gemcitabine combinations, additional combinations are being
tested in clinical trials (Figure 11). Listed are some of the combinations currently in phase 2 and
3 trials. Some trials are single-arm with one treatment group, while others are randomized with
multiple treatment arms. Many of these drugs being tested in combination with gemcitabine were
originally approved for other cancer indications. Since the cost of expanding the indications of a
drug is minimal relative to launching a new drug, pharmaceutical companies are willing to
perform the clinical trial for PDAC even in the absence of very strong pre-clinical and early
clinical efficacy. Consequently, many of these gemcitabine chemotherapy combinations are
unlikely to show efficacy.
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Treatment Groups Phase #of Patients Notes Reference
Gerncitabine ± Capecitabine ± Dalteparin 3 136 Randomized, four-arms Stathis, Nat Rev Olin Onc 2010
Dalteparin + Chernotherapy 3 NR Single-Arm; for Multiple Solid Tumors Stathis, Nat Rev Clin Onc 2010
Chemotherapy ± Enoxaparin 3 NR Randonized; for Lung, Colon, Pancreas Stathis, Nat Rev Olin Onc 2010
Gemcitabine ±Dalteparin 3 400 Randomized; for Miltiple Solid Turmors Stathis, Nat Rev Clin Onc 2010
Chemotherapy + Nadroparin 3 NR Single-Arm; for Lung, Prostate, Pancreas Stathis, Nat Rev Clin Onc 2010
Germitabine + Cisplatin + Nadroparin 2 69 Single-Arm Stathis, Nat Rev Clin Onc 2010
(GeLucoorin) ±sat + 5- U + 2 540 Randomized Stathis, Nat Rev Clin Onc 2010
Gemcitabine Dalteparin 2 120 Randonized Stathis, Nat Rev Clin Onc 2010
ON
Drug Phase
AGS-1C4D4 2
Archexin 2
Bavituximab 2
GVAX 2
Capoxigem 2
CRS-207 2
GI-4000 2
GSK1120212 2
INNO-206 2
LE-DT 2
Nexavar 2
PM01183 2
Reolysin 2
Revlirid 2
Selumetinib 2
TH-302 2
Abraxane 3
Ganitumab 3
GV1001 3
HyperAcute 3
Masitinib 3
PEP02/MM-398 3
S-1 (Japan/Taiwan Only) 3
Estybon 3
Nimotuzumab 3
Clivatuzumab 3
Figure 12. Ongoing PDAC Clinical Trials with Targeted Agents. Drugs currently in phase 2 or 3 clinical
trials for PDAC are listed.
In addition to chemotherapy combination therapies, targeted agents are also being tested
for PDAC (Figure 12). Some of these drugs are being tested for indication expansion, similar to
the chemotherapy compounds mentioned above. Other drugs were originally developed for
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PDAC and are being tested accordingly. While many targeted compounds have failed in the past,
these new agents provide hope for an efficacious PDAC therapy.
One particularly promising compound is CO- 101, a lipid-conjugated form of
gemcitabine, which is being developed by Clovis Oncology. Gemcitabine and other nucleoside-
based drugs such as capecitabine, cladribine, and fludarabine, require nucleoside transporters
such as human equilibrative nucleoside transporter 1 (hENTI) to get into cells. The lipid-
conjugation allows gemcitabine to enter tumor cells without having to go through hENT1.
As expected, hENT1 correlates inversely with survival for patients treated with
gemcitabine. Patients with lower levels of hENT 1 have worse survival than those with higher
levels of hENT 1, as less gemcitabine is able to enter and inhibit the tumor cells. Low levels of
hENTI is present in 40-60% of pancreatic cancer patients. Patients treated with therapies that are
not transported by hENTI, such as 5-FU, do not show a correlation between survival and levels
of hENT1.
CO-101 is in an ongoing pivotal phase 2/3 trial for first-line metastatic PDAC. CO-10 1
is also in a phase 2 trial for second-line cancer that failed gemcitabine and show low levels of
hENT1. In a phase 2 trial, patients with low ENTI levels who took CO-101 showed a median
survival of 9.1, while those who took gemcitabine showed a median survival of 3.3 months. To
summarize, CO- 101 is a promising new form of gemcitabine that may be particularly effective
for PDAC patients with low levels of hENT 1.
Targeting! the Kras oncogene
The importance of Kras in pancreatic cancer has been established in various systems.
Studies with a Kras dominant negative mutant have illustrated the important of Kras in advanced
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PDAC (Hirano et al., 2002). RNAi knockdown studies have provided additional evidence in
PDAC (Brummelkamp et al., 2002; Fleming et al., 2005). Since Kras is arguably one of the most
well characterized oncogenes and is mutant in over 90% of PDACs, it is not surprising that it is
necessary for the survival of PDACs.
A post-translational modification, prenylation, or more specifically protein famesylation
and geranylgeranylation, is required for the oncogenic activity of Kras (Jackson et al., 1990).
Famesylation is the addition of a 15 carbon chain, while geranylgeranylation is the addition of a
20 carbon chain. Moreover, many of the pathways through which Kras signals also require
prenylation for activity. To summarize, post-translational modifications of Kras are necessary for
it to maintain its function.
Famesylation can be inhibited by preventing the carboxy-terminal CAAX motif of Ras
from binding to famesyltransferase. To do this, CAAX peptidomimetics can be introduced that
will bind up the famesyltransferase, preventing the famesyltransferase from acting on Ras.
Another approach is to introduce compounds that compete with the famesyl pyrophosphate
group. A more recent approach is to combine CAXX and famesyl pyrophosphate mimietics in a
single compound, thereby inhibiting famesylation through two separate mechanisms. These
drugs are known as bisubstrate analogues. Since famesylation is necessary for the function of
other proteins, inhibiting famesylation may be toxic to the organism. In summary, preventing
prenylation may inhibit Kras function and PDAC development, but may also have deleterious
side effects.
Prenylation is necessary for many proteins to carry out their biological function (Cox et
al., 1992; Yang et al., 2000). From a physiological perspective, prenylation is necessary for
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normal development of mamals. More specifically, prenylation allows for membrane localization
of an otherwise cytosolic protein. In non-tumorgenic conditions, several hundred proteins are
estimated to be prenylated (Perez-Sala, 2007). Consequently, inhibition of prenylation is likely to
have notable side effects.
Embryonic deletion of the catalytic p-subunit of farnesyltransferase (FNTB) results in
embryonic lethality, suggesting that proper prenylation is required for embryogenesis (Mijimolle
et al., 2005). On the contrary, deletion of FNTB in the adult mouse only results in slight
abnormalities in would healing and liver regeneration. Therefore, the administration of a
farnesyltransferase inhibitor (FTI) to an adult patient may not have excessive toxic effects. A
caveat to the above mentioned study is that the designed frameshift mutation did not actually
give rise to a null allele of Ftnb as expected. Rather, Fntb protein was produced with a short in-
frame deletion (Yang et al., 2009). This mutated Fntb may still be able to carry out some Fntb
functions, raising questions about the non-essential nature of Fntb in the adult system. In
summary, inhibiting famesyltransferase may be a potential therapeutic strategy although it may
be excessively toxic. Another protein that induces prenylation is a geranylgeranyltransferase.
More proteins are geranylgeranylated than those that are farnesylated, suggesting that
geranylgeranyltransferase inhibitors may be even more toxic than FTIs (Reid et al., 2004). In
brief, FTIs and GGTIs may be effective, but excessive toxicity is a potential concern.
FTIs are effective at inhibiting tumor growth in pre-clinical studies in vitro and in vivo.
The promising pre-clinical results inspired hope that FTIs would be effective against the 20% of
cancers that carry Ras mutations. FTIs inhibit xenograft growth of cancer cell lines with various
genetic alterations including Kras, p53, and CDKN2A mutations (Sun et al., 1995). Since FTIs
were effective in cancers without Kras mutation, this suggests that FTIs are inhibiting tumor
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growth by acting on pathways besides Kras. FTIs generally inhibit tumor proliferation in the cell
cycle phase of mitosis at prometaphase by preventing bipolar spindle formation and chromosome
alignment (Crespo et al., 2001). FTIs induce tumor regression in transgenic mutant Hras models
(driven by the MMTV promoter) with little general toxicity. In contrast, FTIs only induce tumor
growth inhibition in transgenic mutant Kras models and wild-type Nras overexpression models
(Mangues et al., 1998; Omer et al., 2000). Unfortunately, cancers primarily harbor Kras or Nras
mutations, not Hras alterations. In the presence of FTIs, Kras and Nras were no longer
farnesylated, but they became geranylgeranylated. Nevertheless, FTIs were generally effective in
pre-clinical models. In certain cancer types, FTIs may induce apoptosis. FTIs cause apoptosis in
breast cancer mouse models that exhibit transgenic mutant Hras and express Myc or lack p53
(Kohl et al., 1995). In contrast, FTIs merely inhibit tumor progression in Erbb2 transgenic breast
cancer models (Barrington et al., 1998). Since FTIs were phenotypically effective, despite not
successfully inhibiting their designated targets Kras or Nras, FTIs were moved along into clinical
trials.
Genetic inhibition of famesyltranferasecan also inhibit tumor progression in pre-clinical
models. In a Kras G12V -driven GEMM of lung adenocarcinoma and a carcinogen-induced mouse
model of skin cancer, deletion of the catalytic p-subunit of famesyltransferase (FNTB) inhibited
tumor progression (Mijimolle et al., 2005). Additionally, in a Kras G12D -driven GEMM of lung
cancer, conditional deletion of FNTB inhibited lung tumor formation (Liu et al., 2010b). In
summary, FT is a validated target from both pharmacological and genetic studies.
Even though FTIs do not inhibit Kras prenylation, FTIs can inhibit downstream Kras
signaling. FTIs inhibit Pi3k-Akt signaling in certain contexts such as ovarian and pancreatic
cancer lines that overexpress Akt (Jiang et al., 2000). In other contexts, such as lung cancer lines
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with low p-Akt, FTIs do not affect Akt signaling yet induce apoptosis, suggesting that there are
other pathways through which FTIs act (Sun et al., 2004). FTIs given to 3T3 cells with mutant
Hras inhibit the farnesylation of Hras, in contrast to Kras farnesylation. Consequently, Hras does
not translocate to the membrane or activate the Mapk pathway (Lerner et al., 1995). In summary,
FTIs can inhibit Ras downstream effector signaling despite not affecting Kras prenylation.
While FTIs have been efficacious in pre-clinical studies, clinical studies have shown
weak results. Four FTIs (tipifamib, lonafarnib, BMS-214662, and L-778123) have been
evaluated in 64 clinical trials. 35 of the trials were phase I, while 29 were phase II or III. 18 of
the 64 trials showed no objective response. 23 of the 64 trials showed little antitumor activity
with an ORR (objective response rate) of less than 15%. The median ORR for FTI monotherapy
is 2.3%.In summary, monotherapy with FTIs has shown limited activity in both hematologic and
solid tumors (Berndt et al., 2011). As illustrated, only a very small group of patients receive any
benefit from FTIs. Additional studies have been performed with two FTIs, tipifarnib and
lonafarnib, which were tested in phase III trials for pancreatic, colon, non-small cell lung cancer,
and AML (Harousseau et al., 2009; Rao et al., 2004). Unfortunately, none of the trials showed a
benefit. In trials for various solid tumors and acute myeloid leukemia, FTIs failed to significantly
improve survival (Harousseau et al., 2009; Rao et al., 2004; Tran et al., 2011; Van Cutsem et al.,
2004). To determine whether the patients who are benefitting are benefitting from on-target
efficacy of the FTI, FT activity was measured by the prenylation status of marker proteins, most
commonly Hdj2 (also known as prelamin A). Inhibition of prenylation of Hdj2 did not correlate
with clinical response, suggesting that the on-target effect of the FTI was unlikely responsible for
the clinical response. In summary, FTIs are not only ineffective clinically but are not acting
through their expected mechanism of action.
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Upon more careful examination of the clinical trials, FTI treatment benefitted a subset of
patients with hematological malignancies. To identify patients that are likely to be responsive, a
two-gene expression signature has been developed for AML patients who are likely to respond to
tipifamib, a FTI (Raponi et al., 2007). In addition, some early trials on leukemia have shown
promising results (Cortes et al., 2003). It is unclear why certain tumors are responsive to FTI
treatment while others are not. In summary, FTIs failed in many large-scale phase III clinical
trials, but subsets of patients were sometimes responsive.
There are multiple potential reasons for the different results observed in pre-clinical
versus clinical studies. While many of the preclinical studies studied Hras farnesylation, it is
Kras that is often mutated in human cancers. In contrast to Hras, Kras can be geranylgeranylated
if FTIs were given to inhibit famesylation (Rowell et al., 1997; Whyte et al., 1997).
Geranylgeranylation is sufficient for Kras to carry out its cellular function. Another potential
explanation is that most of the patients in the clinical trials had advanced or metastatic disease.
Inhibition of Kras in this later stage of cancer may not be as effective. Yet another possible
reason is that FTIs do not actually inhibit Ras prenylation. While FTIs were originally developed
to inhibit famesylation of Ras, tumor growth inhibition by FTIs have not correlated with
mutations in Ras in multiple settings (cells, animal models, and human patients) (End et al.,
2001; Sepp-Lorenzino et al., 1995). Since FTIs are effective at inhibiting Kras-mutant tumors in
nude xenografts and GEMMs, other farnesylated proteins are likely responsible for this response
(Kohl et al., 1994; Omer et al., 2000). There are greater than 100 proteins that have been
experimentally shown to be prenylated (Lane and Beese, 2006). To conclude, there are multiple
potential reasons why FTIs may not have been effective in clinical trials for Kras-mutant
cancers.
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Despite its failure as a treatment, FTI inhibition may be a potential cancer-prevention
strategy. When mice were given dietary fish oil, which contains high levels of omega-3
polyunsaturated fatty acids, farnesyltransferase activity and colon cancer formation were
inhibited (Singh et al., 1998). This is consistent with the opposing finding that
famesyltransferase (FT) activity is elevated in human colorectal adenocarcinoma (Caruso et al.,
2003). Inhibition of FT does not seem toxic at certain levels and may be a suitable
chemoprevention strategy (Lantry et al., 2000; Zhang et al., 2003). In conclusion, FTIs may be
efficacious as a preventative measure.
After FTIs failed in many clinical trials, GGTIs were developed since Kras (specifically
the alternatively-spliced Kras4B variant) and Nras became geranylgeranylated after FTI
treatment (Rowell et al., 1997). GGTIs may be particularly effective as RalA and RalB, key
mediators of pancreatic cancer development, require geranylgeranylation for activity.
Additionally, other genes involved in Ras-dependent tumorgenesis that are exclusively
geranylgeranylated (as opposed to having other types of prenylation) include Cdc42, Rac 1, ,
Rhob, and Rhoc (involved in metastasis) (Clark et al., 2000) (Prendergast, 2001). GGTIs
generally arrest cells during the G1 phase of the cell cycle by inducing expression of Cdk
inhibitors (p21 and p27), inhibiting Cdk2 and Cdk4 activity, and dephosphorylating Rb (Sun et
al., 1999; Vogt et al., 1997) . In cell lines and animal models, GGTIs have shown promising
results. Unfortunately, in clinical trials, the combination results in excessive toxicity, so further
development has been halted (Lobell et al., 2001).
In addition to pharmacological inhibition, genetic inhibition of GGT has been effective
in preclinical models. In a KrasG2D -driven GEMM of lung adenocarcinoma, conditional genetic
deletion of the GGT1 catalytic p-subunit (PGGT1B) inhibited lung tumor formation (Sjogren et
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al., 2007). Since Kras, in the absence of geranylgeranylation, can be farnesylated, the efficacy of
GGT1 deletion is due to defective prenylation of other targets such as RalA and RalB (Sjogren et
al., 2011). Conditional deletion of both catalytic p-subunits of FT and GGT resulted in more
substantial inhibition of tumor formation than either deletion alone, suggesting that the
combination of FTIs and GGTIs may be effective (Liu et al., 201 Ob). More importantly, the
lifespan of the mice were substantially extended. The preclinical evidence supports further
development of combination FTI and GGTI therapy.
FTIs are effective in combination not only with GGTIs but chemotherapeutics. In cell
culture studies, FTIs have enhanced the anti-proliferative and anti-apoptotic effects of various
therapies including radiation, taxanes, cisplatin, 5-fluorouracil, Mek inhibitors, Cdk inhibitors,
and Bcr-Abl inhibitors (Bernhard et al., 1996; Moasser et al., 1998). In xenograft experiments,
FTIs have enhanced the anti-tumorigenic effects of cyclophosphamide, 5-fluorouracil,
vincristine, paclitaxel, cisplatin, and gemcitabine (Liu et al., 1998; Shi et al., 2000). A
particularly effective combination was tipifamib and triciribine phosphate, an inhibitor of Akt, in
an Erbb2-transgenic breast cancer mouse model (Balasis et al., 2011; Berndt et al., 2010). The
combination caused tumor regression, while each agent alone was ineffective. To summarize,
pre-clinical models demonstrate that FTIs are effective in combination with chemotherapeutics.
In clinical trials, FTIs in combination with chemotherapy did not perform as expected.
When FTIs were used in combination with carboplatin, paclitaxel, or gemcitabine, the median
ORR was 11.4%, which is not considered effective (Van Cutsem et al., 2004). Two FTIs,
tipifamib and lonafarnib, were tested in combination with carboplatin, paclitaxel, or gemcitabine
in phase III trials for pancreatic, colon, non-small cell lung cancer, and AML (Harousseau et al.,
2009; Rao et al., 2004). Unfortunately, not a single one of the trials showed a benefit. In a phase
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III trial of 688 pancreatic cancer patients, comparing Tipifarnib + gemcitabine with gemcitabine
alone, there was no significant difference in overall survival, PFS, or objective disease response
(Van Cutsem et al., 2004). Some possible explanations for the lack of activity include 1)
insufficient inhibition of Kras famesylation in the tumor cells 2) the tumors had become Kras
independent as additional genetic mutations were acquired 3) additional post-translational
modifications were occurring to Kras, such as geranylgeranylation, that allowed for Kras
activation without farnesylation (Lobell et al., 2001). On the contrary, FTI with chemotherapy
benefitted those with locally advanced breast cancer and certain other types of solid tumors
(Adjei et al., 2003; Siegel-Lakhai et al., 2005; Sparano et al., 2009; Sparano et al., 2006). In
general, FTI in combination with chemotherapy has not been effective in clinical trials, but for
certain subsets, there may be a benefit.
Another approach to inhibiting Ras is antisense inhibition of Ras itself. Antisense
inhibition involves the introduction of a short antisense synthetic oligonucleotide that is specific
for a particular sequence in the mRNA of the target gene (Crooke, 2000). Upon binding to the
cRNA, the oligonucleotide inhibits protein production through two methods: 1) binding
promotes degradation of the mRNA by prompting RNaseH to the RNA-DNA duplex; 2) binding
interferes with translation of the mRNA. ISIS Pharmaceuticals has designed stabilized
phosphorothioate derivatives of oligonucleotides that effective inhibit Kras (ISIS6957), Hras
(ISIS2503), and c-Rafl (ISIS5132) in cell culture (Chen et al., 1996; Monia et al., 1996). In
Kras-mutant lung xenograft models, the Hras and c-Rafl oligonucleotides surprisingly reduced
tumor growth (Mukhopadhyay et al., 1991). Although the Hras oligonucleotide targeted Hras as
opposed to Kras, it still had an effect Although c-Rafl is a member of the Raf family and is a
component of the Mapk signaling pathway, the primary Raf family member involved in cancer
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signaling is Braf. Braf can substitute for part of the function of c-Rafl and activate Mapk
signaling. Despite this substitution, inhibition of craf was still effective in the pre-clinical lung
model. A general challenge to antisense inhibition is the delivery of these oligonucleotides to the
cancer cells and the subsequent uptake. Another difficulty is the non-specific toxicity that these
oligonucleotides have demonstrated. The Kras, Hras, c-Rafl, have been tested in clinical trials,
but all further development was halted due to lack of efficacy or excessive toxicity. In
conclusion, targeting Kras has not been an efficacious strategy for cancers as illustrated by the
late-stage clinical trial failures
Kras and its Effector Pathways
Kras
The Ras family of GTPases consists of Hras, Nras, and Kras. Ras proteins are members
of a superfamily of low-molecular-weight GTP-binding proteins. Hras, Kras, and Nras are
widely expressed, with Kras being expressed in almost all cell types. Hras and Nras are not
required for development, as illustrated by knockout studies. In fact, knockouts deficient for both
Hras and Nras can survive. In contrast, Kras is required for mouse embryogenesis (Johnson et
al., 1997). Different members of the Ras family interact with slightly different effector pathways.
Post-translational modifications of Ras are required for its function (Seabra, 1998). Ras is first
famesylated, where a franesyltransferase catalyzes the transfer of a 15-carbon isoprenoid chain
from famesyl pyrophosphate to Ras. In the presence of farnesyltransferase inhibitors (FTIs),
Kras and Nras bypass the inhibition by being geranylgeranylated. Geranylgeranyltransferase
catalyzes the addition of a 20-carbon isoprenyl chain. In contrast, Hras is not geranylgeranylated
even in the presence of FTIs. After farnesylation, an endopeptidase removes the last three amino
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acids from the carboxyl terminus of Ras. Subsequently, the carboxyl terminus is methylated by a
methyltransferase. For Hras and Nras, one more step occurs afterwards where a
palmitoyltransferase catalyzes the addition of two palmitoyl long-chain fatty acid chains. These
post-translational modifications stabilize the interaction between Hras/Nras and the membrane.
To summarize, Kras is critical for mouse embryogenesis and requires post-translation
modifications for its function.
Ras proteins were first identified as oncogenes hijacked from the host genome by
integrating Kirsten and Harvey rat sarcoma retroviruses (Barbacid, 1987). The Ras family is
critical in development, as they are conserved across various organisms including yeast, slime
mould, worms, flies, frogs, and man (Campbell et al., 1998). 20% of all tumors contain an
activating point mutation in one of the Ras proteins (Bos, 1989). Of the tumors containing a Ras
mutation, 85% are in Kras, 15% are in Nras, and less than 1% is in Hras. Kras is most commonly
mutated in pancreatic cancer, followed by colorectal and lung cancer (Figure 13). Pancreatic,
colorectal, and lung cancer are the 4th 2 nd and Ist most lethal cancers (as measured by the
number of deaths each year). The point mutations in Kras almost always occur in codons 12, 13,
or 61. In summary, Kras is frequently altered in some of the most lethal cancers.
Ras proteins regulate cellular functions including proliferation, differentiation, apoptosis,
invasion, and angiogenesis. When Ras is bound to GTP, it is active. When bound to GDP, Ras is
inactive. The inherent GTPase activity in Ras will cleave GTP and convert it into GDP (Bourne
et al., 1990; Field et al., 1987). Point mutations in Ras that give rise to cancer cause Ras to
accumulate in the GTP-bound, active form. GTP-bound Ras will bind to effectors and induce
downstream signaling. GDP-bound Ras will not interact with the effectors. Consequently, Ras is
not constitutively activated but rather is automatically inactivated after a period of time.
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Subsequently, the GDP in GDP-bound Ras will dissociate, allowing GTP to bind, and the
process repeats itself. The overall activity of Ras is controlled by the ratio of GTP to GDP and by
guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). The Ras
family signals through various downstream effector pathways.
Freq of KrasTumor Type Mutation
Pancreatic 72 - 90%
Colorectal 32 - 57%
Lung 15-50%
Endometrium 5 - 50%
Gallbladder 14 - 38%
Multiple Myeloma 16 - 33%
Testicular 9 - 12%
Figure 13. Frequency of Kras mutation in Various Tumor Types. Adapted from Friday, BBA Revs 2005.
There are several Ras GEFs that have been identified. The best characterized are SOSI
and SOS2, the mammalian homolgoues to the drosophila's son of sevenless gene. SOS1 and
SOS2 are regulated by Egfr. Activation of receptor tyrosine kinase (such as Egfr) results in
activation of Grb2, which binds to SOS1/2, recruiting SOS to the plasma membrane. Once at the
plasma membrane, SOS can bind to Ras, promoting the release of GDP. Since GTP is at a higher
concentration in the cytosol, the released GDP is oftentimes replaced by GTP. Other receptors
and adaptor proteins are involved in GEF activation, including G-protein-coupled receptors and
SHC, respectively. On the other hand, there are at least 6 different Ras GAP proteins. Less work
has been done on Ras GAPs. One GAP is neurofibromin (Nfl), a tumor suppressor (Weiss et al.,
1999). In patients with type I neurofibromatosis, one allele of NF1 is lost in the germline.
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Subsequent loss of the additional NF 1 allele give rise to neural-crest derived tumors with
activated Ras. The balance between GEFs and GAPs help regulate Ras activity.
A recent study in 2012 demonstrated, in a genetically engineered mouse model (GEMM)
of pancreatic cancer, that Kras is necessary for both the initiation and maintenance of pancreatic
cancer (Collins et al., 2012). The study used a mouse transgenic for an inducible allele of Kras,
TetO-KraSG12D. The model was designed to allow for pancreas-specific and reversible expression
of oncogenic Kras. A pancreas-specific promoter (p48 or Ptfl a) that drives Cre expression is
used to activate rtTA, which is located in the Rosa26 locus and expressed constitutively in all
cell types. Consequently, rtTA is only expressed in pancreas-specific cells. Subsequent
administration of doxycycline will activate rtTA and expression of transgenic Kras G12Din
pancreatic cells. Discontinuation of doxycycline will cease expression of KrasG12D. The study
demonstrates that the combined activation of Kras G12D and loss of one allele of p53 is sufficient
to induce PanIN development and subsequent PDAC formation. The tumors that form resemble
the human disease and the previously published Pdxl-Cre; LSL-Kras G12D/+; LSL-p53R172H/+
mouse model of PDAC. After tumor formation, discontinuation of KrasG12D expression inhibits
continued tumor formation. A caveat is that KrasG12D is being overexpressed, in contrast to
GG12Dhuman PDAC tumors, where KrasG2 is likely eXpressed at normal, endogenous levels.
Consequently, the PDAC in the GEMM may be particularly dependent on Kras G12D. In summary,
this study supports the knowledge that continued expression of KrasG12 D is likely necessary for
the maintenance of PDAC.
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Gene Reference Paper Name
Kras Mol Cancer Res, 2005 Molecular consequences of silencing mutant k-ras in pancreatic cancer cells: justification for k-ras directed therapy.
Akt2 PNAS, 1996 Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.
Egfr Cancer Res, 2000 Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
3k Cancer Res, 2000 Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Mekk1 Oncogene, 2002 Dominant negative NEKK1 inhibits survival of pancreatic cancer cells.
Erbb2 Oncogene, 2003 Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.
Igf-1R Cancer Res, 2003 Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
Ksr1 Nature Med, 2003 Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer.
NfKb Clin Cancer Res, 2003 Function of nuclear factor KB in pancreatic cancer metastasis.
Stat3 Oncogene, 2003 Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.
Myc Oncogene, 2004 The PI 3-kinase/akt signaling pathw ay is activated due to aberrant pten expression and targets transcription factors nf-Kb and c-myc in pancreatic cancer cells.
Mek& Kp
p27 Kp Cancer Res, 2005 Pharmacologic inhibition of raf->mek->erk signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27K
Biochem and
mTOR Biophys The rapamycin analog cci-779 is a potent inhibitor of pancreatic cancer cell proliferation.
Res Comm, 2005
RaIA & RaIB Current Bio, 2006 Divergent roles for rala and raib in malignant growth of human pancreatic carcinoma cells.
Mek & Egfr \ol Cancer Ther, 2007 Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Mirk Cancer Res, 2007 The survival kinase Mirk/Dyrk1 B is a dow nstream effector of oncogenic k-ras in pancreatic cancer.
Ezh2 Clin Cancer Res, 2008 Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransf erase enhancer of zeste homologue 2.
Mek& Cancer Letters, 2008 Mek inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth.ImatinibI
Figure 14. Genes Important in PDAC. Pre-clinical studies with drugs and genetic studies in models have
identified a variety of genes that are important in PDAC. Inhibition of these genes by genetic or
pharmacological methods have implicated their importance in PDAC.
Many studies in in vitro and in vivo mouse systems have been performed to identify
genes that are important in PDAC (Figure 14). Inhibition of the genes listed in Figure 14 by
genetic or pharmacologic methods results in the slowing down or regression of PDAC
development. Some of these genes are in canonical Kras effector pathways, including Akt2,
Pi3k, Mek, mTOR, RalA, and RalB. The canonical pathways are illustrated in Figure 15. Some
of the targets are being further pursued in clinical trials, i.e. Akt, Egfr, Pi3k, Igf-1R, Mek, and
mTOR. Although many studies have shown promising pre-clinical results, later phase clinical
trials generally do not show drug efficacy.
77
Araf Braf Craf
~I2
Mek1 Mek2
Erk1 Erk2
I
p110a p110p p110y p1105
p85a p85p
Akt1 Akt2 Akt3
eNOSmTOR I k
Raptor
Rictor
NfKBP-3
RaIGDS RGL1
RGL2 RGL3L1
R_
Se05 RaBP1
Tbk1 Exo84
Figure 15. The Canonical Effector Pathways Downstream of Kras. The canonical effectors include the
Mapk, Pi3k, and Ral pathways.
Mapk
Historically, the first identified Ras effector arm is the Mapk signaling pathway (Moodie
et al., 1993; Warne et al., 1993). Mapk signaling is involved in various cellular processes
including growth, differentiation, inflammation, and apoptosis (Roux and Blenis, 2004). The
Mapk pathway is activated in 30% of human tumors, as determined by elevated levels of
phospho-Erkl/2 (Hoshino et al., 1999). The Mapk pathway can be activated by Kras signaling or
by mutations in the Mapk pathway itself. Braf is mutated in 70% of melanomas and 15% of
colon cancers. Mutations in BRAF occur in a particular few residues in the kinase domain,
resulting in constitutive kinase activation. Moreover, Raf and Mek have been demonstrated to be
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capable of transforming rodent fibroblasts (Rapp et al., 1983). In summary, elevated Mapk
signaling is often observed in cancer.
The Mapk pathway begins with the Raf family of proteins including A-Raf, B-Raf, and
C-Raf. Ras binds to the Raf family of serine/threonine kinases, relocating them to the membrane.
At the membrane, Raf gets phosphorylated and activated (Fabian et al., 1994; Marais et al.,
1998). Activated Raf phosphorylates and activates mitogen-activated protein kinase kinases 1
and 2 (Meki and Mek2). Mekl/2, in turn, phosphorylates and activates extracellular signal-
regulated kinases 1 and 2 (Erkl/2), which are also known as the mitogen-activated protein
kinases (Mapk) (Crews and Erikson, 1993). Erkl/2 then phosphorylates target proteins in the
cytosol and the nucleus. One set of targets is the ETS family of transcription factors, including
Elk 1, which regulates the expression of Fos. Another target is c-Jun, leading to activation of the
AP 1 transcription factor (Yordy and Muise-Helmericks, 2000). These activated transcription
factors can go on to induce expression of cell-cycle regulatory proteins such as D-type cyclins.
D-type cyclins promote cell cycle progression through the GI phase (Pruitt and Der, 2001).
Inhibiting the Mapk pathway suppressors PDAC development. Inhibiting Mapk through
dominant negative mutants or inhibiting the upstream molecule, Mek, by pharmacological
inhibitors results in reduced proliferation of PDAC cell lines and cell cycle arrest. Kinase
suppressor of RAS (Ksr) is a scaffolding protein that is required for the activation of the Mapk
pathway. Inhibition of Ksr by antisense inhibits proliferation, soft-agar growth, invasion, and
xenograft growth of PDAC cell lines (Xing et al., 2003). In summary, pre-clinical studies suggest
that the Mapk pathway is important for tumor survival.
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Target Inhibitor Phase Company Indication(s) Reference
Raf
BrafV6 00 E RAF-265 1 Novartis
Vegfr-2 Solid Turmors Chappell, Oncotarget 2011
Raf Exelixis/
BrafV600E BMS Solid Tumors Chappell, Oncotarget 2011
Raf Rexxikon/
BrafV6 00 E PLX-4032 1 Roche Solid Tumors Chappell, Oncotarget 2011
Mek XL-518 1 Exelixis Solid Tumors Chappell, Oncotarget 2011
Mek Selumetinib/ AZD-6244/ 1/2 Astra Zeneca/ARRY-142886 Array BioPharma Solid Tumors Chappell, Oncotarget 2011
Mek RDEA-119/ 1/2 Ardea/BAY-869766 Bayer Solid Tumors Chappell, Oncotarget 2011
Figure 16. Mapk Inhibitors in Clinical Trials for Cancer. Inhibitors targeting genes in the Mapk pathway
are described in the table along with the phase of the clinical trial, the maker of the drug, and the targeted
indication.
Much effort has been placed into developing Mapk inhibitors for cancer (Figure 16).
Many of these inhibitors are in clinical trials for cancer. The inhibitors either target Mekl/2 or
Braf, including the common V600E mutation observed in Braf. PD98059 and U0126 are non-
ATP-competitive Mek inhibitors (Dudley et al., 1995; Favata et al., 1998). They inhibit Erk
activation and reduce proliferation, survival, and motility of some cancer cell lines. However,
over time they have been retired to research purposes as they demonstrate non-optimal clinical
characteristics. Another protein often targeted by pharmaceutical companies is c-Rafl. Raf
inhibitors can inhibit growth of Ras-transformed tumors in soft-agar and nude mice (Lyons et al.,
2001). BAY43-9006 is an oral ATP-competitive inhibitor of c-Rafl, with some inhibition of
Braf (Lyons et al., 2001). BAY43-9006 inhibits Erk activation in Ras and Braf mutat cell lines,
most notably in melanomas (Davies et al., 2002). In summary, much news will likely arise from
these Mapk-targeting compounds.
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Pi3k
The second best characterized Ras effector arm is the Pi3k signaling pathway. Ras
physically binds to the catalytic subunit of type I phosphatidylinositol 3-kinases (PI3Ks) Pi3k
plays a role cell survival and proliferation (Castellano and Downward, 2010; Vivanco and
Sawyers, 2002). It converts phosphatidylinositol (4,5)-bisphosphate (PIP2 ) into
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 binds to many proteins through the
pleckstrin homology domain. These proteins include Akt (also known as Pkb) and Pdkl (3-
phosphoinositide-dependent protein kinase- 1). Activated Akt phosphorylates several downstream
proteins, driving cell growth, cell cycle entry, and cell survival (Cantley, 2002). Pdk1, a kinase,
activates many protein kinases in the AGC family, including Akt, some Pkcs, p70s6k and Rsk.
Pi3k also activates Rac, a Rho family protein that regulates the actin cytoskeleton and
transcription factor pathways including NfKb. One of these downstream targets is Rac, which is
involved in cytoskeletal reorganization. In summary, Pi3k is a critical signaling arm downstream
of Ras.
The Pi3k family can be divided into three classes (I, II, and III) based on their structure
and substrates (Fruman et al., 1998). Class I enzymes are those directly activated by cell surface
receptors. Class I Pi3ks can be further divided into class IA and IB enzymes. Class IA enzymes
are activated by RTKs, GPCRs, Ras, and other oncogenes. Class IB enzymes are exclusively
regulated by GPCRs.
Class IA enzymes are heterodimers that consist of a p110 catalytic subunit and a p85
regulatory subunit. The regulatory subunit binds to the receptor, localizes the enzyme, and
activates the enzyme. The regulatory subunits are PIK3R1, PIK3R2, and PIK3R3, which encode
p85a, p85p, and p55y, respectively (Bader et al., 2005). Collectively, these regulatory subunits
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are known as p8 5 . P85 interacts with receptors through two primary methods: 1) binding to the
tyrosine phosphate motif on the intracellular portion of activated receptors. 2) binding to adaptor
proteins associated with the intracellular portion of the receptor. The former method is observed
for platelet-derived growth factor receptor, while the latter method is used by insulin receptor
substrate 1. Upon binding of p85, the p110 catalytic subunit converts PIP 2 to PIP 3, and PIP3 goes
on to activate multiple downstream signaling pathways.
Class IB enzymes are heterodimers that consist of the p11 Oy catalytic subunit and one of
the following regulatory subunits p101, p84, or p87 (Voigt et al., 2006). p1 I 0 y is directly
activated by GPCRs (Katso et al., 2001). p1 Oy is primarily expressed in leukocytes, but also
expressed in the heart, pancreas, liver, and skeletal muscle (Chang et al., 2007).
Class IL and ILL Pi3ks have not been clearly implicated in cancer. Class II Pi3ks consist of
a single catalytic subunit that uses phosphatidylinositol or phosphatidylinositol-4-phosphate
(PtdIns4P) as substrates (Bader et al., 2005). Class II Pi3ks can be activated by RTKs, cytokine
receptors, and integrins, but their specific cellular functions are unclear. Class III Pi3ks consist of
a single catalytic subunit, VPS34. VPS34 produces Ptdfns3P, which is involved in membrane
trafficking (Engelman et al., 2006). Further studies will be needed to clarify the role of Class III
Pi3ks in cancer.
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Target Inhibitor Phase Company Indication(s) Reference
P3k BKM-120 2 Novartis Endometrial Holmes, NRDD 2011
CLLPi3k GS-1101 2 Gilead NHL Holmes, NRDD 2011
Pi3k (a,y,6) PX-866 2 Oncothyreon Brain Holmes, NRDD 2011
Pi3k SAR-245408 2 Sanofi Endometrial Holmes, NRDD 2011BreastHomsNDD21
Pi3k XL-147 1 Exelixis Solid Tumors Liu, NRDD 2009
Pi3k GDC-0941 1 Genentech Solid Tumors Liu, NRDD 2009
Pi3k (6) CAL-101 1 Calistoga Liquid Tumors Liu, NRDD 2009
Pi3k, Akt, Pdk-1 AR-12 1 Arno Solid Tumors Chappell, Oncotarget 2011
Multiple Myeloma
Akt Perifosine 3 Keryx Colorectal Holmes, NRDD 2011
Cancer
NSCLC
Akt MK-2206 2 Merck Haematological Holmes, NRDD 2011
Cancer
Akt, S6k XL-418 1 Exelixis Solid Tumors Liu, NRDD 2009
A R-67/
Akt DB-67 1/2 Arno Solid Tumors Chappell, Oncotarget 2011
Ak1/2/3 GSK-690693 1 GSK Liquid Tumors Chappell, Oncotarget 2011
Figure 17. Pi3k Inhibitors in Clinical Trials.
including both the Pi3k and Akt genes.
Depicted are inhibitors that target the Pi3k pathway,
While the Pi3k pathway can be activated by activated Kras, it can also be activated by
mutations in the Pi3k pathway. Phosphate and tensin homologue (Pten) is deleted in 30-40% of
human tumors, making it the second most commonly mutated tumor suppressor after p53
(Bellacosa et al., 1995). Pten is a lipid phosphatase that dephosphorylates the 3' phosphate on
Ptdlns(3,4,5)P 3, converting it into Ptdlns(3,4)P 2. In addition, P110aX is amplified in a small
fraction of ovarian cancers, and AKT2 is amplified in ovarian and breast cancer (Simpson and
Parsons, 2001). To conclude, there are many ways the Pi3k pathway can become activated.
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Inhibiting the Pi3k pathway is likely effective against PDAC. Inhibition of Akt by
antisense oligonucleotides reduces the growth rate of PDAC lines (Cheng et al., 1996).
Moreover, small molecule inhibition of Pi3k in PDAC cell lines reduces proliferation, sensitizes
to chemotherapy, and promotes TNFa-induced apoptosis (Ng et al., 2000; Perugini et al., 2000;
Shah et al., 2001). Nfkb, a downstream component of Pi3k, is upregulated in PDAC cell lines
and tissue samples (Chandler et al., 2004; Wang et al., 1999). This upregulation is likely due to
Kras, as a dominant-negative Kras reduces Nfkb activation in PDAC cell lines (Liptay et al.,
2003). In summary, targeting the Pi3k pathway is likely a good approach towards cancer therapy.
Many drugs targeting the Pi3k pathway, particularly the p110 isoforms and Akt, are
currently in clinical trials for cancer indications (Figure 17). Perifosine is the lead compound in
phase 3 clinical trials for multiple myeloma and colorectal cancer. All the other compounds are
still in phase 1 and 2 trials. While none of the drugs in clinical trials are focused particularly on
pancreatic cancer, many are in phase I trials for solid tumors, which sometimes include
pancreatic cancer. In summary, many results regarding the clinical trials for Pi3k are likely to be
reported in the next few years.
Ral
The third best characterized Ras effector arm is the Ral pathway. Kras signals through
Ral GTPases by engaging their exchange factors, Ral-GEF's (Feig, 2003). Ral-GEF proteins
(RalGDS, RGL, RGL2, and RGL3) activate the RalA and RalB small GTPases (D'Adamo et al.,
1997). RalA and RalB are Ras-like GTPases and are members of the Ras GTPase superfamily
(Chardin and Tavitian, 1986). RalA and RalB are 82% identical and cycle between a GDP-bound
inactive and GTP-bound active state (Feig, 2003). Activated Ral and Ral exchange factors
enhance Ras-induced transformation (Chien and White, 2003). The constitutive expression of
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both RalGDS and Raf induce focus formation in vitro (White et al., 1996). To summarize, the
Ral pathway is a well-characterized downstream pathway of Ras.
Inhibition of RalA suppressed tumorigenicity in Ras-transformed human cancer cell
lines (Lim et al., 2005). Dominant-negative Ral mutants inhibit Ras-induced cellular
transformation. Both RalA and RalB have been shown to play an important role in Ras-mediated
transformation in vivo (Gonzalez-Garcia et al., 2005; Rodriguez-Viciana and McCormick, 2005).
In particular, RalA is required for matrix-independent cell proliferation, while RalB is critical for
survival (Chien and White, 2003), (Chien et al., 2006). More specifically, RNAi inhibition of
RalA had no effect on normal or tumorgenic cells growing under adherent cells but severely
inhibited anchorage-independent proliferation of tumor cells (Chien and White, 2003; Lim et al.,
2005). In a large panel of human pancreatic cancer cell lines, hairpin knockdown of RalA
inhibited the ability of these lines to form tumors in nude mice (Chien and White, 2003; Lim et
al., 2005). In prostate cancer, inhibition of RalA prevented bone metastasis without an obvious
effect on the primary subcutaneous tumor (Yin et al., 2007). To conclude, RalA is likely
important for the growth of tumor cells in more physiological conditions.
RNAi inhibition of RalB demonstrated its importance in survival for various tumor cell
lines but not for normal proliferating epithelial cells. Moreover, the Ras oncogene appears to
confer sensitivity to RalB inhibition. In bronchial epithelial cell lines and telomerase-
immmortalized human mammary epithelial cell lines, the introduction of oncogenic Ras
conferred sensitivity to RalB inhibition (Chien and White, 2003). In contrast, studies using
human pancreatic cancer and prostate cancer cell lines do not find that hairpin-induced RalB
depletion affects the primary tumor in a subcutaneous transplant model (Lim et al., 2006).
However, inhibition of RalB prevents lymph node metastases of various pancreatic cancer lines
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when injected in the tail vein of mice. In summary, RalB is important for tumor growth, but
further work is necessary to clarify the contexts and stages of tumorigenesis that RalB is most
important.
Another experiment that further implies the importance of RalA and RalB is the analysis
of mice with homozygous deletion of RalGDS, a gene upstream of RalA and RalB (Gonzalez-
Garcia et al., 2005). RalGDS-null mice are resistant to carcinogen-induced skin papillomas. The
number of papillomas is reduced, and their formation is delayed. In addition, the papillomas
failed to metastasize. Histological analysis of these tumors revealed that proliferation rates are
similar in RalGDS-containing and RalGDS-null mice, but that apoptosis rates are higher in
RalGDS-null mice. This suggests that RalGDS signaling prevents apoptosis in tumors. In
summary, RalGDS is also a potential target in PDAC.
There are many Ral effectors, of which Sec5 is a critical effector of RalB. Depletion of
Sec5 results in the same anti-tumorigenic phenotype as does depletion of RalB (Chien et al.,
2006). Other Ral effectors include phospholipase Dl and Cdc42/RalBP1 (Ral binding protein 1).
Moreover, RalA and RalB, along with Akt, inhibits the FoxO family of transcription factors (De
Ruiter et al., 2001). FoxO factors promote 1) cell-cycle arrest by transcribing p27 (also known as
a cyclin-dependent kinase inhibitor, Kipl) 2) apoptosis through inducing expression of Bim and
Fas ligand. In summary, Ral signals to many downstream molecules.
Other pathways that have been shown to be Ras effectors include Tiam 1, p120GAP,
NF1, MEKK1, Rini, AF-6, PKC-(, Norel, Canoe, Racl, and Rho (Ehrhardt et al., 2002). These
proteins bind directly to the activated form of Ras. Rho-C and Vav 1 are members of the Rho
protein family. Overexpression of Rho-C in human PDAC has been inversely correlated with
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prognosis and metastasis (Suwa et al., 1998). Expression of the exchange factor VavI in human
PDACs has also been inversely correlated with prognosis. Moreover, RNAi knockdown of VavI
reduces the tumor formation ability of xenografts (Fernandez-Zapico et al., 2005). While there
have been no studies inhibiting Rac 1 in the context of developed PDAC, genetic loss of Rac1 at
tumor initiation inhibits tumor formation. More specifically, in a Ptfl a+/Cre ; G12D model,
addition of Rac 1 fo"/fox resulted in impaired acinar-ductal metaplasia likely due to impaired actin
rearrangements (Heid et al., 2011). In summary, there is a variety of pathways through which
Kras signals.
While Ras mutations can result in constitutive Ras signaling, mutations in growth-factor
receptor tyrosine kinases that are upstream of Ras also often activate the Ras pathway. The most
commonly overexpressed growth-factor receptors are Egfr and Erbb2 (Her2/Neu) in breast,
ovarian, and stomach carcinomas (Mendelsohn and Baselga, 2000). Egfr and its close relative
Her2 stimulate Ras through Grb2 and Sos. A truncation mutation in Egfr is observed in
glioblastoma that results in a constitutively activated Egfr (Kuan et al., 2001). Another way Egfr-
family tyrosine kinases become over-activated is through excessive autocrine production of Egf-
like ligands such as Tgf-a. In summary, Egfr mutations can drive Ras signaling.
Egfr may be a suitable target for drug inhibition in Kras-mutant cancers. Inhibiting Egfr
in a Kras-mutant cancer may seem to be a poor approach as the causative mutation is
downstream of the target. However, Kras-mutant tumors often have autocrine signaling
involving excessive production of Egf family growth factors (Normanno et al., 2001).
Consequently, reducing the autocrine signaling by inhibiting Egfr may reduce tumor growth. For
instance, in a transgenic mouse model of skin cancer that has constitutively activated Sos (a Ras
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GEF), inhibition of Egfr reduced autocrine signaling and significantly reduced skin tumor
formation (Sibilia et al., 2000). The two primary methods of inhibiting Egfr are by small-
molecule inhibitors against the intracellular tyrosine kinase of Egfr or by humanized antibodies
against the extracellular domain of Egfr. In summary, Egfr inhibition may be an effective
strategy in Kras-mutant cancers.
RNAi
Endoigenous RNAi
RNA processing in cells allows for micro-RNAs and small noncoding RNAs to regulate
gene expression 1,2. The RNAi processing machinery is as follows: primary miRNA (pri-
miRNAs) transcripts are encoded by the genome and produced in the nucleus. They are then
cleaved by the nuclear Drosha/DGCR8 complex, resulting in the formation of precursor miRNAs
(pre-miRNAs). AGO2 performs strand selection and removes the passenger strand 3,4. The guide
strand is used to identify complementary mRNA substrates and promote mRNA degradation or
translational inhibition.
Exog~enous or experimental RNAi
RNAi uses exogenously introduced DNA and the RNA processing machinery to
selectively knockdown target genes of interest. The most common method of targeted RNAi
inhibition is through the use of small interfering RNA, or siRNA 5. To introduce the siRNA, the
target cell needs to be transfectable, i.e by nanoparticles or electroporation. siRNAs resemble
Dicer products and allow for potent, but transient inhibition. An alternative approach uses
retroviral vectors to introduce genetic sequences into the genome of the target cell. These
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sequences would encode short hairpin RNAs, which allows for stable and heritable gene
silencing 6,7. shRNAs resemble the pre-miRNAs that are transferred from the nucleus to the
cytoplasm. shRNAs allow for long-term gene suppression in vitro and in vivo.
To design the shRNAs such that they effectively inhibit the target gene of interest,
Computational prediction rules help create a hairpin sequence that is thermodynamic asymmetry,
contains low G/C content, and exhibits a strong bias for A/U at the 5' end of the guide strand 14-
17. A recent study demonstrated a high-throughput method to experimentally screen a large set of
hairpins in a cost and time efficient manner 18. Exogenous shRNAs can also be created to have a
sequence that is similar to that endogenous miRNAs (miR-30 shRNAs). This enables the hairpin
to be driven by polymerase-JI promoters, thereby allowing for better control of expression levels
10-12
and reducing hairpin-associated toxicity . More recently, shRNAs have been used in pool-
based RNAi screening 8,9. In summary, hairpin technology has developed significantly over the
recent years.
RNAi may also inhibit unintended transcripts that have a similar sequence to the sense or
antisense strand of the RNAi. This may result in a false positive interpretation if the off-target
effect is functionally relevant. To prevent such as misinterpretation, multiple RNAi hairpins
targeting the same gene can be constructed. It is also known that high levels of RNAi expression
can saturate the hairpin expression machinery, leading to cell death 13. To control for this,
hairpins targeting non-essential genes can be used to ensure that cell death is not occurring due to
overexpression of the hairpins. In review, using the appropriate controls allow for more
interpretable results with RNAi.
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Synthetic Lethality and RNAi screens
Multiple RNAi screens have been performed recently to identify genes that are synthetic
lethal for Kras (Error! Reference source not found.). Synthetic lethal genes are those that,
hen inhibited, are deleterious to Kras-mutant cancers but not to non-Kras-mutant cancers. From a
therapeutic perspective, a Kras-synthetic lethal target is ideal because Kras-mutant tumors would
be sensitive to the therapeutic, while neighboring non-Kras mutant healthy tissue would be less
sensitive. These RNAi screens were performed using an individual well-by-well format or a
high-throughput pooled strategy. In a well-by-well approach, individual hairpins are tested in
separate wells in a 384-well plate. In a pooled strategy, hairpins were barcoded such that
hundreds of hairpins could be tested in each well. All but one of the screens used hairpins
(shRNAs), where a viral vector is used to integrate the hairpin into the genome of the cancer cell.
The Sarthy 207 study used siRNAs, which are RNA duplexes that enter the cytoplasm of the cell
and allow for temporary inhibition (on the order of a few days) of the target gene. Hairpins allow
for more dramatic and sustained inhibition of the gene of interest. All the studies had the initial
screen performed in vitro in either mouse or human cancer cell lines. In summary, in the last few
years, much effort has been placed into identifying synthetic lethal targets for Kras-mutant
cancers.
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Gene Gene
Identified Function Method Kras-Mutant Line(s) Non-Mutant Line(s) Reference
Survivin Involved in apoptosis Individual - Colon Cancer - Human Colon Cancer Sarthy
siRNAs (DLD-1, Kras G13D) (Isogenic counterpart, DKS-8) Mol Cancer Ther 2007
Transcription Factor 
- Mouse Lung Cancer
Wilms Tumor 1 that is a tumor Pboled (LKR10/13, Kras G12D) Mouse Embryonic Fibroblasts Vicent
suppressor in certain Hairpins Mouse Embryonic Fibroblasts (Wild-type) JCO 2010
contexts (Kras G12D/+)
Non-Canonical Individual NSCLC Human NSCLC BarbieTbk1 IKB Kinase Hairpins (H1792, H23, H1944, (H2110, HCC-1359, HCC-193, Nature 2009H2887, H2030) H1568, H28, H1437)
Pik1 Mitotic Kinase Pboled - Colon Cancer - Human Colon Cancer Luo
Hairpins (DLD- 1) (Isogenic counterpart) Cell 2009
Breast Cancer - AM L (THP-1)
(NOMO-1) * Breast Cancer (MDA-MB-453)Serine/Threonine Individual Coo C- Glioblastom a (U-87-MG) Scholl
Stk33 Kinase of Unknown Hnivia -Colon Cancer - Prostate Cancer (PC-3) Cll
Function Hairpins (DLD-1, HCT-116) - Human Fibroblasts Cell 2009
(MDA-MB-231) - Immortalized Human
Mammary Epithelial Cells
- Tyrosine Kinase
Syk - Macrophage- Hypothesis-driven Kras-Mutant & Kras-Dependent: Kras-Mutant but Kras-Independent:
Ron stimulating Protein Gene Expression- - NSCLC (H358) - NSCLC (A549) Singh
Integrin p6 Receptor based - PDAC (YAPC) - PDAC (PANC1 & PATU8988T) Cancer Cell 2009
- Integrin Receptor
Zinc Finger
Fooled - Colon Cancer WangSnai2 Transcriptional 
, G13D) Isogenic pair w/o mutant Kras 2Repressor Hairpins (HCT116, Kras Oncogene 2010
Figure 18. RNAi-Based Synthetic Lethality Screens in Kras-Mutant Cancers. Listed above are synthetic
lethal screens using RNAi technology to identify genes that are important in Kras-mutant cancers but not
in non-Kras mutant cells.
In the Sarthy 2007 study, DLD 1 colon cancer cells expressing mutant Kras were used to
identify survivin from a 4,000 gene RNAi screen (Sarthy et al., 2007). Survivin is also known as
baculoviral inhibitor of apoptosis repeat-containing 5. The screen looked for siRNAs effective
against the Kras-mutant DLD- 1 colon cells but not against an isogenic counterpart in which the
mutant Kras had been removed, the DKS-8 line. Survivin siRNA induces transient G2-M arrest,
polyploidy, and caspase-3 activation. In summary, tumors with a mutant Kras may be
particularly sensitive to inhibition of Survivin.
In the Vicent 2010 study, a pooled hairpin screen was performed on Kras mutant MEFs
as well as non-Kras mutant MEFs. Wilms Tumor 1 (Wtl) was identified as a synthetic lethal
gene. Wtl is a transcription factor and is a tumor suppressor in Wilms Tumor. Wtl was
demonstrated to be also important in Kras mutant mouse lung cancer cell lines. In summary, a
pooled hairpin screen in vitro on normal cells (MEFs) allowed for the identification of a
synthetic lethal gene that was subsequently validated in lung cancer cells.
In the Barbie 2009 study, Kras-mutant and non-Kras mutant human NSCLC cancer cell
lines were analyzed (Barbie et al., 2009). Using an individual well-by-well hairpin screening
approach, Tbkl, a non-canonical iKB kinase, was identified as a synthetic lethal gene. In contrast
to the previous studies, many cell lines were assessed: 5 Kras-mutant NSCLC lines, and 6 non-
Kras mutant NSCLC lines. Inhibition of Tbkl induced apoptosis specifically in Kras-mutant
cancer cell lines. Mechanistically, Tbkl activates Nf-KB anti-apoptotic signals, involving c-Rel
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and Bcl-XL (also known as Bcl2ll), which are critical for cell survival. In brief, Tbkl signaling
is critical for Kras mutant cancers, particularly for NSCLC.
In the Luo 2009 study, Plkl, Apc/c, and the proteasome, were identified from a 13,000
gene pooled hairpin screen (Luo et al., 2009). A pair of isogenic colon cancer cell lines, where
they differed on the presence of mutant Kras, were usedInhibition of the pathway consisting of
the mitotic kinase Plkl, the anaphase-promoting complex/cyclosome (Apc/c), and the
proteasome, induces cell cycle accumulation at prometaphase and subsequent death of the cells.
The study also demonstrates that in human tumors with a Ras transcriptional signature, reduced
expression of these genes correlates with increased survival. In conclusion, Plkl, Apc, and the
proteasome, are potential targets for Ras-mutant cancers.
In the Scholl 2009 study, the serine/threonine kinase Stk33 was identified in an
individual, well-by-well assay (Scholl et al., 2009). Like the previous study, many human cell
lines were analyzed, although the screen was originally performed in AML cells. After
identifying Stk33, Stk33 was tested in cancer lines from various tissues of origin and found to be
important irrespective of tissue type. In contrast, cancer lines without mutant Kras are not
sensitive to Stk33 knockdown. In Kras-mutant cells, Stk33 promotes cell survival by regulating
S6kl. S6kl inactivates the death agonist BAD, thereby preventing mitochondrial apoptosis. To
summarize, Stk33 is a potential target for Kras-mutant cancers.
In the Singh 2009 study, Syk, Ron, and Integrin p6 were identified as being potential
targets (Singh et al., 2009). Instead of performing a screen, this study compared the gene
expression profiles of Kras-dependent versus Kras-independent lung and pancreatic cancer cell
lines. Note that both the Kras-dependent and Kras-independent cell lines contained Kras
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mutations, but only the Kras-dependent lines demonstrated sensitivity to hairpin-mediated
knockdown of Kras. Based on the differences in gene expression in the two populations, the
study identified Syk and Ron kinases and integrin P6 as potential pharmacologically tractable
proteins. Inhibition of these targets induces apoptosis and EMT in Kras-dependent cells. In
summary, a hypothesis-driven approach identified Syk, Ron, and Integrin P6 as synthetic lethal
targets.
In the Wang 2010 study, a pooled hairpin study was performed in an isogenic pair of
Kras-mutant colon-cancer cell lines. Snail2, a zinc finger transcriptional repressor was identified
as a synthetic lethal target. To summarize, the various Kras-synthetic lethal targets are
therapeutic possibilities. Additional studies across a larger spectrum of cell lines will be
necessary to validate the findings. Moreover, clinical studies will likely be the bottleneck in
determining effective therapies for PDAC.
Kras synthetic lethal genes have also been identified by more focused, hypothesis-driven
studies. In a Kras-mutant NSCLC GEMM, Cdk4 was identified as a synthetic lethal gene (Puyol
et al., 2010). Genetic ablation of Cdk4, but not Cdk2 or Cdk6, induced senescence and prevented
lung tumor progression in a NSCLC GEMM. In other Kras-expressing tissues, they did not
observe such a response, suggesting that inhibition of Cdk4 may not be generally toxic.
Pharmacological inhibition of Cdk4 may be a potential therapeutic strategy for Kras-mutant
NSCLC patients. In summary, Cdk4 has been shown to be a Kras-synthetic lethal target in an in
vivo model. In another recent study, the GATA2 transcription factor was found to be synthetic
lethal in a NSCLC GEMM (Kumar et al., 2012). Genetic ablation of GATA2 was important in
NSCLC cells but not in wild-type cells.
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Chemical Synthetic Lethality Screen
Not only are synthetic lethal screens being performed with RNAi but also with small
molecules (Figure 19). In these various screens, Kras-mutant and non-Kras mutant cell lines are
screened with a library of small molecules. The Kras-mutant lines can be normal cell lines
(mouse embryonic fibroblasts, human fibroblasts, pancreatic ductal epithelial cells) with mutant
Ras introduced or they can be cancer lines (colon cancer line) with mutant Kras. The non-Kras-
mutant lines are of the same lineage but without the Kras mutation. These screens identified a
group of small molecules with a variety of functions: induces reactive oxygen species, affects
voltage-dependent anion channels, and unknown functions. In summary, these compounds will
need to be tested across a broader panel of cell lines to verify their effectiveness.
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# of
Drug Mechanism Drugs Kras-Mutant Line(s) Non-Mutant Line(s) Reference
Shaw
lanperisone Induces reactive oxygen species 50,000 MEFs (KrasG12D) MEFs PNAS, 2011
Acts through VDAC (Voltage-Dependent 23,550 Primauman Foreskin imarDolma
Erastin Anion Channels) Fibroblasts (Hrasv12) Primary Huran Foreskin Fibroblasts Cancer Cell, 2003
RSL5 acts through VDACs Isogenic line w ith addition of Primary Human Foreskin Fibroblasts w/ Yang
RSL3 & RSL5 RSL3 activates death mechanism in a 47,725 Hrasv12  hTERT, SV40 Large and Small T Antigen Chemistry & Biology,
VDAC-independent fashion (LT, ST) 2008
1 compound Isogenic line w ith addition of Human Pancreatic Ductal Epithelial Cell i
(unknown mechanism) Unknow n 3,200 Krasv12  Line w/ E6/E7 from HFV-16 virus Frontiers 0 oscience,
Cytidine Nucleoside Human Colon Cancer Cell Torrance
Analog Unknown 29,440 Line (DLD-1) Isogenic with mutant Kras removed. Nature Biotech, 2001
Figure 19. Kras Synthetic Lethal Screens with Small Molecules. Listed are synthetic lethal screens
performed with small molecules.
mTOR Biology
mTOR, also known as FRAP (FKBP12-rapamycin-associated protein), is a 289 kDa
serine/threonine kinase that regulates cell growth and survival (Ma et al., 2005). mTOR is
considered a member of the Pi3k-kinase-related kinase (PIKK) superfamily because the c-
terminus of mTOR exhibits strong homology to the catalytic domain of Pi3k (Brugarolas et al.,
2004). mTOR forms two complexes, mTORC 1 and mTORC2, through which mTOR acts. The
mTORC 1 complex consists of mTOR, regulatory-associated protein of mTOR (Raptor),
mLST8/GPL (G-protein p-subunit-like protein), Deptor, and Pras40 (proline-rich Akt substrate
40 kDa) (Kim and Sabatini, 2004). mTORC 1 is regulated by various upstream environmental
signals including nutrients, growth factors, energy signals, and cellular stress (Zoncu et al.,
2011). The PI3K/Akt pathway is an important upstream mediator of mTORCl as it activates
mTORC 1 by phosphorylating and inactivating Tuberous Sclerosis Complex (Tsc), which is an
inhibitor of mTORC 1.
mTORC 1 regulates cell growth and proliferation by enhancing biosynthesis of proteins,
lipids, and organelles, and by preventing catabolic processes. mTORC 1 activates protein
biosynthesis by phosphorylation of ribosomal protein S6 kinase I (S6kl/p7OS6k) and eukaryotic
initiation factor 4E-binding protein 1 (4eBP1) (Gibbons et al., 2009). Moreover, mTORC1 can
also affect metabolic changes that are beneficial to tumor growth, such as enhancing glycolysis,
increasing flux through the oxidative branch of the pentose pathway, and enhancing lipogenesis
(Yecies and Manning, 2011). Lipogenesis is affected by mTORC 1 through activation of sterol
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regulatory element binding protein 1, a transcription factor that controls genes involved in lipid
and cholesterol synthesis (Laplante and Sabatini, 2009; Porstmann et al., 2008). In addition,
mTORC 1 signaling inhibits autophagy, preventing destruction of the cell and allowing for tumor
growth (Foster and Fingar, 2010). Furthermore, mTORCl also affects nutrient entry into the
cells by controlling cell surface expression of transporters for glucose, amino acids, iron, and
lipoproteins (Edinger and Thompson, 2002). Administration of rapamycin or its closely related
compounds, rapalogues, reduce phosphorylation of S6K1 and 4EBP 1 in cells with activated
mTORC 1 (Gingras et al., 1998). From a genetic perspective, raptor is required for the mTORC-
mediated phosphorylation of 4EBP1 and S6K1 (Hara et al., 2002; Kim et al., 2002). In summary,
mTORC I regulates many biological processes and can be inhibited by rapamycin.
Activated mTORC 1 signaling will induce phosphorylation and inactivation of 4eBP 1.
mTORC1 phosphorylates 4eBP1 at four residues: Serine 37, Threonine 46, Serine 65, and
Threonine 70. There is some evidence that 4eBP 1 controls proliferation, while S6kl controls
growth (Hsieh et al., 2010). 4eBP1 represses the initiation of protein translation by binding
eIF4E, the subunit of eIF4F that binds to mRNA caps (Pain, 1996). Phosphorylated 4eBP1 no
longer binds to eIF4E and instead binds to eIF4A, eIF4B, and eIF4G, forming the eIF4F
complex. eIF4F promotes cap-dependent protein translation, increasing translation of mRNAs
with 5' untranslated terminal regions (5'-UTRs). These mRNAs include c-MYC, cyclin D1, and
ornithine decarboxylase, genes that are involved with the Gl/S cell cycle transition and with
tumorigenesis. Overexpression of eIF4E can by itself induce cell transformation (Rousseau et al.,
1996; Smith et al., 1990). Consequently, activated mTOR signals through 4eBP1 to promote
protein translation and cell cycle transition.
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mTORC1 phosphorylates the serine/threonine kinase, S6K1, at Thr389. Activated S6K1
phosphorylates the 40S ribosomal protein S6K1 (rpS6K1) (Park et al., 2002). Phosphorylated
and activated rpS6K1 binds to actively translating polysomes, driving translation of mRNAs
with a 5'-terminal oligopolypyrimidine (5'-TOP). In addition, S6kl regulates eIF4A helicase
activity through phosphorylation of Pdcd4 and eIF4B (Schmid et al., 2008; Shahbazian et al.,
2006). Furthermore, S6kl interacts with Skar, thereby enhancing translation of recently spliced
mRNAs (Ma et al., 2008). Finally, S6kl phosphorylates and inactivates eukaryotic elongation
factor 2 kinase (eEF2K), thereby freeing eEF2 to promote translation elongation (Proud, 2009).
In summary, activated mTOR signals through S6K1 to promote protein translation and supports
cell growth.
The other component formed by mTOR is mTORC2, which consists of mTOR,
rapamycin-insensitive companion of mTOR (Rictor), mLST8/GpL, Protor, Deptor, and
mammalian stress-activated protein kinase interacting protein (mSIN1). In contrast to mTORC1,
mTORC2 is insensitive to inhibition by the rapamycin compound. mTORC2 is stimulated by
growth factors and signals downstream to affect cell growth, proliferation, survival, metabolism,
and the actin cytoskeleton organization (Foster and Fingar, 2010; Zoncu et al., 2011). The
primary downstream signal of mTORC2 that facilitates cancer growth is the phosphorylation of
Akt on the Serine 473 residue (Sarbassov et al., 2005). This phosphorylation increases Akt's
enzymatic activity by 5 to 10 fold. Akt is also phosphorylated on Threonine 308 residue on Akt
by PDK1. When Akt is phosphorylated at both sites, Akt is fully activated and signals
downstream to promote cell survival and proliferation (Efeyan and Sabatini, 2010). Interestingly,
Akt is also upstream of mTORC2 in that it activates mTOR signaling. Therefore, a feedback
loop exists due to mTORC2 signaling. Besides phosphorylating Akt, mTORC2 phosphorylates
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serum and glucocorticoid inducible kinase and protein kinase C, thereby promoting cell-cycle
progression, cell survival, and metabolism (Garcia-Martinez and Alessi, 2008; Guertin et al.,
2006). In summary, mTORC2 primarily signals downstream through Akt.
mTOR is activated in various cancers. Genetic alterations that lead to mTOR activation
in cancers include: Direct activating mutations in mTOR (Hardt et al., 2011). Mutations in
negative regulators of mTOR: TSC1, TSC2, p53, and LKB1, can also result in mTOR activation
(Wander et al., 2011). Amplification of PIK3CA/p1 10a or loss of PTEN, both of which activates
PI3K/Akt signaling and the downstream mTOR (Alvarado et al., 201 1),(Zoncu et al., 2011).
Activation of P13K or AKT or loss of PTEN is necessary and sufficient to activate mTORC1
(Brunn et al., 1997; Chung et al., 1994; Hara et al., 1997). Consequently, the mTOR signaling
pathway is often hyperactivated in cancer.
Inhibiting mTOR by genetic methods have demonstrated the importance of mTOR
signaling in cancer. Embryonic knockout mice of mTOR are embryonic lethal (Gangloff et al.,
2004; Murakami et al., 2004). Knockout of Raptor or Rictor also leads to embryonic lethality
(Guertin et al., 2006; Gulhati et al., 2009). Inhibition of mTORC 1 or mTORC2 by shRNA
inhibits in vivo growth of colon cancer xenografts (Gulhati et al., 2009). The mTOR pathway is a
potential therapeutic target for cancer therapy.
mTOR is not only involved in tumor formation but also in metastasis. mTORC1 and
mTORC2 are involved in the epithelial-mesenchymal transition, motility, and metastasis in
colorectal cancer (Gulhati et al., 2011). mTORC2 is also involved in metastatic disease in other
cancer types: breast cancer and gliomas (Masri et al., 2007; Zhang et al., 2010). The mechanism
through which mTOR is signaling to affect metastasis is uncertain, although one proposed
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mechanism is through signaling to the actin cytoskeleton and cell motility by RhoA, Rac 1, and
Cdc42 (Gulhati et al., 2011; Liu et al., 2010a). Moreover, mTORC1 may signal to focal adhesion
protein such as focal adhesion kinase, paxillin, p130 Cas, and F-actin (Zhou and Huang, 2010).
These proteins can affect the cytoskeleton to promote metastasis. To summarize, mTOR is
involved not only in tumor initiation but also in various steps of tumor development, including
metastasis.
mTOR Inhibitors
Rapamycin
Rapamycin is a macrocylic lactone produced by Streptomyces hygroscopicus.
Streptomyces hygroscopicus was originally isolated from a soil sample from Rapa Nui, also
known as Easter Island. Rapamycin/sirolimus (Wyeth-Ayerst) was originally approved in the US
1999 for the prevention of graft rejection in kidney transplant recipients. In 2002 to 2003,
rapamycin was approved as an anti-restenosis agent for patients who have stents. Moreover,
rapamycin is also an antifungal drug targeting Candida albicans, Cryptococcus neoformans, and
Aspergillusfumigates. Most of all, rapamycin has been approved as a treatment for solid cancers.
Although mTOR inhibition has immunosuppressive effects that may be pro-tumorigenic,
the anti-cancer effects of mTOR inhibition outweigh the immunosuppressive effects.
Rapamycin's mechanism of action allows for on-target efficacy with relatively little side-effects.
Rapamycin binds to FKBP12, an intracellular immunophilin, forming a complex that then binds
to the FRB domain on mTOR. FKBP12 is an enzyme, but it serves as merely a cofactor in the
Rapamycin-mediated inhibition of mTOR. The FRB domain is unique to mTOR, so Rapamycin
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has notable selectivity for mTOR. Because of Rapamycin's method of action, its selectivity is
likely to be higher than that of ATP-competitive inhibitors that inhibit the active site of mTOR.
Rapamycin is very specific because it binds no other protein besides FKBP 12, and it only affects
FKBP12's binding with mTOR. Although Rapamycin theoretically inhibits mTOR, it prevents
mTORC 1 activity but not mTORC2 activity, except in some cell lines after prolonged exposure
to rapamycin.
Rapamycin demonstrates anti-tumor activity in pre-clinical models. Rapamycin inhibits
growth, in a dose-dependent fashion, of several murine and human cancer cell lines covering a
variety of cancer types including melanoma, leukaemia, and pancreatic cancer (Busca et al.,
1996; Grewe et al., 1999). While rapamycin's effect in vitro is limited to partial inhibition of cell
proliferation, its effect on established xenograft tumors is notably greater. Rapamycin has an
effect on angiogenesis in vivo, thereby increasing its efficacy. Moreover, rapamycin also inhibits
tumor metastasis in mouse models (Humar et al., 2002).
Unfortunately, rapamycin was not as effective in human clinical trials. First, resistance
against rapamycin develops. Cells that are overexpressing BCL2 show resistance to mTOR
inhibitors. Antisense oligonucleotides against BCL2 can sensitize the cells to rapamycin and
everolimus (Aguirre et al., 2004). Among patients with ovarian cancer, those with high levels of
BCL2 expression show resistance to mTOR inhibitors (Shinoura et al., 1999). More generally,
rapamycin had poor bioavailability, low chemical stability, and a short remaining patent life.
Consequently, it was difficult to achieve the doses at the tumor site necessary for efficacy. In
response to rapamycin's weaknesses, Wyeth developed Torisel/temsirolimus for the treatment of
tumors.
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Rapamycin inhibits downstream signaling of mTORC 1, specifically the phosphorylation
of S6kl and 4eBPl. Rapamycin inhibits S6kl in a wide variety of cell lines with a half-life of
approximately two minutes (Chung et al., 1992). Rapamycin induces the de-phosphorylation of
many sites on S6kl including T389 (Pearson et al., 1995). Many clinical studies of rapamycin
use p-S6kl in the peripheral blood cells and the tumor site as a readout for pharmacodynamic
efficacy. While rapamycin at low single-digit nano-molar concentrations can inhibit S6kl
phosphorylation, rapamycin needs to be given at micro-molar concentrations to induce apoptosis
in various cancer cell lines (Chen et al., 2005; Chen et al., 2003; Gadir et al., 2008).
Consequently, p-S6kl may not be a useful marker since its successful inhibition does not
necessarily lead to tumor regression.
In contrast to p-S6kl, 4e-BP1 phosphorylation is inhibited by rapamycin only at doses
above 500nM (Choo and Blenis, 2009; Choo et al., 2008; Thoreen et al., 2009). In ex vitro
studies, prolonged treatment (2 hours) of rapamycin at 1 OOnM was necessary to suppress
phosphorylation of purified 4e-BP1 at T37/46, while S6k phosphorylation was suppressed after
just 5 minutes of treatment. Unfortunately, the maximum tolerated dose for rapamycin results in
[nM] levels of the drug in the plasma (Hsieh et al., 2010). To increase the concentration of
rapamycin at the tumor site, rapamycin can be tagged with glucose, which is preferentially taken
up by tumor cells (DeBerardinis et al., 2008). This increases [rapamycin] at the tumor site while
maintaining relatively low levels elsewhere, reducing potential toxicity. Rapamycin treatment in
vitro only transiently dephosphorylates S65, T70, and T37/46 on 4e-BP1 (McMahon et al.,
2002). In contrast to in vitro studies, T37/46 on 4e-BP1 is insensitive to rapamcyin treatment in
vivo (Gingras et al., 2001). A different kinase is likely responsible for phosphorylation of T37/46
in vivo (Wang et al., 2005). De-phosphorylation of 4e-BP1 is functionally responsible for
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apoptosis or the inhibition of proliferation. A recent study demonstrates that the apoptosis that
arises from rapamycin is from inhibition of 4e-BP 1 phosphorylation and subsequent
sequestration and inhibition of eIF4E (Yellen et al., 2011). More specifically, there is strong
correlation between apoptosis and the suppression of 4e-BP1 phosphorylation at T37/46 and
S65. De-phosphorylated 4e-BP 1 results in the sequestration of eIF4E, resulting in apoptosis
(Gingras et al., 2001). Consistent with this mechanism, ablation of eIF4E results in apoptosis.
Furthermore, eIF4E is frequently implicated in cell proliferation and oncogenesis (Gingras et al.,
2001; Hsieh et al., 2010; Lazaris-Karatzas et al., 1990; Petroulakis et al., 2009; Ruggero et al.,
2004; She et al., 2010; Wendel et al., 2004).
Inhibition of mTORCl by rapamycin releases the negative feedback loop between S6k
and Irs 1, promoting activation of Akt and mTORC2. Moreover, treatment in vitro with high
levels of rapamycin resulted in feedback hyper-phosphorylation of Akt(S473) in two breast
cancer lines, thereby conferring subsequent rapamycin resistance (Yellen et al., 2011). Feedback-
induced activation of mTORC2 is believed to enhance tumor progression and to be deleterious
for patients. A study of Pten-deficient Glioblastoma patients demonstrated that hyperactivation
of Akt after rapamycin treatment correlated with a shorter time to progression. One approach to
enhance the therapeutic efficacy of rapamycin is to prevent the feedback-induced hyperactivation
of Akt. Treatment with an ATP-competitive mTOR inhibitor that inhibits both mTORC1 and
mTORC2 suppressed feedback phosphorylation of Akt (S473) and induced apoptosis in a breast
cancer cell line.
Rapalogs
Rapalogs are modeled after rapamycin and are also FKBP12-dependent allosteric
inhibitors of mTORC 1. Consequently, rapalogs would be expected to have relatively little side
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effects. Afinitor/RADO0 1/Everolimus (Novartis), an orally administered drug, was first approved
in the EU in 2003 and later in the US in 2010 for the prevention of allograft rejection.
Everolimus was approved in 2009 for advanced kidney cancer and in 2010 for SEGA tumors in
patients with tuberous sclerosis. Despite the expectation that rapalogs would not be very toxic, in
a phase 3 trial for kidney cancer, everolimus induced grade 3-4 adverse events in 65% of all
patients, as compared to a rate of 28% for the placebo group (Motzer et al., 2008). Everolimus is
currently in phase 3 label expansion trials for the following cancer types: gastric, liver, Her-2+
breast cancer, ER+ breast cancer, angiomyolipoma in TSC, sporadic lymphangioleiomyomatosis,
subependymal giant cell astrocytomas in TSC, and diffuse large B-cell lymphoma. Everolimus is
also being assessed in a variety of phase 1 and 2 trials. For instance, a recently completed phase
1 trial in colorectal cancer demonstrated efficacy.
Torisel/CCI-779/Temsirolimus (Wyeth-Ayerst/Pfizer) is a prodrug of rapamycin, and it
can be delivered orally or intravenously. Temsirolimus becomes rapamycin after being
metabolized in the body. In most pre-clinical tumor models, temsirolimus treatment resulted in
cytostasis, with little apoptosis. In liquid tumor models, such as acute lymphoblastic leukaemia,
acute myeloid leukaemia, and multiple myeloma, temsirolimus resulted in tumor regression.
Torisel was approved for advanced renal cell carcinoma (both non-clear cell and clear cell
subtypes) in 2007. In a multi-center phase 3 trial, temsirolimus extended overall survival of
patients with RCC when compared to other therapies (Hudes et al., 2007). Torisel has more side
effects than expected, as depicted in a phase 3 trial for kidney cancer, where it induced grade 3-4
adverse events in 67% of all patients. This rate of grade 3-4 events was comparable to that of a-
interferon, a well-known relatively toxic cancer treatment that has shown grade 3-4 events in
78% of patients. To improve the efficacy of Torisel for advanced RCC, it is currently in a phase
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3 trial in combination with bevacizumab. In 2008, Torisel was approved for mantle cell
lymphoma. In the associated pivotal trials, Torisel demonstrated a 22% ORR (complete or partial
response) for refractory mantle cell lymphoma, as compared to the 2% ORR for the
investigator's choice of a currently-approved therapy (Feldman et al., 2005). Torisel is also being
tested in other cancers, with ongoing large scale trials in melanoma, endometrial cancer, non-
clear cell kidney cancer, metastatic RCC, and glioblastoma.
Ridaforolimus/AP23573/MK-8669/Deforolimus (Merck/Ariad) is another rapalog that
can be administered orally or intravenously. Ridaforolimus has yet to be approved for any cancer
indications. It is currently being tested in phase 3 trials for soft tissue and bone sarcomas. In
addition phase 2 and 3 trials are ongoing for endometrial cancer, NSCLC, and prostate cancer.
Rapalogs have generally been an improvement over rapamycin. Afinitor, Torisel, and
Ridaforolimus, unlike rapamycin, do not have an immunosuppressive effect (Vignot et al.,
2005). In addition, prolonged exposure to rapalogues actually results in inhibition of mTORC2
(Zeng et al., 2007). mTORC2 inhibition has been observed in the clinical setting for patients with
acute myeloid leukemia receiving everolimus or temsirolimus. This may be due to sequestration
of free-floating mTOR by FKBP12, thereby making mTOR unavailable to form the mTORC2
complex (Zoncu et al., 2011). As described above, rapalogs are being assessed in various cancers
including PDAC, assorted lymphomas, sarcomas, endometrial cancers, and other solid tumors
(Ansell et al., 2008; Smith et al., 2010; Witzig et al., 2005).
One line of evidence demonstrating that rapalogs are effectively inhibiting mTOR is that
rapalogs are effective for patients with TSC deficiencies. TSC is a suppressor of mTOR
signaling. Consequently, individuals with TSC deficiencies demonstrate overactive mTOR
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signaling, resulting in proliferative syndromes. Rapalog treatment has improved symptoms for
patients of various syndromes, including facial angiofibroma, renal angiomyolipoma, and
pulmonary lymphangioleiomyomatosis (Bissler et al., 2008; Herry et al., 2007; Wienecke et al.,
2006). In a phase 2 trial for TSC patients with subependymal giant cell astrocytomas, everolimus
reduced tumor size and the frequency of seizures (Krueger et al., 2010). In a phase 1 trial for
patients with the same indication, rapamycin induced substantial regression of tumor volume
(Franz et al., 2006).
Although elevated mTOR signaling in cancer may suggest sensitivity to rapalogs, this
has not proven to be true in gliomas, melanomas, endometrial, and breast cancer. Gliomas and
melanomas often display Pten-deficiency and upregulated mTOR signaling. Pre-clinical studies
show that these cancers are sensitive to rapalogs. Consequently, mTOR inhibitors were tested in
such tumors, but were not efficacious (Galanis et al., 2005; Margolin et al., 2005). Similarly,
Pten-loss is observed early on in endometrial cancer, but a phase 2 trial of rapalogs showed no
regression of disease and only disease stabilization for 26 to 44% of the patients. Breast cancer
often shows upregulated mTOR signaling due to HER2 amplification, overexpression of Igf- 1 r
or Egfr, a PIK3CA mutation, or PTEN loss (Chiang and Abraham, 2007). Despite involvement
of the mTOR pathway, everolimus and temsirolimus demonstrated limited efficacy in breast
cancer with an ORR of 12% and 9%, respectively (Chan et al., 2005; Ellard et al., 2009). In
summary, rapalogs have been successful in advanced RCC and a few other rare tumors, but have
not been effective in many more common solid tumors.
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Ongoing Trials
Drug Company Approved Indication Phase Indication Reference
3 NHL
3 Gastric
Advanced Kidney Cancer 3 Liver
Everolimus / (in 2009) 3 Breast Wander, JCI 2011
RAD001 / Novartis SEGA tumors in tuberous sclerosis 2 Ovarian Benjamin, NRDD(in 2010)Af initor (n21)2 Head and Neck 2011Pancreatic Neuroendocrine Tumors
(in 2011) 2 Colorectal
2 Glioblastoma
2 Prostate
Temsirolinus / Advaned Kidney Cancer 3 NHL Wander, JCI 2011(in 2007)CCI-779 / Wyeth Man -------- Benjamin, NRDD
Torisel (in 2008) 2 Glioblastoma 2011
Raparnycin / Wyeth Advanced Kidney Cancer 1/2 Solid Tumors Liu, NRDD 2009
Sirolimus
Figure 20. mTOR Inhibitors Approved for Cancer Treatment. All known mTOR inhibitors that have been
approved by the FDA for a cancer indication are depicted. The particular cancer indication for which the
drug is approved is described. The additional clinical trials that the drugs are undergoing are indicated
with the phase of the trial and the target indication.
To summarize, all the mTOR inhibitors that have been approved for cancer are depicted
in Figure 20. Everolimus, temsirolimus, and rapamycin were approved for advanced kidney
cancer. Everolimus is also approved for SEGA tumors in tuberous sclerosis in and for pancreatic
neuroendocrine tumors. Temsirolimus is also approved for mantle cell lymphoma. The different
rapalogs may have been approved for different indications because 1) of subtle differences in the
drugs 2) the drugs were tested in different indications 3) the clinical trials may have been
successful, by chance, for one compound but not the other. To expand indications, everolimus is
being tested in a wide variety of cancers including gastric, liver, and breast cancers.
Temsirolimus is being tested in non-hodgkin's lymphoma and glioblastoma. Rapamycin is in
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earlier stage trials across a variety of solid cancers. In summary, despite being approved for some
cancer indications, the rapalogs are continued to be tested in a variety of cancers.
Target Drug Company Indication Phase Reference
Rdaforolimus Sarcoma 3
/Prostate 2
mTORC1 Deforolimus / Merck/Ariad NSCLC 2 Wander, JCI 2011
AP-23573 Endometrial 2
MK-8669
mTORC1/2 OSI-027 OSI Solid Tumors 1 Zaytseva, Can Let Rev 2012
mTORC1/2 AZD-8055 AstraZeneca Solid Tumors 1/2 Zaytseva, Can Let Rev 2012
mTORC1/2 AZD-2014 AstraZeneca Solid Tumors 1 Zaytseva, Can Let Rev 2012
mTORC1/2 PP-242 UCSF Solid Tumors 1 Chappell, Oncotarget 2011
mTORC1/2 INK-128 Intellikine Solid Tumors 1 Zaytseva, Can Let Rev 2012
mTORC1/2 PKI-179 / Wyeth Solid Tumors 1 Dancey, Nat Rev Cin Onc 2010PK-587
mTORC1/2 TORKi CC-223 Celgene Solid Tumors 1 Benjamin, NRDD 2011
Solid Tumors 1/2 Zaytseva, Can Let Rev 2012
Pi3k/mTOR NVP-BEZ-235 Novartis Endometrial 2 Holmes, NRDD 2011
Breast 2 Wander, JCI 2011
Pi3k/mTOR XL-765 / Solid Tumors 1 Zaytseva, Can Let Rev 2012SAR-245409 Antis Breast 2 Wander, JCI 2011
Pi3k/mTOR SF- 1126 Semafore Solid Tumors 1 Zaytseva, Can Let Rev 2012
Pi3k/mTOR GSK-2126458 GSK Solid Tumors 1 Zaytseva, Can Let Rev 2012
Pi3k/mTOR BGT-226 Novartis Solid Tumors 1 Zaytseva, Can Let Rev 2012Breast 2 Wander, JC 2011
Pi3k/mTOR GDC-0980 Genentech Solid Tumors 1 Zaytseva, Can Let Rev 2012
Pi3k/mTOR PF-04691502 Pfizer Solid Tumors 1/2 Zaytseva, Can Let Rev 2012
Pi3k/mTOR PKI-587 / Pfizer Solid Tumors 1 Zaytseva, Can Let Rev 2012PF-05212384
Figure 21. mTOR Drugs Currently In Clinical Trials for a Cancer Indication.
Besides the above mentioned rapalogs, there are many other mTOR drugs currently being
tested in clinical trials for cancer indications (Figure 21). Ridaforolimus is another rapalog that is
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being tested in various phase 2 and 3 trials for NSCLC, sarcoma, prostate, and endometrial
cancer. Moreover, there are many ATP-competitive drugs, which inhibit both mTORC 1/2, being
developedThey are mostly in phase I trials for a variety of solid tumors. In addition, there are
many Pi3k/mTOR dual inhibitors that are being tested. The majority of Pi3k/mTOR inhibitors
are in phase 1 trials, with the exception of NVP-BEZ-235, being assessed in phase 2 trials for
endometrial and breast cancer, and XL-765 and BGT-226, both of which are being assessed in
phase 2 trials for breast cancer.
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Temsirolimus 2 Single 0 0 5 Only examined baseline phospho-levels Javle, BMC Cancer 2010Arm
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+ 2 Single 0 0 16 Only exanined baseline phospho-levels Javle, BMC Cancer 2010
Erlotinib Arm
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Although there are currently no mTOR inhibitors being assessed in phase 3 clinical trials
for PDAC, there are many failed phase 2 trials of mTOR inhibitors for PDAC (Figure 22). For
these trials, the majority of patients show progressive disease. Only one patient out of all the
trials showed any response (partial response). In a study with everolimus, 7 out of 33 patients
showed stable disease, while the rest exhibited progressive disease. In a trial with temsirolimus,
5 out of 5 patients demonstrated progressive disease. Even when combined with other targeted
agents (Erlotinib) or chemotherapy (Paclitaxel), the mTOR inhibitors have not been effective. In
a study combining everolimus with erlotinib, 16 out of 16 patients showed progressive disease.
In a trial combining ridaforolimus with paclitaxel, 1 out of 9 patients demonstrated a partial
response while the rest demonstrated exhibited progressive disease. To understand whether the
lack of efficacy is due to mTOR being a poor target in PDAC or due to the drugs not
successfully inhibiting mTOR, the studies looked at the effect of the drugs on phospho-signaling
downstream of mTOR. As the phospho-signaling analysis was performed not on tumor tissue but
on peripheral cells, no definitive conclusion regarding the inhibition of mTOR at the tumor site
can be drawn. Generally speaking, mTOR inhibition has not been successful in clinical trials for
PDAC.
Dual Pi3k/mTOR inhibitors
Dual Pi3k/mTOR inhibitors can inhibit mTOR, albeit at significantly higher
concentrations than that which is required for Pi3k inhibition. These inhibitors were originally
developed as P13K inhibitors but were found to also inhibit mTORC1 and mTORC2. This has
been observed for inhibitors such as Wortmannin, LY294002, caffeine, and Theophylline.
Wortmannin, a naturally occurring bacterial product, was the first pan-pi3k inhibitor, discovered
in 1993. Wortmannin and LY294002 (Lilly) lacked the specificity required to be of clinical
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value. Many pharmaceutical companies are developing drugs targeting Pi3k, including Bayer,
GSK, Novartis, Merck, Roche, and Sanofi. The latest class of such inhibitors demonstrate IC50
values in the sub-micromolar to low nanomolar range (Zhang et al., 2011). Pi3k compounds
currently being developed in clinical trials include: GS-101 (Gilead), which inhibits Pi3k, is in
phase 2 trials for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. SAR245408
(Sanofi), which inhibits pan-class I Pi3k, is in phase 2 trials for endometrial and breast cancer.
BKM120 (Novartis) is in phase 2 trials for endometrial cancer and NSCLC. PX-866
(Oncothyreon) is in phase 2 trials for brain cancer.
NPV-BEZ235 (Novartis), which inhibits pan-Pi3k and mTOR, is in phase 2 trials for
endometrial cancer. NVP-BEZ235 was generated by structure-based design. BEZ235 is effective
in combination with other cancers drugs including bortezomib, vincristine, doxorubicin, and
melphalan (Baumann et al., 2009; Manara et al., 2010). It is also being combined with BKM120,
a pan-Pi3k inhibitor because BEZ235 poorly inhibits Pi3kp (Zhang et al., 2011). BEZ235 is not
effective in the Kras-mutant lung cancer xenograft model. However, when BEZ235 is combined
with a Mek inhibitor, AZD6244, the combination is effective in a transgenic model of lung
cancer and in melanoma cell lines (Aziz et al., 2010; Engelman et al., 2008). Consequently,
BEZ235 is being combined with a Mek inhibitor, MEK162 (Novartis), in a clinical trial for
selected advanced solid tumors. A similar trial combining another dual mTOR/PI3K inhibitor,
GSK2126458 (GSK), and GSK's MEK inhibitor, GSK1 120212, is currently underway for
advanced solid tumors. In summary, BEZ235 is being tested in a variety of combinations in
different cancer types.
XL765 (Exelixis/Sanofi-Aventis) is currently in phase 1 trials for solid cancers and in
phase 2 trials for breast cancer (Molckovsky and Siu, 2008). Administration of XL765 results in
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down-regulation of mTORC2 signaling through decreased Akt (Ser473) phosphorylation. In
contrast to rapalogs, XL765 inhibits mTORC2 in addition to mTORC 1. 5 out of 19 patients
displayed disease stabilization for greater than 3 months. Two patients demonstrated disease
stabilization greater than 6 months. XL765 is a promising Pi3k/mTOR inhibitor for cancer
therapy.
ATP-competitive mTOR inhibitors
ATP-competitive mTOR inhibitors (Pan-mTOR inhibitors), are a novel class of mTOR
inhibitors that, in contrast to rapalogs, allow for inhibition of both mTORCl and mTORC2. In
addition, they are significantly more selective for mTOR than for P13K, as indicated by their
notably lower IC50's for mTORC1 and mTORC2 than IC 50's for PI3KThey are ATP analogues
that compete with ATP to bind to the kinase domain of mTOR. Since mTOR is the kinase
component of both mTORC1 and mTORC2, ATP-competitive inhibitors inhibit both mTORC1
and mTORC2, in contrast to rapalogs. Due to structural similarity between the kinase domain of
mTOR and that of PI3K, these inhibitors also inhibit PI3K, although to a lesser degree. In
contrast, dual mTOR/PI3K inhibitors have more similar selectivity towards mTOR and Pi3k. It is
still to be decided whether more selective inhibition of mTOR or combined inhibition of mTOR
and Pi3k is more effective against cancer. Studies in pre-clinical models have shown that ATP-
competitive mTOR inhibitors are notably more effective than rapalogs. Rapalogs fail to inhibit
protein synthesis in many cancer cell lines, as there is only partial or temporary inhibition of
mTORCl-mediated 4eBP1 phosphorylation (Choo and Blenis, 2009). In contrast, ATP-
competitive inhibitors such as WYE354, WYE132 (Pfizer), PP30, PP242/INK-128 (Intellikine),
AZD8055 (AstraZeneca), and Torini more substantially inhibit protein synthesis due to a more
complete inhibition of mTORC1 's activity on 4eBP1 (Choo and Blenis, 2009; Chresta et al.,
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2010; Feldman et al., 2009; Thoreen et al., 2009; Yu et al., 2009). Moreover, the ATP-
competitive inhibitors prevent feedback activation of mTORC2 by also inhibiting mTORC2,
thereby preventing an increase in protein synthesis through AKT/GSK33 and PKC. ATP-
competitive inhibitors, unlike rapamycin, induce apoptosis and autophagy (Chresta et al., 2010;
Thoreen et al., 2009; Yu et al., 2009). This is partly due to a more complete inhibition of Akt due
to the inhibition of phospho-S473 (Manning and Cantley, 2007).
Another reason why ATP-competitive inhibitors may be particularly effective is through
their inhibition of glycolysis. Most cancer cells have shifted their glucose metabolism from
oxidative phosphorylation to glycolysis, allowing them to survive in hypoxic and energy-poor
environments. Consequently, cancer cells are particularly dependent on glycolysis. The
glycolytic shift involves Akt-dependent activation of glucose transporter 1 (Glutl). Rapalog
treatment induces feedback activation of Akt, which may activate Glut 1 and glycolysis,
promoting cancer survival (Yu et al., 2009). On the other hand, ATP-competitive inhibitors also
inhibit mTORC2, thereby preventing phosphorylation of S473 on Akt and Akt-dependent Glut1
activation. By reducing glycolysis, ATP-competitive inhibitors may be more effective at
preventing tumor growth.
Yet another benefit of ATP-competitive inhibitors is that they inhibit the lipid
biosynthesis required for tumor cell proliferation. Tumor growth requires an increase in biomass
and lipid biosynthesis for cell membrane synthesis and lipid-based energy metabolism.
Moreover, lipid-modified molecules will be required for tumor cell signaling. Akt-activation
increases lipogenesis through a few mechanisms. First, Akt inhibits GSK3-6, which would
otherwise phosphorylate lipogenic transcription factors known as stabilize sterol-responsive
element-binding proteins (SREBPs), thereby targeting them for degradation. Active SREBPs will
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promote lipogenesis (Horton et al., 2002; Porstmann et al., 2005). Akt also phosphorylates and
activates ATP citrate lyase (ACL), a key regulator of fatty acid synthesis (Bauer et al., 2005;
Berwick et al., 2002). Consequently, upon rapalog treatment, feedback activation of Akt will
induce lipogenesis, thereby promoting tumor growth. In contrast, ATP-competitive inhibitors
will also inhibit mTORC2 and thereby prevent Akt activation and tumor-contributing lipogenesis
(Laplante and Sabatini, 2009; Shor et al., 2009).
One more advantage of ATP-competitive inhibitors is their ability to achieve more
complete cell cycle inhibition and GI arrest in preclinical models when compared to rapalogs
(Chresta et al., 2010; Feldman et al., 2009; Garcia-Martinez et al., 2009; Thoreen et al., 2009; Yu
et al., 2009). While rapalogs inhibit mTORC 1-dependent translation of cyclin D1, ATP-
competitive inhibitors also inhibit Akt-dependent activation of cyclin D1 transcription (Yu et al.,
2009). Moreover, ATP-competitive inhibitors (TorKIs) inhibit the Akt-mediated degradation of
GSK3-p, thereby promoting the degradation of cyclin D1 and cyclin E (Diehl et al., 1998; Liang
and Slingerland, 2003). In addition, TorKIs more effectively inhibit Akt and Sgkl -mediated
phosphorylation of p27, which allows for more effective inhibition of cyclin-Cdk2 (Chu et al.,
2008). Furthermore, by preventing phosphorylation of p27, p2 7 is localized to the nucleus and
does not bind to RhoA. Consequently, actin stability is restored and tumor cell motility and
metastasis is prevented (Larrea et al., 2009). In summary, through inhibiting Akt, TorKIs more
effectively inhibit cell cycle progression.
Finally, TorKIs also have anti-angiogenesis effects, likely through inhibition of hypoxia-
induced Hifla and Hif2a activation and reduced Vegf production (Yu et al., 2009). In addition to
conveying hypoxic signals, Hif2a mediates growth through upregulation of RTKs, thereby
providing another reason for the effectiveness of TorKIs (Franovic et al., 2009). In conclusion,
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there are many mechanistic explanations to the benefits of TorKIs over rapalogs, including their
sustained dephosphorylation of p-4eBP 1, inhibition of Akt, and suppression of glycolysis,
lipogenesis, cell cycle progression, and angiogenesis.
PP242 is a TorKI that has been shown to be effective in liquid tumors. It inhibited both
mTORCl and mTORC2 with sustained 4eBP1 de-phosphorylation (Apsel et al., 2008; Feldman
et al., 2009; Thoreen et al., 2009). It suppressed tumor growth in a mouse model of AKT-driven
lymphangiogenesis, where rapamycin was ineffective (Hsieh et al., 2010). It synergized with
imatinib or dasatinib to induce apoptosis in a BCR-ABL mutant cancer cell line (Janes et al.,
2010) PP242 likely inhibits mTORC2 effectively, as there is abrogation of insulin-induced
activation of mTOR in fat cell, skeletal muscle, and the liver. This is in contrast to rapamycin,
which induces an increase in p-Akt in those organs (Feldman et al., 2009). A derivative of PP242
with more favorable drug characteristics, INK128 (Intellikine), is currently in Phase 1 trials
(Hsieh and Ruggero, 2010). In multiple myeloma cell lines and transplant models, INK128 is
significantly more effective than rapamycin (Maiso et al., 2011). This is likely through inhibition
of both mTORC 1 and mTORC2, as it was shown that hairpin inhibition of mTORC 1 and
mTORC2 significantly inhibit the proliferation of multiple myeloma cells. To summarize,
TorKIs can also be effective in liquid tumors
AZD8055 and AZD2014 are in early clinical trials for advanced solid tumors (Marshall
et al., 2011). AZD8055 inhibits mTOR with an IC50 of 0.8nM and a very good selectivity profile
(Chresta et al., 2010). AZD8055 inhibits phosphorylation of 4eBP 1 on the rapamycin-resistant
T37/46 sites, preventing protein translation. It also inhibits mTORC2 as demonstrated by
reduced Akt phosphorylation (Ser473) and NDRG1 phosphorylation. Examining downstream of
Akt, Pras40 and forkhead box 01 (Foxol) also show reduced phoshporylation. De-
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phosphorylation of these sites further inhibit cap-dependent translation (Chresta et al., 2010).
AZD8055 induces a more complete cell cycle arrest (G1) than does rapamycin. Rapamycin has a
partial effect on cyclins, while AZD8055 significantly affects the cyclins as well as the Cdk
inhibitors, p27 and p21. In some cell lines, AZD8055 induces apoptosis and autophagy (Sini et
al., 2010). AZD8055-treated cancer cells showed a transient increase in ERK phosphorylation.
Consequently, AZD8055 was combined with a MEK inhibitor, AZD6244, in a xenograft model
of NSCLC, resulting in tumor regression and cell death.
In acute myeloid leukemia (AML), AZD8055 was particularly successfully (Willems et
al., 2011). AZD8055 blocked mTORC1/2 signaling, as indicated by dephosphorylation of
Akt(S473) and sustained dephosphorylation of 4e-BP . Moreover, there was no feedback
activation of PI3K/Akt that is typically associated with rapamycin-treatment. AZD8055 was
effective from a phenotypic perspective, as it decreased blast cell proliferation, cell cycle
progression, clonogenic growth of leukemic progenitors, and increased apoptosis in leukemic
cells, but not in their counterpart, normal immature CD34+ cells. Most importantly, AZD8055
reduced tumor burden and increased the survival of AML transplanted mice, without apparent
toxicity. To conclude, AZD8055 has been effective in both solid and liquid tumor settings.
OSI-027 can inhibit mTOR kinase at sub-nM concentrations. More specifically, the ex
vitro IC50 for mTORCl and mTORC2 is 22nM and 65nM, respectively. OSI-027 shows more
than 100-fold selectivity for mTOR relative to PI3Ka, PI3Kp, PI3Ky, and DNA-PK (Bhagwat et
al., 2011). OSI-027 effectively inhibits phosphorylation of mTORCl substrates (4E-BP1 and
S6Kl) and mTORC2 substrates (AKT) in various cancer models in vitro and in vivo.
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OSI-027 demonstrated activity in a variety of tumor xenograft models. In two colon
cancer xenograft models, OSI-027 exhibited superior efficacy compared to rapamycin. Chronic
myelogenous leukemia cell lines with the refractory T3151 mutant BCR-ABL undergo apoptosis
upon treatment with OSI-027 (Vakana et al., 2010). These T3151 mutant lines are refractory to
standard BCR-ABL inhibitors. A phase 1 trial of OSCI-027 is currently ongoing (Carayol et al.,
2010). Upon treatment with OSI-027, just over half the patients show a substantial decrease in
4EBP1 (Thr37/46) phosphorylation. OSI-027 showed strong activity in in vitro and in vivo
models of renal cell carcinoma. In addition, it synergized with sorafenib and bevacizumab in
preclinical models. OSI-027 has also been combined with a Vegfr inhibitor (OSI-930),
demonstrating substantial vascular and tumor regression (Falcon et al., 2011).
OSI-027 is also effective in liquid tumorsOSI-027 demonstrates activity in various
lymphoid cell lines including B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma,
marginal zone lymphoma, and sezary syndrome (Gupta et al., 2011). Moreover, in a xenograft
model of mantle cell lymphoma, OSI-027 induced regression. OSI-027 suppresses growth and
colony formation of primitive leukemic progenitors from AML patients (Altman et al., 2011 a).
Moreover, OSI-027 does so more effectively than rapamycin. In summary, OSI-027 has shown
effectiveness in both solid and liquid tumors.
WYE-125/WYE-132 (Wyeth) is a highly potent, ATP-competitive, orally-administered
small-molecule mTOR inhibitor (Yu et al., 2010). Its IC50 against mTOR is 0.19 nM 4 0.07 nM.
Its selectivity for mTOR is 5,000-fold greater than that for P13K. WYE-132 inhibits both
mTORC 1 and mTORC2 in a variety of cancer models in vitro and in vivo. In particular, WYE-
132 administration downregulates p-Akt (S473) without significantly affecting p-Akt (T308).
This demonstrates that treatment-induced feedback upregulation of the Pi3k/Akt pathway is not
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significant. WYE- 132 is notably more effective than temsirolimus, a rapalog, at inhibiting cancer
growth and survival. WYE- 132 demonstrated activity in vivo against breast, brain, lung, and
renal cancer models. For lung cancer, combining WYE- 132 with bevacizumab resulted in
complete regression in one lung cancer line. To summarize, WYE-132 is a promising TorKI.
Torin1 is a TorKI originally developed from an academic lab and has shown activity in
various preclinical models. Torin1 more effectively induces autophagy than does rapamycin. It
inhibits both mTORC 1 and mTORC2 and induces sustained inhibition of 4EBP 1
phosphorylation. Torin2 is an improvement on Torin1 and demonstrates better pharmacokinetic
properties and has a higher yielding synthetic route (Liu et al., 2011 a).
TorKIs have been tested in various cancer types including breast cancer, gliomas,
NSCLC, and AML (Altman et al., 201 1b; Martelli et al., 2010; Zhang et al., 2011). Clinical trial
results have been described for the following compounds: Ku0063794, (Kudos Pharmaceuticals),
WJD008, (Shanghai Institute of Material Medica), PK1402, (Novartis), NVP-BBD130, NVP-
BAG956, (Novartis), OXA-01, (OSI Pharmaceuticals) (Falcon et al., 2011; Garcia-Martinez et
al., 2009; Li et al., 2010; Mallon et al., 2010; Marone et al., 2009).
As pan-TorKIs have been better studied in colorectal cancer (CRC) than PDAC, we have
described below the findings in CRC. 30 to 50% of CRCs show a mutation in Kras (Liu et al.,
201 1b). While CRCs with Egfr amplification are responsive to Egfr-targeted therapies, those
with Kras-mutations are resistant. In primary human CRC tumors, mTOR is often
hyperactivated. RNAi knockdown of mTOR inhibits CRC growth in vitro and in vivo (Zhang et
al., 2009a). In contrast, rapamycin did not as effectively inhibit CRC growth in vitro and in vivo
(Zhang et al., 2009b).
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A recent study analyzed rapamycin, two TorKIs, and one mTOR/Pi3K inhibitor in the
context of 12 CRC cell lines (Zhang and Zheng, 2012). TorKIs were effective in 60% of the cell
lines, while rapamycin was only effective in 17%. Moreover, any cell lines sensitive to
rapamycin were also sensitive to TorKIs. In the lines that were sensitive to the two drugs,
treatment abolished 4e-BP1 (T37/46) phosphorylation. In the lines that were not sensitive to the
drugs, treatment only transiently inhibited phosphorylation of 4e-BP1 (T37/46). Re-
phosphorylation of 4e-BP1 (T37/46) occurred via an mTOR-independent mechanism.
Identifying and targeting the kinase responsible for this phosphorylation would be an effective
next step. This study shows that a suitable pharmacodynamic biomarker for mTOR inhibitor
therapy is p-4eBP 1 (T37/46), as opposed to the more commonly used p-S6kl. In further support,
other studies have shown that an inability for rapamycin to inhibit 4e-BP 1 phosphorylation
correlates with resistance in other cancer types (Choo and Blenis, 2009; Dowling et al., 2010;
Yellen et al., 2011). Somewhat surprisingly, PTEN and PI3KCA mutation status did not
correlate with cell line sensitivity, as one may expect such mutations to increase mTOR signaling
and sensitivity to mTOR inhibition. Moreover, most of the cell lines that carried Kras mutations
were sensitive to TorKIs, suggesting that TorKIs may be useful in other Kras-mutant cancers
such as PDAC. In summary, the studies performed in CRC suggest that TorKIs are a promising
therapy for solids tumors including PDAC.
One weakness to mTORC1/2 inhibitors is that feedback activation of Pi3k still occurs. As
described before, inhibition of mTORC 1 gives rise to feedback activation of Pi3k. While
inhibition of mTORC2 will prevent phosphorylation of S473 on Akt, activation of Pi3k can
signal to Pdk1 to phosphorylate Akt on T308. Akt, when phosphorylated at T308 but not S473, is
partially active and can continue propagating tumor growth (Feldman et al., 2009). mTOR/Pi3k
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inhibitors allow for inhibition of both mTOR and feedback activated Pi3k. Consequently, these
compounds may allow for more complete inhibition of tumorgenesis.
Epidemiological studies show that patients taking metformin have a lower incidence of a
broad range of cancers (Currie et al., 2009; Evans et al., 2005; Libby et al., 2009). Metformin is a
frequently prescribed anti-diabetic drug. It inhibits mTORC1 through a variety of mechanisms. It
has anti-proliferative effects at 10 iM in a wide range of cancer models in vitro and in
xenografts. 10 pM is 10 to 100-fold greater than the plasma concentration attained when dosing
diabetic patients (Chong and Chabner, 2009). However, metformin has demonstrated strong
epidemiological evidence of anti-tumor activity in diabetic patients taking the drug. Metformin's
efficacy suggests that partial inhibition of the mTOR pathway may be a potential tumor
prevention strategy.
Other drugs are available that also inhibit mTOR. Famesyltransferase inhibitors inhibit
RHEB, a direct activator of mTORC1 (McMahon et al., 2005). Amino acid deprivation inhibits
mTORC 1. Asparaginase (Elspar/Merck), approved for the treatment of acute lymphoblastic
leukemia, reduces the levels of asparagines and glutamine in the circulation and inhibits
mTORCl activity (Bunpo et al., 2009). mTOR inhibition is also beneficial for the treatment of
other diseases including diabetes, life extension, neurological disorders (Chong et al., 2010). To
summarize, mTOR inhibition can be achieved by various drugs and is beneficial in diseases in
addition to cancer.
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Effects of mTOR Inhibition
Downstream Signaling
There are two possibilities as to why rapalogs may be ineffective in the clinic: A) because
inhibition of mTORC 1 is insufficient to suppress tumorigenesis B) because the rapalogs do not
reach the tumor in sufficient concentration to substantially inhibit mTORC 1. If it is the former,
targets besides or in addition to mTORC1 (i.e. mTORC2) should be explored. If it is the latter,
more pharmacokinetically favorable drugs should be designed to allow for substantial inhibition
of mTORC 1. To determine whether mTORC 1 is substantially inhibited, phospho-signaling
molecules downstream of mTORC 1 are measured. Everolimus was given to patients with a
variety of cancers (35% with breast cancer, 29% with colorectal cancer, 78% with pancreatic
cancer, 4% with either NET, renal cancer, NSCLC, gallbladder cancer, or melanoma, and 11%
with other types of cancer), resulting in inhibition of signaling molecules downstream of mTOR
(Tabernero et al., 2008). In specific, two phosphorylation sites on S6 were downregulated in both
the tumor site and the peripheral skin. S6 is a target of S6kl, which itself is a primary target of
mTORCl (Figure 23). Substantial down-regulation was achieved such that no signal was
detectable by immunohistochemistry in all 30 tumor and 43 skin samples examined (Figure 24).
Moreover, everolimus induced substantial downregulation of eIF-4G such that no p-eIF-4G
signal was detectable in all the tumor samples. In the skin samples, there was a slight signal in a
few samples. In conclusion, there is essentially complete inhibition of p-S6 and p-eIF-4G from
mTOR therapy. Although S6kl and S6 are downstream targets of mTOR, their phosphorylation
status do not correlate with rapamycin response in preclinical models. Rather, rapamycin
response correlates with the phosphorylation status of 4eBP1 (Choo et al., 2008; Feldman et al.,
2009; Noh et al., 2004; Yu et al., 2009).
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Tum or Skin
Pospho 30 Samples 43 SamplesProtein (p-Value) (p-Value)
p-S6_S235/236 4 (< 0.001) 44 (< 0.001)
p-S6s 240/244 4 (< 0.001) 44 (< 0.001)
p-4e-BP1Th7O 1 (0.058) 1 (< 0.001)
p-elF-4Gs1 108 44 (< 0.001) 14 (< 0.001)
p-Akts473 1(0.006) T (< 0.001)
Figure 23. Summary of the Effects of Everolimus Treatment on Signaling in Various Cancers.
Everolimus was given to patients with a spectrum of various cancers. The effect on a variety of mTOR
downstream signaling molecules was assessed. Adapted from Tabernero, JCO 2008.
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Figure 24. Effect of Everolimus Treatment on Signaling in Various Cancers. Pharmacodynamic effects
after everolimus treatment in all the patients included in the study with (A) assessable paired tumor (n =
30) and (B) skin samples (n = 43). Box-plots showing the expression at baseline and on-treatment for the
following markers: pS6er235/6, pS6er2 40 /4, peIF4Gserl 108, p4E-BP I Thr7O, pAktser4 73 . Boxes indicate 90% of
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I
the values. Bold lines indicate the mean of the values. External lines indicate the complete range when
beyond 90% of the values. Day 0: baseline sample; day 22: sample obtained at fourth week 24 hours after
dosing. Adapted from Tabernero, JCO 2008.
p-4eBP I is a particularly important downstream signaling molecule to examine, as
inhibition of p-4e-BP 1 is correlated with anti-tumor efficacy. In vitro studies show that rapalogs
are unable to sustain prolonged inhibition of p-4e-BPl, thereby allowing cap-dependent
translation to resume (Choo et al., 2008; Feldman et al., 2009). Consequently, clinical studies of
rapalogs may result in incomplete inhibition of p-4e-BP 1. Although eIF-4G is downstream of 4e-
BP1, p-4e-BP 1O was surprisingly less inhibited than p-eIF-4Gsio8. In the tumor samples,
there was an approximately 30% decrease in signal strength, although not statistically significant
(p = 0.058). In the skin samples, there was a more substantial and significant reduction of 50% (p
< 0.001). In summary, at the more important site (tumor sample), we do not observe a significant
reduction in signal. Consistent with other studies, significant and sustained inhibition of p-4e-
BP1 is difficult to achieve. The new TorKIs may be more effective, as they have at least shown
sustained inhibition of p-4e-BP1 in vitro. It would be ideal to measure inhibition of mTOR at the
tumor site, but pancreatic tumor biopsies are invasive and risky. Instead, skin and peripheral
blood mononuclear cells (PBMCs) are used as proxies for the tumor site.
Patients receiving temsirolimus demonstrated reduced levels of p-S6K1 in PBMCs and
tumor biopsies (Peralba et al., 2003) 9 patients were treated with temsirolimus at doses of 25, 75,
or 250mg. After a single intravenous dose, p-S6k levels in PBMCs were assessed by western
blot. After one day, p-S6k levels were, on average, at 30% of baseline. After 3 and 8 days, they
were at 20% and 15%, respectively. Dosing levels did not correlate with the level of p-S6k
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inhibition, suggesting that 25 mg of temsirolimus was sufficient to achieve significant inhibition
of p-S6k.
Administration of everolimus reduced levels of p-S6kl by 93% to 100% and p-4eBP1 by
6% to 64%, respectively, at the tumor site. In addition, p-S6kl levels also decreased in PBMCS
(Raymond et al., 2004). As illustrated, p-S6kl is effectively inhibited in the tumor, while p-
4eBP1 is only partially inhibited. These findings are in parallel with those found in pre-clinical
models.
Deforolimus is able to cross the blood brain barrier, as in glioblastoma, inhibition of p-
S6K1 was achieved in 6 out of 8 brain biopsies (Mita et al., 2008). This reduction was observed
even a week after dosing. Additionally, skin biopsies revealed a significant reduction (>85%) of
p-S6K1 in 22 of the 28 patients examined, implying that the drug is efficiently entering the skin.
In another study of deforolimus in 32 patients, a rapid and significant reduction of p-4eBP1 was
observed in PBMCs (Peralba et al., 2003). Deforolimus was given at various doses: 3, 6.25, 12.5,
15, 18.75, and 28 mg. After a 1 hour of infusion, there was a median reduction of p-4eBP1 of
96% for the 32 patients. After 4 hours of infusion, the reduction had increased slightly to 97%.In
summary, deforolimus substantially inhibits p-4eBP 1 in peripheral cells, but it is unclear whether
such inhibition is observed at the tumor site. Moreover, in vitro studies have shown that
sustained inhibition of p-4eBP 1 is difficult to attain, and this study did not look at time points
beyond 4 hours. As described above, multiple studies have shown that rapalog treatment results
in notable inhibition of p-S6kl but not of p-4eBP l.
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Drug Resistance
Consistent with our knowledge that Kras-mutant tumors are particularly resistant to
therapies, they are also more resistant to mTOR inhibition. Patients with Kras-mutant tumors
show resistance to Everolimus, when compared to non-Kras-mutant tumors (Di Nicolantonio et
al., 2010). In a clinical trial with pancreatic cancer (2 patients), colon cancer (23), breast cancer
(15), head and neck cancer (1), and melanoma (2), patients with a Kras mutation demonstrated
resistance to Everolimus. Of the 12 patients with mutant Kras, only 1 showed stable disease,
while the other 11 had progressive disease. Of the 31 patients with wild-type Kras, 14 showed
stable disease, 1 showed a partial response, and 16 had progressive disease. The difference in
response was significant with a p-value of 0.017. As illustrated, patients with wild-type Kras
showed much better response to Everolimus than those with mutant Kras. Consequently, for the
treatment of PDAC, which is often Kras-mutant, mTOR inhibitors will likely need to be
improved or combined with other therapies.
Biomarkers can allow us to identify patients that are more likely to respond to mTOR
inhibitors. Biomarkers that have been used to identify patients that will respond to rapalogs
include HER2 amplification in breast cancer, overexpression of RTKs, PTEN loss, PIK3CA
mutations, increased phospho-Akt, CyclinD 1 overexpression in mantle cell lymphoma, and von
Hippel-Lindau (VHL) loss in renal cell carcinoma and Kaposi sarcoma (Cho et al., 2007; Duran
et al., 2006; Iwenofu et al., 2008; Thomas et al., 2006). Depending on the study and the tumor
type, low or high basal levels of Pi3k/Akt signaling can correlate with rapalog sensitivity or
resistance. In one study of renal cell carcinoma, resistance to temsirolimus was associated with
low baseline levels of p-Akt and p-S6kl in the tumor. On the other hand, in another study,
tumors with loss of PTEN or activation of Akt, S6kl, or 4e-BP 1 were particularly sensitive to
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mTOR inhibitors. In yet another study, Pi3k activation or PTEN loss enhanced sensitivity to
everolimus. However, this sensitivity was lost if oncogenic KRAS or BRAF mutations were also
present (Di Nicolantonio et al., 2010). For TorKIs, efforts have been made to identify a
biomarker for mTORC2. AZD8055 administration in xenografts reduced glucose (radioactively-
labeled [18] FDG) uptake, and this decline correlated with decreased p-Akt and p-S6 in the
tumor. Consequently, labeled glucose may be a suitable biomarker for mTORC2 activity. In
conclusion, markers are being identified that can help predict patients who would respond better
to mTOR inhibitors.
One reason why rapalogs may be ineffective for various cancers is an inadequate
inhibition of p-4eBP 1. To address this insufficiency, TorKIs have been created, which have
demonstrated substantial and sustained inhibition of p-4eBP 1 in vitro. Clinical trials for TorKIs
are currently underway. Another reason why rapalogs may be ineffective is the feedback-induced
upregulation of various pathways, including Pi3k/Akt and Mapk (Carracedo and Pandolfi, 2008;
Zhang et al., 2007). Pre-clinical trials have demonstrated efficacy of combining mTOR inhibition
with inhibitors that target these various pathways. Many of these combinations are currently in
clinical trials. Yet another approach being taken is combining mTOR inhibition with inhibitors of
other pathways that may not necessarily depict feedback-induced upregulation. For instance, in a
rapamycin-resistant ovarian cancer cell line that expressed high levels of BCL2, antisense
oligonucleotides against BCL2 re-established sensitivity to rapamycin (Shinoura et al., 1999).
These various approaches are described in more detail in the section below.
mTOR Inhibition + Other Compounds
AZD8055 or rapamycin treatment causes a transient upregulation of p-Erk, suggesting
that simultaneous inhibition of the Mapk pathway and mTOR may be effective. As evidenced in
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a clinical trial, everolimus-treatment induced upregulation of Mapk in metastatic solid tumors
(Carracedo et al., 2008). Normally, S6kl has the effect of inhibiting Mapk through the pathway
S6kl -> Pi3k -> Ras -> Mapk. Therefore, upon inhibiting mTORC1 and S6kl, Mapk is
activated. AZD8055 and Selumetinib/AZD6244/ARRY-142866, an allosteric Mek inhibitor,
each individually only inhibit NSCLC xenograft growth. The combination of the two drugs
results in cell death and tumor regression. Surprisingly, the level of transient upregulation of p-
Erk did not correlate with the response to AZD6244, suggesting that the level of p-Erk alone is
not predictive of response to the combination therapy. Another combination, that of temsirolimus
and a MAPK inhibitor, SL327, significantly reduced brain metastases in vivo, whereas
temsirolimus alone has no effect (Zhao et al., 2012). To conclude, combining mTOR and Mapk
inhibition has been effective in various cancer settings.
Rapamycin-treatment activates Akt through negative-feedback loops. mTORC 1 inhibits
mTORC2 by signaling to S6kl to phosphorylate and inhibit Rictor (Dibble et al., 2009; Julien et
al., 2010). Consequently, rapalog-treatment will inhibit mTORCl and drive mTORC2-mediated
Akt activation. Patients who demonstrate a strong increase in p-Akt are those who respond less
well to mTOR inhibitors. After 4 weeks of rapamycin treatment, patient tumors show higher
levels of activated Akt. Similarly, when patients were given a high dose of everolimus, p-Akt
was upregulated by 22 - 63% at the tumor site (Raymond et al., 2004). In patients with colon
cancer treated with everolimus, histological sections show activation of Akt in the colorectal
tumors (O'Reilly et al., 2006). This suggests a therapeutic strategy that simultaneously inhibits
Pi3k and Akt. In another study, everolimus-treatment induces, in tumor samples, upregulation of
p-AktS4 73 by approximately 300% (p = 0.006) (Figure 24). In the skin samples, p-AktS473 was
upregulated by about 50% (p < 0.001). To summarize, there is substantial and significant
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upregulation of p-Akts4 7 3 . Inhibiting p-AktS4 7 3 in conjunction with everolimus-treatment may
increase anti-tumor efficacy. One approach to inhibit p-AktS473 is to use TorKIs, which inhibit
mTORC2, the kinase responsible for phosphorylation of Akt at Serine 473. TorKIs have
demonstrated successful inhibition of p-AktS473 in vitro. TorKIs are currently being assessed in
clinical trials.
Another approach to inhibit p-Akt (S473) is to combine inhibitors of the Akt pathway
along with rapalog-therapy. Combining rapalogs with Pi3k or Akt inhibitors has led to
synergistic effects in human gliomas (Sun et al., 2005; Takeuchi et al., 2005). Moreover,
combining rapamycin with Pi3k inhibition shows additional benefits compared to rapamycin
alone in leukemia cells (Ikezoe et al., 2007). Another study covalently links Rapamycin to a Pi3k
inhibitor and demonstrates that the conjugate is better tolerated and more effective than either
compound alone (Ayral-Kaloustian et al., 2010). By linking together the two compounds, each
individual cell is likely to experience simultaneous inhibition of mTOR and Pi3k, thereby
increasing the anti-tumorigenic effect. In multiple myeloma cells, nanoparticle-bound rapamycin
has a greater effect when used in combination with Perifosine, an Akt inhibitor (Cirstea et al.,
2010). Moreover, inhibiting molecules downstream of Akt such FoxO may potentiate the
anticancer activity of Rapamycin (Abdelnour-Berchtold et al., 2010). To conclude, combining a
Pi3k or Akt inhibitor with rapalogs is a promising strategy to be pursued in clinical trials.
The combination of mTOR inhibitors and HDAC inhibitors have been shown to be
effective in hepatocellular cell carcinoma in vitro and in vivo (Shao et al., 2012). The mTOR
inhibitors examined include PP242, AZD8055, and OS1027. HDAC inhibitors tested include
SAHA and LBH589. Various human hepatocellular cell carcinoma lines were used in vitro. The
in vivo system was established by injecting patient-derived primary hepatocellular carcinoma
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cells subcutaneously into SCID mice. In vivo studies demonstrate that the combination of
AZD8055 and SAHA almost completely inhibited tumor growth, while each agent alone only
achieved 50% inhibition of tumor growth. In summary, it may be worthwhile to consider
combining mTOR and HDAC inhibitors for PDAC.
Rapamycin in combination with Igflr antagonists give additive anti-proliferative effects
in breast cancer, prostate cancer, and myeloma pre-clinical models. The combination is currently
being clinically evaluated. In patients with neuroendocrine tumors, the combination of
everolimus and somatostatin analogues or ridaforolimus and anti-Igf-1R antibodies have been
effective (Salazar et al., 2011). Another approach to inhibiting Igflr activity is to inhibit Igf.
Everolimus is being tested in combination with octreotide, a somatostatin analog that blocks Igf
production, thereby preventing Pi3k activation. In a phase 2 trial for neuroendocrine tumors,
everolimus in combination with octreotide gave an ORR of 20%, which was notably higher than
that arising from everolimus alone (Yao et al., 2008). The registration trial is currently underway.
To summarize, inhibition of Igf1r along with mTOR inhibitors is a potential therapeutic strategy.
mTOR inhibition can sensitize cells to chemotherapy. Knockdown of mTORCl and
mTORC2 sensitizes colorectal cancer cell lines to apoptosis induced by oxaliplatin (Gulhati et
al., 2011). There is evidence suggesting that combining everolimus with cisplatin or paclitaxel is
a reasonable approach. Cisplatin-resistant squamous cell carcinomas demonstrate upregulated
Akt and Erk signaling upon cisplatin treatment, suggesting that inhibition of the mTOR pathway
may be effective (Aoki et al., 2004; Oki et al., 2005). Combining rapamycin with paclitaxel may
enhance the effect of apoptosis through glycogen synthase kinase 3P (Dong et al., 2005).
Unfortunately, combining rapalogs with gemcitabine and 5-fluorouracil led to unacceptable
toxicity including thrombocytopaenia and mucositis.
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mTOR inhibition may be sensible in combination with Her2/ErbB2 inhibition for breast
cancer. Herceptin/trastuzumab (Genentech), a monoclonal antibody therapy for breast cancer,
eventually becomes futile because PTEN-deficiency promotes resistance and tumor progression.
Patients with PTEN-deficient breast cancer respond less well than those with non-PTEN-
deficient cancers (Nagata et al., 2004). Moreover, pre-clinical studies show that combining
trastuzumab therapy with inhibition of the P13K signaling pathway prevents loss of PTEN and
the development of trastuzumab resistance. Lapatinib, a small molecule inhibitor of ErbB2, is
synergistic with AZD8055 on cell lines. Each agent individually induces growth inhibition, while
the combination causes cell death (Sini et al., 2010). The combination of mTOR and Her2
inhibition may also be effective in PDAC.
Rapalogs have also been tested in combination with Egfr inhibitors and angiogenesis
inhibitors (Garcia-Martinez and Alessi, 2008). In NSCLC cell lines, resistance to Iressa/gefitinib
(AstraZeneca) has been linked to increased Akt phosphorylation and reduced Pten expression,
suggesting that combining Egfr inhibition with mTOR inhibitors may be effective (Kokubo et
al., 2005). A study in epithelioid sarcoma demonstrated that the combination of rapamycin with
erlotinib, an inhibitor of Egfr, resulted in a synergistic effect in vitro and was more effective than
single agent in vivo (Xie et al., 2011). An ongoing phase 1/2 trial is combining everolimus with
bevacizumab, a Vegf inhibitor, in colorectal cancer.
A recent study has shown that combining mTOR with Hsp90 inhibition may be effective
in Kras-mutant tumors (De Raedt et al., 2011). Hsp90 inhibition is effective likely in part due to
its inhibition of Stk33 (Azoitei et al., 2012). Stk33 had been identified as a synthetic lethal target
in a large-scale Kras synthetic lethal RNAi screen. In summary, Hsp90 inhibition may have
synthetic lethal effects through its effect on other known synthetic lethal genes. Moreover,
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targeting the recently identified Kras-synthetic lethal genes may be a promising therapeutic
approach.
While mTOR inhibition can be effective as first-line therapy, it can also be beneficial in a
supporting role for patients who have developed resistance to another therapy. In breast cancer,
elevated AKT signaling correlated with resistance to tamoxifen, an anti-estrogen therapy. In vitro
experiments demonstrate that temsirolimus can restore sensitivity to tamoxifen (deGraffenried et
al., 2004). Pre-clinical studies show that rapalogs augmented the effects of anti-estrogens,
including tamoxifen, fulvestrant, and aromatase inhibitors (letrozole and exemestane) (Beeram et
al., 2007; deGraffenried et al., 2004; Sadler et al., 2006). In clinical trials, while temsirolimus
added to letrozole showed no additional improvement over letrozole alone for metastatic ER+
breast cancer, everolimus complemented letrozole for patients with advanced breast cancer
(Awada et al., 2008; Baselga et al., 2009). Clinical studies ongoing are evaluating the
combination of rapalogs and tamoxifen. Another example of rapalogs being effective in a
supporting role is in gastrointestinal stromal tumors (GIST), where resistance to imatinib
mesylate correlated with the activation of the PI3K/mTOR pathway. Moreover, combining
everolimus with imatinib was synergistic in human GIST cell lines resistant to imatinib mesylate.
Phase I data of the combination therapy was promising, and the drugs are currently in phase 2
trials. In summary, mTOR inhibition can re-sensitize tumors to other therapies.
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Target 1 Drug I Target 2 Drug 2 Target 3 Drug 3 Phase Indication Reference
Pi3k/mTOR NVP-BEZ-235 P13k BKM-120 Mek MEK-162 1 Solid Tumors Benjamin, NRDD 2011
PI3k/mTOR NVP-BEZ-235 P13k BKM-120 Aromatase Inhibitor Letrozole 1 Solid Tumors Benjamin, NRDD 2011
Pi3k/mTOR NVP-BEZ-235 Mek MEK-162 1 Solid Tumors Benjamin, NRDD 2011
P13k/mTOR NVP-BEZ-235 Mitotic Inhibitor Paclitaxel Her2 Trastuzumab 1 Solid Tumors Benjamin, NRDD 2011
P3k/mTOR XL-765 Pi3k XL-147 1 Solid Tumors Benjamin, NRDD 2011
P13k/mTOR XL-765 P13k XL-147 Aromatase Inhibitor Letrozole 1 Solid Tumors Benjamin, NRDD 2011
P3k/mTOR XL-765 Egfr Erlotinib 1 Solid Tumors Benjamin, NRDD 2011
P13k/mTOR XL-765 DNA Alkyating Temozolomide 1 Solid Tumors Benjamin, NRDD 2011
P13k/mTOR GDC-0980 Proton Pump Inhibitor Rabeprazole 1 Solid Tumors Benjamin, NRDD 2011
P13k/mTOR GDC-0980 Vegf Bevacizurmab DNA Damaging Carboplatin 1 Solid Tumors Benjamin, NRDD 2011
P13k/mTOR GDC-0980 Vegf Bevacizumab Combination mFOLFOX6 1 Solid Tumors Benjamin, NRDD 2011
P13k/mTOR GDC-0980 Vegf Bevacizumab Her2 Trastuzumab 1 Solid Tumors Benjamin, NRDD 2011
P13k/mTOR PKI-587 Topo I Inhibitor Irinotecan 1 Solid Turors Benjamin, NRDD 2011
Pi3k/mTOR PF-04691502 Mek PD-0325901 1 Solid Tumors Benjamin, NRDD 2011
P13k/mTOR GSK-2126458 Mek GSK-1120212 1 olid umors Benjamin, NRDD 2011
mTORC1/2 INK-128 Mitotic Inhibitor Paclitaxel Her2 Trastuzumab 1 Solid Tumors Benjamin, NRDD 2011
Many therapeutic combinations are being tested in phase I clinical trials (Figure 25). All
but one of the indicated combinations involve a Pi3k/mTOR dual inhibitor. One study used an
ATP-competitive mTOR inhibitor, INK-128. In the various studies, the other drug that is
combined with the mTOR inhibitor ranges from Mek to Pi3k inhibitors to chemotherapies. It is
not surprising that there are many combinations being tested in phase I trials as many
combinations have been successful in pre-clinical studies. Since Pi3k/mTOR inhibitors do not
completely inhibit Pi3k, combination therapy with Pi3k inhibitors is sensible. In summary, not
only have there been many mTOR inhibitors in clinical trials, but there have been many
combinations of mTOR inhibitors along with other drugs.
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CHAPTER 1: Establishing and Validating an Inducible RNAi
system
Abstract
We established an inducible RNAi system to examine the effect of knockdown of various
Kras effectors. This system consists of mouse PDAC cell lines containing an inducible hairpin
that is activated in the presence of doxycycline. This scheme allows for regulatable knockdown
of genes of interest in vitro. Moreover, we demonstrate that the cell line can be transplanted
subcutaneously and orthotopically into nude mice and knockdown can be assessed. We confirm
that these PDAC lines are sensitive to Kras knockdown. Kras knockdown in vitro inhibits PDAC
cell line proliferation and demonstrates synthetic lethality when using immortalized baby mouse
kidney cells and mouse 3T3 fibroblasts as the comparator normal cells. Synthetic lethality is
enhanced when in vitro glucose concentrations are lowered to a more physiologically
representative concentration, suggesting that Kras is a particularly good target in vivo. In vivo,
induction of Kras knockdown significantly regresses subcutaneous and orthotopic transplants, as
indicated by bioluminescence tracking of the tumor. This model can be used to assess, among
other genes, the importance of various Kras effectors in PDAC.
Introduction
Pancreatic Ductal Adenocarcinoma (PDAC) is the 4 th leading cause of cancer-related
deaths and is a highly lethal cancer with a 5-year survival rate of less than 5% (Anderson KE,
2006) (Figure 26, Figure 27). The currently approved therapies for PDAC are relatively
ineffective (Figure 28). Better therapies are needed for PDAC. As Kras is a frequently mutated
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oncogene in PDAC (95-100% of the cases), it is a natural target to inhibit to hinder tumor
progression (Bos, 1989). Kras has been very difficult to inhibit, as it is not a standard gain-of-
function mutation, but rather a loss-of-function alteration that leads to a constitutively active
gene. In more detail, the common mutation in codon 12 of Kras leads to a loss of the GTPase
activity of the enzyme. Consequently, Kras is bound to GTP for a prolonged period of time and
is overactive. There is yet no known method to restore the GTPase activity.
4 Leading Cause Lowest survival rate
Of Cancer-Related of the 12 most
Deaths common cancers
2011 Estimates Survival Rate
New Cases: 44,000 1-yr: 25%
Deaths: 37,700 5-yr: 5%
. | 50% are G12D
Genotype Tumors
Kras + I Tumor Suppressor 5
Kras + 2 Tumor Suppressor 9
Kras + 3 Tumor Suppressor 10
Total =24
Jones et at, Science 2008
Hezel et al, G&D 2006
Figure 26. Clinical and Genetic Aspects of Pancreatic Cancer. PDAC is the 4 th leading cause of cancer-
related deaths, with an estimated number of new cases of 44,000 in 2011 and deaths of 37,700. Of the 12
most common cancers, PDAC exhibits the lowest survival rate, with a 1-year survival rate of 25%, and a
5-year of 5%. The most commonly mutated genes in PDAC are Kras, p16, p53, and Smad4, with
mutation frequencies of 90-100%, 80-95%, 50-75%, and 50-55%, respectively. Of the mutations in Kras,
50% of them are a glycine to aspartate substitution in codon 12. In the Jones, Science 2008 study, 24
PDAC tumors were examined, and all of them were found to contain the Kras mutation and at least one
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Frequency
Gene Of
Mutation
Kras 90-100%-
p161nk 4a 80-95%
p53 50-75%
Smad4 50-55%
alteration in one of the following tumor suppressors (p16, p53, or Smad4). 5 of the tumors contained
alterations in just one of the tumor suppressors. 9 of them contained alterations in two tumor suppressors,
and 10 of them exhibited alterations in all three tumor suppressors.
Pancreatic Tumor
90%
15% 135%
Figure 27. The Prognosis of Various Stages of Panreatic Ductal Adenocarcinoma (PDAC). 90% of
pancreatic cancers are PDACs. Of PDACs, 15% are resectable, 35% are invasive, and 50% are metastatic.
The overall survival for resectable, invasive, and metastatic PDAC is 15, 9, and 6 months.
IThe Only FDA Approved Therapies for PDAC I
Figure 28. FDA Approved Therapies for Pancreatic Ductal Adenocarcinoma (PDAC). The FDA approved
therapies for PDAC (Gemcitabine and Erlotinib) are indicated. The pivotal trial for gemcitabine extended
median overall survival from 4.4 months for the 5-fluorouracil comparator to 5.7 months for gemcitabine.
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Survival
Drug Comparison Difference Citation
(Months) _______
. Gemcitabine vs Burris,Gemcitabine 5-FluoroUracil 5.7 vs 4.4 JCO 1997
Erlotinib Gemcitabine 6.2 vs 5.9 Moore et al,I Erlotinib JCO 2007
The pivotal trial for erlotinib extended survival from 5.9 months (gemcitabine-alone) to 6.2 months when
erlotinib was used in combination with gemcitabine.
Another approach to inhibit Kras is to inhibit the post-translational modifications of Kras
that are necessary for membrane localization and functionality (Seabra, 1998). In detail,
inhibition of famesyltransferase to prevent farnesylation of Kras has led to compensatory
geranylgeranylation of Kras by geranylgeranyltransferases, allowing Kras to reach the membrane
and perform its activity. Inhibiting both famesyltranferase and geranylgeranyltransferase led to
excessive toxicity in a phase I trial. A major downside to targeting post-translational modifiers is
the likely side effects, as many other proteins undergo famesylation and geranylgeranylation.
Kras Mutation -- Loss of Kras GTPase activity
Cannot Use Standard Inhibitor
Inhibit Post-translational Modifications
Ax /AAx (E34ocH3
Karnoub, Nat Cell Bio Rev 2008
Phase III Trial of Gemcitabine Plus Tipifarnib Compared A Phase I Trial of the Dual Farnesvltransferase and
With Gencitabine Plus Placebo in Advanced Geranylgeranyltransferase Inhibitor L-778,123
Pancreatic Cancer and Radiotherapy for Locally Advanced
Martin, Clin Can Res 2004 Pancreatic Cancer
Van Cutsem, J Clin Oncol 2004
FTI -> Not Efficacious FTI + GGTI -> Excessive Toxicity
Figure 29. Attempts to directly inhibit Kras. As the Kras mutation gives rise to a loss of Kras GTPase
activity, a standard inhibitor would not be effective against Kras. Rather, targeting the post-translational
modifiers of Kras may be an effective therapeutic strategy. A phase III trial of tipifarnib, a
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farnesyltransferase inhibitor, did not show a significant benefit above placebo. L-778,123, a dual inhibitor
of farnesyltransferase and geranylgeranyltransferase, demonstrated excessive toxicity in phase I trials.
Yet another approach to inhibit Kras is to target the genes downstream of Kras,
particularly those that are involved in cancer (Moodie et al., 1993; Wame et al., 1993)
(Castellano and Downward, 2010; Vivanco and Sawyers, 2002) (Feig, 2003). The three best
studied effector pathways are Mapk, Pi3k, and Ral. Studies have examined the importance of
these canonical effector pathways in various cancer types. Prior literature has used RNAi, small
molecules, and even dominant negative mutants to probe the pathways. However, no study has
yet to systematically analyze each pathway and its importance in PDAC. We plan to
systematically assess each pathway using RNAi technology, along with small molecules. There
have been many recent developments in RNAi algorithms and vectors, which allow for
substantial knockdown of the gene of interest.
To perform a screen of Kras effectors, a representative and realistic model of PDAC is
desired. The majority of the studies of PDAC have used human PDAC cell lines. It was only
until the recent development of a knock-in KrasG12D mutant allele that a realistic model of PDAC
was developed (Hingorani et al., 2003). Previously, over a dozen mouse models were developed,
but none gave rise to a human-like PDAC (Brembeck et al., 2003; Grippo et al., 2003). Soon
after, additional tumor suppressor alterations that are found in PDAC, such as p53, were added
such that full-blown PDAC would develop with high penetrance and reasonable latency
(Bardeesy et al., 2006). While human cell lines are one option, we pursued genetically
engineered mouse models of PDAC as the later allows us to eventually study the targets in vivo.
We used a recently developed mouse model of PDAC in our lab that is arguably more realistic in
that the tumor develops in the adult mouse with the CreER construct, as opposed to with the
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standard Cre, which initiates tumor development during embryogenesis. With a novel, inducible
RNAi system and a representative PDAC mouse model, we hope to identify genes that are
important for the maintenance of PDAC.
While many studies have used RNAi to knockdown a tumor suppressor and induce
tumor formation, few studies have used RNAi to prevent or inhibit tumor formation. It is
particularly challenging to use RNAi to inhibit tumor growth, as substantial inhibition in a
majority of the tumor cells will be required to induce an observable phenotypic alteration. In
contrast, to induce tumor formation, sufficient knockdown of a tumor suppressor is only required
in a single cell, as the additional fitness conferred will allow for the cell to proliferate and form a
tumor. Consequently, to successfully inhibit tumor growth, it is critical to select a vector system
that can achieve high levels of knockdown in vitro and in vivo. Moreover, to ensure that all
tumor cells contain the vector, a tight selection cassette is desired. These technologies will allow
for better control of knockdown necessary to inhibit tumor growth.
Results
Our goal is to identify genes that are important in a Kras-mutant PDAC model. We
focused on inhibiting genes in the three canonical Kras effector pathways: the Mapk, Pi3k, and
Ral pathways. The particular effectors that were tested are indicated in Figure 30. The Mapk
pathway consists of Raf kinases (Araf, Braf, and Craf) phosphorylating and activating the Mek
kinases (Meki and Mek2), which in turn phosphorylate and activate the Erk kinases (Erkl and
Erk2). The Pi3k pathway includes the p110 phospholipid kinases (active subunits p1 10a, p1 10P,
p1 y, p1106, and regulatory subunits p85 a and p85 P) which indirectly activate the Akt kinases
(Aktl, Akt2, and Akt3), which activates the mTOR kinase, eNOS, and the ikka and ikkP kinases.
mTOR forms two complexes, mTORC 1 (containing Raptor) and mTORC2 (containing Rictor).
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Ikka and Ikkp phosphorylate NfKb. The Ral pathway consists of the Ral guanine exchange
factors, also known as RalGEFs (RalGDS, Rgll, Rgl2, and Rgl3), which activate the Ral kinases
(RalA and RaiB) by catalyzing the removing of GDP and introduction of GTP. The Ral kinases
will phosphorylate and activate Sec5, RalBP1, Tbkl, and Exo84.
Ksr1
Araf Craf
Mek1 Mek2
Erk1 rk2
p1l0a p11Op p1lOy p110 6
p85a p85p
Akt1 Akt2 Akt3
eNOS mTOR IkaU
Raptorj
Rictor
- I NfKB
RalGDS RGL1
RGL2 RGL3
F"MA RaI73
RaIBPI
bk Exo84
Figure 30. The canonical Kras effector pathways. The three canonical pathways, Mapk, Pi3k, and Ral,
downstream of Kras, are illustrated in blue, red, and green, in the diagram above.
These pathways were studied for the following reasons: 1) Prior work has implicated them in
various cancers. More specifically, inhibiting these pathways by small molecule, dominant
negative mutants, knockout models, or conditional alleles inhibits growth of the tumor in various
cancer models (human cancer cell lines, xenografts, autochthonous mouse models). 2) Signaling
in these pathways can be assessed as reagents such as phospho-antibodies are readily available
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and effective. 3) By focusing on a select group of genes, as opposed to performing an unbiased,
larger-scale screen, more resources can be put into creating hairpins against that can achieve
substantial levels of knockdown. This allows us to more definitively assess the importance of
each tested gene.
The Kras effectors were assessed in a mouse PDAC model because we originally anticipated
testing the genes in an autochthonous (GEMM) mouse model of PDAC. We believe that a PDAC
GEMM would provide the most physiologically representative pre-clinical system to test the
various Kras effectors. However, we were unfortunately unable to successfully establish a
GEMM with an inducible RNAi to allow for such testing. Consequently, we tested the genes in
mouse PDAC cell lines in vitro and in xenograft models.
To test these Kras effectors, we established an inducible RNAi system in mouse PDAC cell
lines, which allows for the inhibition of various selected target genes. By using an inducible
system, the target genes can be inhibited at will upon the administration of doxycycline. We test
these target genes both in vitro and in vivo. A benefit of an inducible system is that inhibition of
the target gene can be induced after the establishment of the tumor in vivo. Non-inducible
hairpin systems would inhibit the target gene even prior to transplantation of the tumor, which is
an unrealistic model of cancer therapy. In contrast, an inducible vector would allow for the
activation of knockdown after the tumor has established and is proliferating. This is more
representative of the clinical situation where therapies are given when the tumor has already
reached a substantial size and is continuing to proliferate. We describe below in more detail the
establishment of the inducible RNAi system.
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The inducible RNAi system was established in a Kras-mutant PDAC system (Figure 31).
More specifically, the RNAi system was introduced into PDAC cell lines derived from a Pdx 1-
CreER, LSL-Kras G12D, p53 , Rosa26-LSL-Luciferase mouse. Pdx1-CreER is a transgene, and
Pdx1 is a pancreas-specific promoter. Pdxl is first expressed in the pancreatic progenitor cell in
mice at embryonic day 9. In the adult mice, Pdx 1 is primarily expressed in the pancreatic ductal
cells of the pancreas. However, Pdxl is also expressed in a subset of the other pancreatic cell
lines including acinar, ductal, centroacinar, and islet cells. Cre is a P1 bacteriophage recombinase
that will, upon expression, recombine loxP sites and remove any intervening genetic sequence
between the LoxP sites. The CreER construct is Cre fused to the estrogen receptor (ER). The ER
keeps Cre in the cytoplasm, preventing it from localizing to the nucleus and recombining LoxP
sites. This allows tumor formation to be induced in the adult mouse, as opposed to standard Cre,
which would recombine and activate the oncogenes and tumor suppressor in any cell that
expresses Cre. Administration of tamoxifen, generally by intraperitoneal introduction, will
promote CreER to enter the nucleus and induce recombination of loxP sites. In summary, upon
the administration of tamoxifen, pancreas cells will undergo activation of Cre recombinase.
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Figure 31. The inducible hairpin system for testing genes in a PDAC system. The pancreatic cancer cell
line system was derived from a genetically engineered mouse model (GEMM) of a pancreatic ductal
adenocarcinoma (PDAC). This schematic describes the development of the dox-inducible hairpin system
in the mouse PDAC cell lines. The TGMP vector contains a GFP fluorescent reporter with a puromycin
selection cassette. TRMN vector contains a dsRed reporter with a neomycin antibiotic resistance gene.
The rtTA is in a MSCV vector with a PGK promoter driving hygromycin. Luciferase, linked to an IRES-
GFP, is also in a MSCV vector.
The LSL-KrasGI 2D allele is a knock-in allele where LSL represents LoxP-STOP-Cassette-
LoxP, a genetic segment placed in front of genes to prevent their expression until the presence of
active Cre removes the intervening sequence between the LoxP sites, allowing for transcription
of oncogenic Kras. Knock-in alleles are more realistic than transgenic alleles because Knock-in
alleles are more physiologically representative than transgenes, as knock-in alleles are driven by
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endogenous promoters and therefore expressed at endogenous levels. In comparison, transgenes
are often driven by a constitutive promoter, leading to its overexpression. Moreover, endogenous
epigenetic regulation of the knock-in allele allow for more physiological expression.
The p5 3flox/flox allele is also a knock-in allele where, in the presence of active Cre, both
copies of endogenous p53 are removed. The activation of oncogenic Kras and removal of the p53
tumor suppressor will promote PDAC formation. By using the CreER construct, upon the
administration of tamoxifen, tumorigenesis is induced. By inducing tumorgenesis in the adult,
the model is more representative of human PDAC development where oncogenic mutations
occur throughout our lives but where cancer manifests at a relatively late age. Consequently,
cells in each of those tissue types will experience Cre activity.
The Rosa26-LSL-Luciferase allele allows us to track tumor development in vivo with
bioluminescence imaging. LSL-Luciferase allele is knocked into the Rosa26 locus. The Rosa26
locus is constitutively expressed, but the presence of the LSL cassette in front of the luciferase
gene will prevent its expression until Cre is activated. Consequently, in cells that express Pdx1,
not only will tumorigenesis be induced, but the cancer cells will be expressing luciferase.
With this PDAC mouse model, we established five independent cell lines (A, B, C, D, and
E) Upon the administration of tamoxifen, tumors formed with relatively low penetrance (~20%)
and a latency that ranged from 2 to 4 weeks. Mice that developed pancreatic tumors were
sacrificed and the pancreatic tumor was minced and digested to create an immortal cell line. To
ensure that the tumors are legitimate PDACs, histology sections were made and examined by an
experienced pathologist. The tumors resemble human PDACs with ductal-like morphology and
abundant stromal infiltration. To ensure that these cell lines are genetically as expected, we
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performed 3-primer PCR and detected, as anticipated, the presence of the mutant alleles of Kras,
p53, and the presence of the luciferase gene. The morphology of the cell lines under light
microscopy varied with respect to size, shape, and adherence. However, all the cell lines
proliferated at relatively rapid and comparable rates. To further establish that these cell lines are
effective models of PDAC, when they were transplanted subcutaneously into nude mice, they
gave rise to tumors with histology that resembled the original mouse PDACs from which they
were derived.
To create an inducible hairpin system, the necessary components were introduced into the
five PDAC cell lines via retroviral infection. A reverse tetracycline transactivator (rtTA),
packaged in a murine stem cell retrovirus (MSCV), was introduced into the cell line. The rtTA
vector has a hygromycin selection cassette, allowing for hygromycin treatment to select for
infected cells. Upon administration of the small molecule, doxycycline, which binds to the rtTA,
the rtTA translocates into the nucleus and activates transcription of genes or hairpins driven by a
tet-responsive element (TRE). In a separate MSCV vector, luciferase, followed by an IRES-GFP,
was introduced into the cells. The intervening ribosomal entry site (IRES) connects the luciferase
and Gfp such that they are transcribed on the same mRNA transcript. Subsequently, luciferase
and Gfp are separately translated. Selection for infected cells was performed by sorting for Gfp-
positive cells.
Afterwards, a dox-inducible hairpin was introduced by a retroviral vector (MSCV) into the
cell lines. Two different versions of the vector construct containing the hairpin were used:
TGMP (TRE, GFP, miR30, Puromycin) and TRMN (TRE, RFP, miR30, Neomycin). We used
these constructs to drive expression of the hairpin because these were the only vectors that had
previously been demonstrated to achieve successful knockdown in an in vivo transplant system.
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TGMP contains a GFP fluorescent gene with a puromycin antibiotic cassette. TRMN contains a
dsRed fluorescent reporter with a neomycin antibiotic gene. Both vectors contain a TRE and a
miR30 element. In more detail, a tet-regulatable element (TRE) drives expression of the hairpin,
with a fluorescent reporter serving as a spacer between the TRE and the shRNA. The fluorescent
spacer increases the level of hairpin expression and is expressed whenever the hairpin is
expressed. Located after the shRNA is a selection cassette (puromycin, neomycin) driven by a
PGK (phospho-glucokinase) promoter. For cells with the rtTA-containing vector and the hairpin-
containing vector, administration of doxycycline will activate hairpin expression and induce
knockdown of the target gene.
To maximize the extent of hairpin-induced knockdown of the target genes, we sub-cloned
the cells. More specifically, we screened for subclones that could achieve maximal knockdown
in the presence of doxycycline and minimal knockdown in the absence. Substantial knockdown
or inducibility is desired because a significant reduction of target gene levels is likely necessary
to achieve an anti-tumorigenic effect. In addition, the cell line ideally would not knockdown the
target gene in the absence of doxycycline. This is desirable as a leaky line may develop
resistance to inhibition of the target gene. If the target gene were important for cancer growth,
low-levels of continuous knockdown of the target gene would select against cells sensitive to its
knockdown and select for cells that are resistant to its knockdown. Different subclones of each
cell line may have different inducibility and leakiness due to different expression levels of rtTA
(reverse tetracycline transactivator). rtTA expression levels may vary from subclone to subclone
because of the varying number of copies of rtTA that integrate into the genome and because of
the site of integration. During the viral introduction of rtTA, an abundance of virus was used to
allow for, on average, 3.4 copies of rtTA to integrate into each individual cell. Multiple copies of
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rtTA allow for elevated expression levels and knockdown inducibility. The genomic site of rtTA
integration also affects rtTA levels due to different epigenetic regulation at different genomic
loci. Higher levels of rtTA are likely to give rise to more inducible knockdown, but also with
greater leakiness. Lower levels of rtTA may give less knockdown, but also with less leakiness.
Described below is the procedure to identify an inducible and non-leaky subcloneTo derive
subclones, individual cells were isolated from cell lines A, B, C, and D, each of which containing
MSCV-rtTA. These isolated cells are allowed to proliferate in culture until an immortal cell line
is developed. For each of the four cell lines, 10 to 40 subclones were derived. Subclones are
screened for those that are relatively small and that proliferate rapidly. Smaller cells allow for
more cells on a given plate, which facilitates the use of fewer plates for xenograft studies.
Rapidly proliferating cells allow studies to be performed over a shorter time period. These
subclones are cryogenized in liquid nitrogen for future retrieval.
To test for inducibility and leakiness, a dox-inducible hairpin against luciferase is introduced
into each of the subclones. To examine inducibility, dox or vehicle control is administered to
cells for 5 days and luciferase levels are compared. To assess leakiness, luciferase levels in
subclones not containing a hairpin are compared to subclones containing a hairpin. Analysis of
the subclones from the cell lines reveals that some of these subclones achieved greater
knockdown than that of the parent population, while others showed lesser knockdown (Figure
32). Subclones that were more inducible than the parent population were further analyzed for
their leakiness. Luciferase levels in cells not containing a hairpin were compared to those
containing a hairpin (Figure 33). The subclones that demonstrated high inducibility and low
leakiness (A 13, B22, C23, D8) were selected for further study. The original subclones for A13,
B22, C23, and D8, prior to the introduction of the luciferase hairpins, were used to test hairpins
225
targeting our genes of interest. From this point forward, A13, B22, C23, and D8 will be referred
to as A, B, C, and D. We will also be using two additional cell lines derived from our PDAC
GEMM, E, and F, neither of which were subcloned because the population lines were
sufficiently inducible and not leaky. In summary, we derived five highly-inducible, independent
PDAC cell lines from mouse PDACs mutant for KrasG12D and p53.
Knockdown Inducibility of Subclones
Cell Line A B C 0
qI I II
Subdones Pop Subdones Pop Sublones Pop Subcones Pop
Y YI
Figure 32. Identifying highly inducible subclones. After a hairpin against luciferase was introduced into
the cancer cell lines A, B, C, and D, they were tested for their ability to knockdown luciferase. Luciferase
levels were measured using the Promega system. Each subclone is exposed to either doxycycyline (dox)
or vehicle only (water) for five days. The y-axis shows the difference in luciferase levels between the
dox-treated and water-treated samples. Experiments were performed in triplicate and standard errors are
noted as an error bar. "Pop" indicates the parent population cell line from which the subclones were
derived.
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Figure 33. Identifying non-leaky subclones. Various subclones and the population from each of the cancer
cell lines A, B, C, and D were analyzed for leakiness. Luciferase levels were analyzed prior to the
introduction of the hairpin (absence of hairpin) and after the introduction of the hairpin (presence of
hairpin).
Before inhibiting the various Kras effectors in these cell lines, we first demonstrated that
these lines are in fact sensitive to knockdown of Kras. In cell lines A through E in vitro,
knockdown of Kras with two independent hairpins substantially reduce Kras protein levels and
cell viability (Figure 34). After five days of doxycycline administration, Kras protein levels are
reduced by 75 to 90% across the five cell lines, while viability is decreased by 35% to 70%.Even
after 7, 9 , or 15 days of dox-treatment, viability was not reduced by more than 75%
(Supplemental Figure 42) The effect of Kras knockdown on viability is less than expected, as
Kras is arguably one of the most promising targets in PDAC. The lack of efficacy is unlikely due
to insufficient knockdown of Kras, as the hairpins inhibit Kras protein levels by over 75%.We
then tested Kras knockdown in a more physiologically representative system, a xenograft model.
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Figure 34. Kras knockdown induces a reduction in viability for multiple PDAC cell lines in vitro. Two
independent hairpins against Kias (Kras-l and Kras-2) were introduced into various cancer cell lines (A,
B, C, D, and E). After 5 days of doxycycline treatment, cell viability and Kras protein levels were
assessed and indicated relative to cells that had undergone 5 days without doxycycline treatment.
Having demonstrated that PDAC cell lines are sensitive to Kras KD in vitro, we tested to
see if this was also the case in vivo in subcutaneous transplants. Five PDAC cell lines (A, B, C,
D, and E) or their subclones were examined in the transplant model (Figure 35). The following
cell lines were transplanted subcutaneously into nude mice: a) cell lines A, B, C2 3, C2, C3, C6 ,
Cpop, D, and E, each containing shKras-1 b) cell lines A, B, and D, each containing shKras-2.
For each cell line, 2*1 0 A 5 cells were transplanted into four different locations on the the backs of
nude mice, thereby creating four tumors for each mouse. The cells were allowed to proliferate
for 12 days, at which point a macroscopically observable mass appeared. The mice were then
separated into two groups, one received dox in their food pellets, while the other received food
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pellets without dox. The mice were given dox for anywhere from 5 to 17 days, at which point,
tumor weight was assessed. The nine shKras- 1 containing cell lines displayed tumor weight
reduction of 80-99%, with the exception of Cp,, which showed a reduction of 50%.The Cpop cell
line may have shown a lesser reduction in tumor weight because the population line is less
inducible and because dox was only administered for 5 days. The three shKras-2 containing cell
lines displayed a tumor weight reduction of 75%.In summary, the in vivo effect of Kras
knockdown (reduced viability by 75-99%) is significantly greater than that in vitro (reduced
viability by 45-70%).To ensure that this difference did not arise due to different amounts of Kras
knockdown in vivo as compared to in vivo, we assessed Kras protein levels.
Kras Knockdown in vivo
Cell Line A B C23 C2 C3 C6 Cpop E A B D
0=
Z
13.
2-
% %
AO. 40-
%0
n~e AL Ad 0
on 0 12 0 12 0 12 0 15 0 16 0 5 0 5 0 17 0 14 0 14 0 8
Dox
shKras-1 shKras-2
Figure 35. The effect of Kras knockdown in subcutaneous PDAC transplants on tumor weight. The
indicated tumor cell lines containing the designated hairpins were transplanted subcutaneously into nude
mice and allowed to proliferate for 12 days. Subsequently, they were treated with dox or vehicle control
for the indicated number of "Days on Dox". The indicated tumor weight takes the tumor weight in the
dox-treated samples and normalizes by dividing by the tumor weight in the vehicle-treated samples. Each
individual point represents a tumor.
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Kras protein levels in vivo, surprisingly, did not decrease substantially (Figure 36). We
believe this is because the cells exhibiting Kras KD are dying off so rapidly that when we are
assessing Kras levels, they are no longer present. Consequently, we are unable to detect KD of
Kras. Even after only two days of dox-treatment, Kras protein levels remain unaltered,
suggesting that cells experiencing Kras KD are rapidly disappearing (Figure 39). Another
possibility is that Kras protein is not actually being knocked down but that the hairpin is
inhibiting an unintended gene and exhibits deleterious effects.
Kras Protein
Cell
Line
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Figure 36. Examining the effect of Kras knockdown on Kras protein levels in a subcutaneous transplant
model. The experiment is performed as described in figure 7 with the exception that instead of measuring
tumor weight, Kras protein levels are being assessed.
To distinguish between the two possibilities, we assessed the fraction of the tumor that
consists of stromal cells. If the majority of the tumor consists of stromal, non-cancer cells, Kras
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KD may not be detected even if the cancer cells exhibit substantial knockdown of Kras. To
estimate the fraction of cancer cells in the bulk tumor, we used a 3-primer PCR based approach
where cancer cells, which contain the LSL-KrasG12D allele, result in a PCR product of a distinct
length than that from normal cells, which contain the wild-type Kras allele (Supplemental Figure
47). To provide benchmarks, the 3-primer PCR was performed on mixtures of cancerous and
non-cancerous cells with 25%, 50%, and 75% cancer cells. By comparing the PCR products by
gel electrophoresis, we estimate that tumors arising from cell line D (containing shKras-1), in the
presence or absence of dox, show a pattern similar to the benchmark mixture with 100% cancer
cells. In conclusion, the inability to detect Kras KD cannot be explained by having a small
fraction of cancer cells in the bulk tumor. To conclude, the in vivo environment increases the
tumor cell's sensitivity to Kras knockdown, suggesting that knockdown of Kras downstream
effectors has potential to be effective.
Another approach to determine whether Kras KD has a deleterious effect is to examine
for removal of cells that express the Kras hairpin. Cells expressing the hairpin will also be
expressing Gfp, as a Gfp cassette immediately precedes the hairpin. If expression of the Kras
hairpin has a deleterious effect, we would expect that the fraction of Gfp positive cells in the
tumor would decrease. Cell line D containing a Kras hairpin showed a statistically significant
decrease in the percentage of Gfp+ cells (7%) relative to the same cell line containing a
Luciferase hairpin (Supplemental Figure 48). Gfp- cells could be either stromal cells (cells from
the nude mouse would not express Gfp) or cancer cells that are not actively expressing the
hairpin. Even in the tumor with the luciferase hairpin, it may be that not all cancer cells are
expressing the hairpin because doxycycline may not have reached all the cells. In summary, a
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reduction in the fraction of Gfp+ cells indicates that cells expressing the Kras hairpin are dying
off.
Yet another approach to determine whether knockdown of Kras was being achieved was
to measure Kras mRNA levels in the Gfp+ cells relative to the Gfp- cells (Supplemental Figure
49). Since the Gfp+ cells are actively expressing the hairpin, we would expect Kras mRNA
levels to be lower in this population. The Gfp+ and Gfp- cell populations could contain different
cell types (cancer versus stromal) and thus different baseline levels of Kras. To control for this
variation, we examined the Kras mRNA levels in a tumor containing a luciferase hairpin. We
found that the Kras mRNA levels in the Gfp+ and Gfp- populations are relatively similar, with
only a few percentage points less in the Gfp+ population. In contrast, with the tumor containing
the hairpin against Kras, Kras mRNA levels were significantly decreased (-5 1%) in the Gfp+
population relative to the Gfp- population. This reduction is specific to Kras, as Erk1 mRNA
levels are relatively unaffected. Moreover, the reduction is statistically significantly different
from 0 at the 0.01 level. In conclusion, Kras mRNA levels are reduced in the population of
cancer cells that are actively expressing the hairpin. Since this Gfp+ population is dramatically
reduced as indicated in the previous paragraph, it is understandable that upon bulk tumor
analysis, Kras levels do not appear to be reduced. Although one could still make the unlikely
argument that while Kras mRNA levels are reduced, Kras protein levels may or may not be
reduced, we believe that this system enables knockdown of Kras
For Kras to be a good therapeutic target for PDAC, not only do the cancer cells need to
be sensitive to Kras knockdown (KD), but the normal cells need to be resistant. This differential
sensitivity is known as synthetic lethality. Kras KD was examined in five cancer cell lines, A
through E, and two normal cell lines, immortalized baby mouse kidney cells (iBMKs) and 3T3
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mouse fibroblasts. iBMKs and 3T3s were selected as the two representative normal cell lines
because they were the only available immortalized but non-tumorigenic mouse cell lines. While
there are many immortalized and non-tumorigenic human cell lines, there are few such mouse
lines. An immortalized line was desired because it allows for a more convenient analysis of the
cells without having to thaw out a new batch of cells after several passages. iBMKs are derived
from the kidneys of baby mice that are p53-/- and that contain the ElA oncovirus. ElA activates
c-Myc and inhibits Rb. While iBMKs can proliferate indefinitely in culture under the proper
conditions, they cannot form tumors in nude mice. 3T3s are the standard mouse fibroblast cell
line that was derived from primary mouse embryonic fibroblast cells in 1962. The cells were
propagated every 3 days by transferring 3 x 10^15 cells, hence the name 3T3s (3 days, Transfer, 3
x 10^5 cells). After 20 to 30 generations in culture, the 3T3 cells spontaneously immortalized
and demonstrated a stable growth rate. 3T3s, like iBMKs, cannot form tumors in nude mice.
We compared the effect of Kras KD on the five cancer cell lines to that on the two non-
cancerous lines (iBMK, 3T3) (Figure 37). At the standard cell culture glucose concentration of
25mM, the 5 cancer lines were notably more sensitive to Kras KD than the two normal lines.
Kras KD caused a reduction in viability of the cancer cells by 45-70%.As for normal cells,
viability was only reduced by 25-35%.This difference could not be explained by a difference in
the extent of Kras KD. The protein levels in the cancer lines were reduced by 80-90%, while
levels in the normal lines were reduced by 75-90%.In conclusion, in standard cell culture
conditions, Kras KD is more deleterious to cancer lines than it is to normal lines.
To more accurately represent human physiological conditions, we tested Kras KD in
vitro at more representative, lower glucose concentrations. While standard cell culture media has
a glucose concentration of 25 mM, in the human blood circulation, glucose levels are
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approximately 3-5mM. Ideally we would like to use the glucose concentration at the tumor site,
but that information was not available for PDAC. Consequently, we used the glucose
concentration in the blood (5 mM) as an approximation. We also tested a variety of glucose
concentrations (0, 0.5, 10, 25 mM) to determine whether there are concentrations at which
PDAC cells are particularly sensitive to Kras KD.
We first determined whether any of the cell lines exhibited decreased viability at the
lower glucose concentrations. We tested the cell lines A, B, iBMKs, and 3T3s, which exhibited
decreased viability at glucose concentrations of OmM and 0.5mM, while they were not
substantially affected at the higher glucose concentrations of 5mM and 10mM (Supplemental
Figure 43). This suggests that Kras KD can be readily assessed at the glucose concentrations of
5mM and 10mM. Kras KD was performed on the cancer and non-cancerous lines at the various
glucose concentrations (Supplemental Figure 44).
The differential sensitivity of cancer and non-cancerous cells to Kras KD becomes most
apparent when the glucose concentration is at 5mM. At 5mM, the cancer cells (A-E) are
sensitive to Kras KD, with a reduction in viability of 45-60%, while the non-cancerous cells
show a reduction of only 0-5% (Figure 37). In comparison, at 25mM, the cancer cells show a
reduction of 40-70%, while non-cancerous cells show a reduction of 25-35%.This difference in
sensitivity cannot be explained by a different amount of Kras KD. At both concentrations of
glucose, the amount of Kras KD across all the cell lines ranges from 70-90%.In conclusion, at a
more physiological glucose concentration (5mM), the difference in sensitivity to Kras KD
between cancer and non-cancerous cells is amplified. This suggests that inhibition of Kras may
be a particularly suitable strategy since, at the more physiological glucose concentrations, the
tumor is notably more sensitive than the surrounding normal tissue.
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Figure 37 Effects of Kras knockdown at low and high glucose concentrations in vitro. Cancer cells (A, B,
C, D, and E) and normal cells (3T3, iBMK) were tested for Kras KD in the context of 5mM or 25mM of
glucose. Cell viability and Kras protein levels were measured after 5 days of doxycycline treatment.
Values plotted on the y-axis are relative to cells that were treated with vehicle control (water) for 5 days.
Relative viability and Kras protein levels at the two glucose concentrations are indicated in red and blue
bars, respectively. Experiments for viability were conducted in triplicate and the error bars indicate
standard deviation.
Besides using tumor weight, another method we used to quantitate tumor volume in vivo
is by bioluminescence imaging (Figure 38). Bioluminescence imaging allows for more facile
measurement of tumor size as mice do not need to be sacrificed for measurements to be taken.
Moreover, the process of imaging is more rapid than that of dissecting and weighing tumors.
Bioluminescence imaging was performed before and after doxycycline-administration, allowing
us to observe the effect on tumor volume over time. Both cell lines A and B, each containing a
hairpin against Kras, show a significant reduction in bioluminescence levels. After 8 days of
dox-treatment, line A containing a hairpin against Kras exhibited a notable decrease (95%) in
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bioluminescence levels. In contrast, untreated cell line A demonstrated a dramatic increase
(1100%) in bioluminescence. As for cell line B, dox-treatment reduced bioluminescence levels
by 50%, while untreated cells increased bioluminescence levels by 200%.The bioluminescence
studies imply that dox-treatment not only inhibits tumor growth but actually induces a reduction
in tumor size. This statement assumes that bioluminescence levels are an appropriate proxy for
tumor volume. Bioluminescence levels may actually decrease even when tumor volume does not
change. For instance, if Kras KD induces "sickness" in the cells such that global mRNA levels
are decreased, thereby resulting in reduced luciferase expression levels, then bioluminescence
levels would decrease despite no change in overall tumor volume.
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Figure 38. Bioluminescence imaging of Kras KD in subcutaneous transplant. Cell lines A and B,
containing Kras-1 hairpin, were transplanted into nude mice (2 tumors per mouse) and allowed to grow
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for 12 days at which point a macroscopically observable mass appeared. For cell line A, Kras-1, one
group of mice (N=5) were treated with doxycycline, while another (N=5) was untreated. Tumor
bioluminescence was assessed on the day of treatment (Day 0). In addition, after 8 days of treatment,
tumor bioluminescence was measured again (Day 8). Bioluminescence levels are normalized to Day 0.
The doxycycline-treated group is indicated by the red line and the secondary y-axis on the right of the
plot. The non-doxycycline-treated group is indicated by the blue line and corresponds to the primary y-
axis on the left of the plot. For cell line B, Kras-1, the experimental design was the same as that for cell
line A, Kras- 1, with the exception that bioluminescence levels were examined just after 6 days of dox-
treatment.
To more definitively assess whether tumor regression in fact was observed, we examined
apoptosis and proliferation markers by immunohistochemistry. Cell line A containing shKras-1
demonstrated, after 2 days of doxycycline treatment, a 100% elevation of the apoptotic marker,
cleaved caspase-3 (CC3) levels, and no change in the proliferative marker, phospho-histone H3
(pHH3) (Figure 39). Note that the change in the marker level is measured relative to the cell line
treated with vehicle control for the same period of time. The levels of CC3 and pHH3 were
termined by counting the number of positively staining cells and normalizing by the total number
of cells within the field-of-view. Experiments were done with many replicates: N= 15 for cleaved
caspase 3 and N=12 for phospho-histone H3. The cells exhibiting Kras KD likely undergo
apoptosis and are removed from the tumor sample being analyzed, explaining our inability to
detect the knockdown. After 12 days of dox-treatment, both CC3 and pHH3 levels are, relative to
baseline, decreased by approximately 50%. Our interpretation of this data is that initially Kras
KD induces apoptosis, as indicated by the elevated CC3 levels. At the later time point of 12 days,
the tumor is recovering from the death induced by Kras knockdown. Consequently, the tumor is
no longer proliferating as quickly as it was previously, explaining the decreased pHH3 staining.
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In addition, the basal apoptosis rate (CC3 levels) has also decreased, as the tumor is no longer
proliferating as rapidly. To summarize, Kras knockdown exerts its effect in vivo primarily by
inducing short-term apoptosis.
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Figure 39. Kras KD in subcutaneous transplants affect apoptosis and proliferation. A, Kras-1 was
transplanted into the backs of nude mice. After allowing the tumors to proliferate for 12 days, one group
of mice were treated with doxycycline, while the other was left untreated. After 2 or 12 days of
doxycycline treatment, the level of Kras protein (N=6), cleaved caspase 3 (CC3) (N= 15), and phosphor-
histone H3 (pHH3) (N=12) were measured by immunohistochemistry. Protein levels were determined by
microscopic examination, counting the number of positively-stained cells relative to the total number of
cells. Protein levels were then normalized to that in tumors not treated with doxycycline for the same time
period, 2 or 12 days. Relative levels after 2 days are indicated in lime green, while those after 12 days are
indicated in dark green. Experiments were done in replicates and the error bars indicate the standard
deviation.
Beyond testing Kras KD in a subcutaneous system, we also tested it in a more
physiological setting, an orthotopic transplant system (Figure 40). We transplanted cell line D
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containing a Kras hairpin (Kras- 1, Kras-2) or a control hairpin (Gfp- 1), into the pancreas of nude
mice. We measured tumor progression by bioluminescence in vivo imaging. After allowing for
12 days of tumor growth such that a detectable increase in the bioluminescence level is observed,
we split the mice into two groups, one receiving doxycycline, and the other not receiving
doxycycline. By giving some time for the tumor to grow, we ensure that the tumor has engrafted
and is proliferating, When we administer dox to Kras-hairpin containing tumors, they show a
regression in bioluminescence levels. In contrast, the Gfp-hairpin containing tumors did not
show a significant difference in bioluminescence levels when compared to time-matched,
untreated tumors.
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Figure 40. Bioluminescence imaging of Kras knockdown in orthotopic transplants shows initial
regression. Cell line D, which expresses luciferase and contains either one of two hairpins against Kras
(Kras-1 or Kras-2) or a hairpin against Gfp (Gfp-1), was transplanted orthotopically into the pancreas of
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nude mice. Tumors were allowed to propagate until bioluminescence levels were detectable and had
notably increased, suggesting that the tumor had engrafted and is actively growing. At this point, mice
were split into two groups, one received doxycycline, while the other was left untreated. On the 3 panels
in the left column, the x-axis indicates the number of days after initiating doxycycline treatment. The y-
axis indicates the level of bioluminescence from the orthotopically transplanted tumor. 2 to 3 mice were
examined in each treatment group. The 3 panels in the middle column are a zoom-in of the early time
points post-treatment, while the 3 panels in the right column are a blown-up of the later time points. These
additional panels better illustrate the effect of Kras KD on bioluminescence levels. The dox-treated group
is indicated by the red line and corresponds with the primary, red axis, while the non-dox-treated group is
represented by the blue line and corresponds with the secondary, blue axis on the right-hand side.
Upon analyzing the tumor regression more carefully, the tumor regression primarily
occurs in the first 18 days of dox treatment. To understand Figure 40, the bioluminescence levels
for each treatment group is normalized to one on the first day of dox treatment (12 days after
injecting the tumor cells). The dox-treated group is indicated by the red line and corresponds to
the primary y-axis on the left side, while the untreated group is indicated by the blue line and
corresponds to the secondary y-axis on the right side. Notice that after a certain time point of 23
days for the Kras- 1 cell line and 30 days for the Kras-2 cell line, the growth rate in both the dox-
treated and untreated cell lines are approximately the same, as suggested by the nearly identical
overlapping lines. This suggests that after some period of time, resistance is acquired and the
tumor reverts to the same growth kinetics that it had prior to dox treatment. To summarize, Kras
KD in the orthotopic model induces a reduction in bioluminescence levels followed by the
development of resistance and subsequent re-growth of the tumor.
Since Kras knockdown in the orthotopic model has a clear phenotypic effect, we would
initially expect to observe Kras knockdown at the mRNA or protein level. However, since we
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did not detect a change in Kras protein levels in the subcutaneous system, we expected to
observe the same phenomena in the orthotopic model. We examined Kras mRNA levels 4 and 10
days after dox treatment (Supplemental Figure 46). We saw a slight decrease in Kras mRNA
levels of 15% and 11% at 4 and 10 days, respectively. The change was not statistically
significant, and the standard deviation as indicated by the error bars were large. We believe that
there was adequate knockdown of Kras, as indicated by the phenotypic effect observed by
bioluminescence imaging for two independent hairpins against Kras. For similar reasons as
described above for the subcutaneous model, we were unable to detect a statistically significant
decrease in Kras levels. To conclude, the levels are Kras knockdown are likely higher than that
observed (10-15%), as cells that exhibit Kras knockdown are likely to quickly die off and evade
measurement.
To determine whether the tumor regression effect from Kras knockdown in the
orthotopic model is from the induction of apoptosis or the inhibition of proliferation, we assessed
the levels of cleaved caspase 3 (CC3) and phospho-histone H3 (pHH3) by
immunohistochemistry (Supplemental Figure 45). CC3 and pHH3 are protein markers used in
immunohistochemistry analysis to measure the level of apoptosis and proliferation, respectively.
Levels of CC3 and pHH3 were measured as the number of positively-staining cells relative to the
number of assessed cells. This value was determined after 4, 10, or 25 days of dox-treatment and
then normalized to tumors at the corresponding time point but without dox-treatment. For pHH3,
Kras knockdown reduced levels by 63%, 50%, and 1% at 4, 10, and 25 days of dox-treatment.
As for CC3, Kras knockdown reduced levels by +5%, 64%, 31% at 4, 10, and 25 days of dox-
treatment. This illustrates that proliferation is dramatically inhibited shortly after Kras
knockdown, but that proliferation resumes over a period of time. By day 10, the tumor is
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recovering and demonstrates reduced proliferation and apoptotic signals. It is natural to expect
decreased proliferation rates when the tumor is recovering. As for apoptotic signals, the basal
rate of apoptosis in the tumor likely also decreases as the proliferation rate of the tumor
decreases.
To further understand the tumor response in the orthotopic model of Kras knockdown,
we looked to see if there was any relation between CC3 and pHH3 on a per tumor basis
(Supplemental Figure 45). There was a statistically weak positive correlation between CC3 and
pHH3 in that tumors that display elevated CC3 also tend to show elevated pHH3. This can be
understood as more rapidly proliferating tumors are likely to also demonstrate a higher apoptosis
rate, as the basal apoptosis rate is likely to be elevated. Comparing the group of dox-treated
tumors to that of untreated tumors did not reveal any obvious trends besides that dox-treatment
tends to result in tumors with lower levels of apoptosis. In summary, additional segmentation of
the data did not give rise to further conclusions.
Comparing the response of Kras KD in the orthotopic model and the subcutaneous
model, we find that in the short-term, the subcutaneous model demonstrates increased apoptosis,
while the orthotopic model exhibits reduced proliferation. The subcutaneous model shows
apoptosis within 2 days of Kras KD. The orthotopic model exhibits decreased proliferation
within 4 days of Kras KD. After prolonged dox-treatment (10 and 12 days in the orthotopic and
subcutaneous model, respectively), both apoptosis and proliferation levels were reduced relative
to time-matched untreated tumors. Our interpretation is that in both models, tumors are
recovering from Kras KD and are not exhibit decreased basal proliferation and apoptosis levels.
In summary, different environmental contexts can cause a PDAC tumor to respond differently to
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Kras KD. Additional studies will be necessary to determine whether this finding is consistent
across cell lines and hairpins.
We show that in the orthotopic model, Kras KD extends survival, which is arguably the
most important phenotype. Cell line D containing one of two independent hairpins against Kras
(shKras-1, shKras-2) were injected into the pancreas of nude mice. After allowing the shKras-1-
containing and shKras-2-containing tumor to grow for 32 and 12 days, respectively, by which
time bioluminescence imaging had revealed an expanding tumor, dox was administered. This
was shown with two independent hairpins against Kras. With shKras-1, survival was extended
from approximately 45 to 60 days. With shKras-2, survival was extended from approximately 75
to 200 days. The control haripins against Gfp did not notably extend survival. Additional studies
will help clarify the large difference in survival response between the two hairpins. In summary,
KD of Kras significantly extends the lifespan of mice
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Figure 41. Kaplan Meier Survival Curves of Kras knockdown in an orthotopic transplant model. Cell line
D had either a hairpin against Kras (Kras-1, Kras-2) or Gfp (Gfp-3) introduced. The line was
subsequently transplanted into the pancreas of nude mice. After allowing the tumor to grow for 12 days
(top panel) or 32 days (bottom panel), dox was administered to one group of mice, while the other group
was left untreated. The number of mice in each treatment group is indicated in parentheses (n= # of mice).
On the x-axis, the days after tumor transplantation is indicated. The p-value for statistical significance is
indicated for each cell line and hairpin combination, comparing the doxycycline treated group with the
untreated group. P-values less than 0.05 are indicated in red. The dox-treated and untreated group are
indicated with the same color line, where the dox-treated group represents the line that is further to the
right. The y-axis indicates the percentage of mice that are still alive.
Discussion
We have established a dox-inducible RNAi system to test the phenotypic effect of
knockdown of various Kras effectors. We wanted to establish an inducible hairpin system that
would allow us to systematically assess the importance of various Kras effectors in Kras-mutant
PDAC. Our system allows for testing both in vitro and in vivo in subcutaneous and orthotopic
transplant models. In vitro studies allow us to more rapidly screen a large number of candidates.
244
In vivo experiments are more physiologically representative and allow for more definitive
conclusions as to the importance of a gene.
We made a particular effort to create a hairpin system that would allow for high levels of
knockdown. This is important as it is likely necessary to achieve significant inhibition of the
target gene in the majority of the tumor in order to observe substantial tumor inhibition. We used
one of the most advanced algorithms to design the hairpins, thereby increasing our chances of
identifying an effective hairpin. In addition, we used a regulatable vector that has been shown to
successfully inhibit in vivo tumor growth. This suggests that the vector is capable of expressing a
hairpin at high enough levels in and enough of the tumor to have a significant phenotypic effect
in vivo. Moreover, we subcloned cells to identify the most inducible subclone. In contrast, to
inhibit a tumor, inhibiting the growth or even inducing the death of a single tumor cell is trivial,
as the tumor has millions of cells. Consequently, a significant fraction of the million cells will
need to experience substantial inhibition of the target gene in order to significantly inhibition
tumor growth.
We demonstrate that the mouse PDAC model is sensitive to Kras KD, suggesting that
focusing on the downstream Kras effectors is a promising strategy. Considering that 95% of
PDACs contain a Kras-mutation and that our PDAC GEMM was initiated with Kras mutations,
it is as expected that the tumor is dependent on Kras. We demonstrate that five independent
PDAC cell lines show sensitivity to Kras KD in vitro. Multiple cell lines were studied in
subcutaneous transplants and Kras-sensitivity was demonstrated. The effect of Kras KD in vitro
is surprisingly weak, but that in vivo was significantly stronger. It is important that the tumors be
sensitive to Kras KD, as the screen is examining the importance of downstream Kras effectors. If
inhibiting Kras isn't effective, then inhibiting genes downstream of Kras is unlikely to be
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effective. Since inhibiting Kras is effective, targeting the Kras effectors may be an effective
strategy.
Materials and Methods
Cell viability assay for hairpin studies in vitro
Cells were plated in a 96-well plate and grown in standard cell culture media (DMEM)
inside a standard cell culture incubator (37 C) For the mouse-derived PDAC cell lines A, B, C,
D, E, and their sub-clones, 500 cells were plated. For 3T3s, 1000 cells were plated. As for
iBMKs, 500 cells were plated. Cells were split into a treatment and non-treatment group.
Doxycycline (dox) was administered at a final concentration of lug/mL in cell culture media
over a period of 5 days. The stock solution of dox is maintained in water at a concentration of
50ug/ul. The control population was not given dox for 5 days. Cell viability was measured by
Cell Titer Glo (Promega), which measures the level of ATP in the assayed well.
Protein knockdown assays in vitro
Cells were split into a treatment and non-treatment group. The treatment group received
dox for 5 days, while the non-treatment group was left untreated for 5 days. Cells were cultured
in standard conditions in DMEM. For each experimental condition, one 15cm dish of cells was
harvested for analysis (see quantitative western blot for more detail).
Protein lysate preparation in vitro
Cells were harvested from cell culture dishes on ice. The protein lysis solution used
contained RIPA buffer, allowing for complete lysis of the cells, including lysis of the nucleus. 3x
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the volume of lysis solution was used for lx volume of centrifuged cells. The lysate was diluted
in RIPA buffer until a final protein concentration of 3ug/ul was reached.
Protein lysate preparation in vivo
Tumors were harvested from mice. Ideally, 0.5cm 3 of the tumor would be resected. In the
case when the tumor is smaller than that size, the entire tumor is analyzed. A homogenizer was
used to mix the tumor in the lysate buffer.
Quantitative western blotting
At the end of this time period, the level of protein was assessed by quantitative western
blot (Licor). The Kras (SC-30) from Santa Cruz was used. Protein levels were normalized using
various control antibodies including Hsp90, p-actin, and p-tubulin. For the rabbit primary
antibodies, the secondary antibody used was a goat anti-rabbit conjugated to a 700nm
fluorophore. For mouse primary antibodies, the secondary was a goat anti-mouse conjugated to a
800nm fluorophore. The western blot was run in 10% ethanol (when one gel was used in a
container) or 20% ethanol (when two gels are used in a container). 30ug of protein was used per
lane. A nitrocellulose membrane was used. A fluorescent imager was used to quantitative the
levels of fluorescence (Odyssey).
Bioluminescence imaging
150 pl of luciferin at a concentration of 15 [tg/ul was injected intraperitoneally into mice.
A 26 gauge 1mL syringe was used. After a minute of allowing the luciferin to equilibrate in the
active mouse, mice were made temporarily unconscious by infusion of isofluorane gas. Mice
were placed in an IVIS imager and imaged for bioluminescence levels. To allow for cross-
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comparison of bioluminescence levels from mouse to mouse, all mice were placed in the same
position such that the pancreas was in direct line sight to the camera. A rectangle was drawn
around the tumor to compute the amount of bioluminescence. Background bioluminescence is
removed by the standard method embedded in the software. Exposure time was at least 1 minute
to give adequate exposure and consistent results.
Tumor weight analysis
Tumors were dissected from the mice soon after asphyxiation by CO2. Effort was made
to keep the skin separated from the actual tumor itself. This allows for a more accurate
determination of the tumor weight. Tumors were weighted on a sensitive milligram scale soon
after dissection to prevent dehydration from affecting the tumor weight.
Subcutaneous tumor transplants and in vivo RNAi
100-330 thousands cells (depending on the PDAC cell line) were transplanted under the
skin of NCr/NCr nude mice from Taconic. 100,000, 330,000, and 200,000 cells were
transplanted for cell lines A, B, and C (and their subclones), respectively. Cells were mixed with
PBS (phosphate buffered saline) and blue dye (to ensure no leakage of cells post-transplantation)
and introduced under the skin of nude mice by a 26 gauge needle. Tumors were allowed to grow
until they became macroscopically obvious before subjecting the mice to doxycycline-treatment.
This is representative of the human situation, as it allows time for the tumors to engraft and begin
growing before giving them therapy.
Genotyping mice
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Genotyping primers were used to determine the presence of the following alleles in mice:
G12D flox LSL-Luciferase EKras , p53 , Rosa26 , and PdxI-CreER. Mice of various genotypes were crossed
together to create a mouse with the following composition: Kras G2D/+, p53 , Rosa26LSL-
Luciferase/LSL-Luciferase , and Pdx 1 -CreER. While the first three alleles are knock-ins, the last allele is a
transgene. The mice were of a mixture of SvJae (brown hair) from the Pdx 1 -CreER allele, the 129
(brown hair), and B6 (black hair) strain. Kras G12D is a homozygous lethal mutation, so
heterozygotes are the only possibility. The genotyping reactions involved 3-primer PCR
reactions such that the wild-type allele gives a PCR product of one length, while the mutant
allele gives a product of another length. PCR reactions were performed in a standard temperature
cycler. The PCR products were resolved by either standard gel electrophoresis or by the e-GENE
machine, which allows for more high-throughput assessment of PCR products.
Creating the mouse PDAC cell lines
Tamoxifen was administered to mice of the following genotype to induce pancreatic
G1I2D/+ flox/flox L5L-Luciferase/LSL-Luciferase ERtumor development: Kras , p53 , Rosa26 -L, and Pdx 1-Cre . Some
of the mice were heterozygous as opposed to homozygous for the luciferase allele at the Rosa26
locus. 1 00ul of Tamoxifen (4.5mg/ml) was injected intraperitoneal into the mice. Tamoxifen was
prepared by dissolving tamoxifen at a concentration of 20mg/ml in corn oil at 65'C with
agitation and protected from light. 5mg of tamoxifen is injected with a 27-gauge needle for every
40g of body weight. The injection is performed twice weekly. Previous work (Gidekel et al.) had
demonstrated that injection three times a week allows for maximum recombination. After 2-6
weeks when a macroscopic mass had developed in the abdomen of the mice, mice were sacked
and the pancreatic tumors were harvested. The harvested tumor was hand-sliced using a single-
use blade and digested with a cocktail of enzymes (1mL of PBS, 0.01mg of Fibrinogen, 0.01mg
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of BSA, 0.03mg of Vitrogen, 20ptl of HEPES). The resulting cells were plated on a dish and
allowed to proliferate until an immortalized cell line is formed.
Subcloning cell lines
The original population cell line is plated at low-density (100-10,000 cells in 10-fold
increments) in 15cm cell culture dishes. After allowing cells to grow for 2-4 weeks, single cell
colonies will appear on the dish. Cloning rings are dipped in grease and placed on the colonies.
Trypsin is added to remove the cells and allow for clonal isolation. The isolated cells are initially
plated on a 24-well plate and then transferred to progressively larger plates.
Luciferase assay
Cells were assessed in an optically transparent 96-well plate with white or black walls to
prevent light from one well contaminating the surrounding wells. The luciferase assay (Promega)
was performed on the cells according to manufacturer's protocol. Retroviral infection (for
hairpins and genes) Hairpins or genes are contained in the MSCV vector and introduced by the
following procedure: 293T cells in a 6-well plate are infected with 1.5 pg of the target construct,
1.5 ptg of the helper virus, pCL-Eco, and 3 1l of FuGENE 6 (Roche). Standard manufacturer's
protocol was followed (Roche). After 48 hours, the virus-containing supernatant is filtered
through a 0.2-0.45 jim filter and transferred onto the target cells, i.e. the mouse PDAC cell lines.
Polybrene was added to the target cells reach a final concentration of 8 pg/mL, enhancing the
infectivity of the virus. At 72 hours, the supernatant is removed from the target cells and a new
batch of supernatant is transferred from the 293 cells to the target cells. After 24 hours, the
supernatant is removed and discarded. To select for infected cells, antibiotic drug selection is
used. Depending on the antibiotic resistance cassette in the target vector, the corresponding
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antibiotic is used (puromycin, neomycin, or hygromycin). For puromycin, the drug is given at a
final concentration of 2-25ug/mL depending on the cell line. As for neomycin and hygromycin,
the final concentration range is 50-1000ug/mL. Puromycin was given for 4-6 days, while
neomycin and hygromycin were given for 4-10 days. An uninfected cell line is also used as a
control to ensure that antibiotic treatment completely removed uninfected cells. Prior to infection
with the target construct, each PDAC cell line and the normal cell lines were tested for their
antibiotic-sensitivity. Various concentrations of the antibiotics were given to identify the
appropriate concentration to completely kill the cell line at hand.
Glucose conditions
Different glucose levels were achieved in cell culture media by obtaining glucose-free
DMEM (Invitrogen) and adding various concentrations of glucose (Invitrogen) to obtain the
desired final concentration. Glucose-containing media was made fresh right before performing
the experiment.
mRNA level assessment
Standard phenol (Trizol)-chloroform extraction is used to isolate the RNA from the cells.
Ethanol precipitation is used to purify the RNA. 250ng of purified RNA from each sample is
assessed. Taqman probes (Applied Biosystems) are used to measure the level of mRNA.
Orthotopic transplantation
The cells originally in cell culture media were centrifuged and the supernatant was
aspirated. The remaining cells were mixed with PBS and methylene blue dye. To knock out the
mice, Avertin was injected into the mice. Mice were turned on their side and an incision was
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made above their pancreas. A tweezer was used to extract the easily identified spleen and the
attached pancreas. Under a microscope (Nikon), the cells were injected in 5 tl with a high-
precision syringe. The methylene blue dye allowed us to track any leakage that may arise from a
poor injection. The injected cells would form an observable bubble under the microscope.
Afterwards, the spleen and pancreas is placed back into the peritoneum of the mice, and the open
would is sutured shut. In addition, staples are placed on the sutures to ensure rapid healing of the
wound.
Digesting and separating cells in an in vivo tumor
The tumor is isolated from the mouse and hand-minced into pieces with a reusable razor.
The pieces are incubated in digestion media [1.4mL HBSS-free (GIBCO), 2 0 0 pl Trypsin-EDTA,
2 0 0 pl Collagenase IV (Worthington), 200pl Dipase] on a rotator at 37 'C for 20 minutes.
Afterwards, quench media [3.6mL of L15 Media, 460pl FBS, 15pl DNase (Sigma)] is added at
twice the volume to halt the digestion reaction. The resulting mixture is put through a 40pjM cell
strainer to remove chunks of cells before preparing the sample for FACs via a standard protocol.
Immunohistochemistry
Immunohistochemistry for CC3 and pHH3 was performed according to standard
protocols. Dissected tumors were fixed with 10% formalin, incubated overnight in 70% ethanol
if necessary, and paraffin-embedded prior to sectioning. The antigen retrieval buffer consists of
100mM of citric acid monohydrate at a pH of 6.0. PBST was used as the washing solution. ABC
and DAB solutions were used in the process. The level is determined by counting the number of
positively staining cells and dividing by the number of cells in the analyzed fields. This
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percentage of positively staining cells is used when comparing the baseline or untreated group to
the treatment group.
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Supplemental Figure 42. Kras Knockdown in vitro over an extended time period. In cell line D containing
either shKras-1 or shKras-2, doxcycyline is administered for 7, 9, or 15 days. The resulting effect on the
viability is denoted on the y-axis. The change in viability is determined relative to cells treated with
vehicle control (water).
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Supplemental Figure 43. Determining the sensitivity of PDAC and normal cells to low glucose. Cancer
cells (A13 and B22) and normal cells (iBMK and 3T3s) were subjected to various glucose concentrations
(0, 0.5, 5, 10mM) in vitro for 3 days. Cell viability was measured relative to that at 25mM of glucose.
Experiments were performed in triplicate, and the error bar indicates the standard deviation.
Supplemental Figure 44 Kras knockdown affects viability across various glucose concentrations. Cell
viability in vitro was measured after 5 days of doxycycline treatment. Plotted on the y-axis is the
previously mentioned viability relative to the viability of cells untreated for 5 days. Cancerous (A13, B22)
and normal (iBMK, 3T3) cell lines were examined.
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Supplemental Figure 45. Analyzing proliferation (pHH3) and apoptosis (CC3) by immunohistochemistry
in an orthotopic model of Kras knockdown. Cell line D with a hairpin against Kras (Kras-1) was
transplanted into the pancreas of nude mice and allowed to proliferate for 15 days, at which point
bioluminescence imaging revealed an expanding tumor. At this point mice were split into two groups, one
receiving doxycycline (dox) and one without receiving dox. As represented by the figure on the left, at
various times points with dox treatment (4, 10, 25 days), mice were sacked and tumors were assessed for
levels of phospho-histone H3 (pHH3) and cleaved caspase 3 (CC3) by immunohistochemistry. The levels
of pHH3 and CC3 were measured as the number of positive cells divided by the number of cells in the
assessed region. In addition, the levels indicated on the y-axis are levels in the dox-treated group relative
to those in the untreated group. At the 4 day time point, there were 11 mice in the treated group and 4
mice in the untreated group. At the 10 day time point, there were 11 and 3 mice, respectively. As for the
25 day time point, there were 11 and 5 mice, respectively. Error bars represent standard deviation. **
indicates a statistically significant difference from 0 with a p-value of < 0.05. With regards to the figure
on the right, each data point represents a tumor and its level of CC3 and pHH3 on an arbitrary but fixed
scale. Tumors from the dox-treated group are indicated in yellow, while those from the untreated group
are indicated in red.
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Supplemental Figure 46. Kras mRNA knockdown in the orthotopic transplant model. Cell line D
containing a hairpin against Kras (Kras-1) was transplanted into the pancreas of nude mice. After
allowing the tumor to engraft and grow for 15 days, at which point bioluminescence imaging revealed an
expanding tumor, doxycycline was administered to one group, while the other group was left untreated.
After 4 or 10 days, the tumor was dissected and Kras mRNA levels were measured. Kras mRNA levels in
the dox-treated group are measured relative to those in the untreated group and indicated according to the
y-axis. At each time point (4 and 10 days), there were 5 mice in the dox-treated group and 3 mice in the
untreated group. Error bars indicate standard deviation.
Supplemental Figure 47. Determining the fraction of cancer versus stromal cells in the bulk tumor. In the
upper portion of the future, a titration curve is established where the tumor cells have the LSL-KrasG12D
allele. The pictures indicate the products of a 3-primer PCR reaction run through gel electrophoresis.
Non-cancerous cells with two wild-type Kras alleles give rise to the band pattern indicated under the 0%,
with a prominent lower band but no upper band. On the other hand, cancer cells with one LSL-KrasG12D
allele show a pattern as indicated under the 100%, with a more prominent upper band than lower band.
Cancer cells were mixed with non-cancer cells at the various proportions: 25%, 50%, 75%. As the
fraction of cancer cells relative to non-cancerous cells increases, the prominence of the upper band
increases. In the lower portion of the figure, cells from a subcutaneous tumor generated from cell line D
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with a hairpin against Kras (Kras-1) is analyzed for the proportion of cancer cells relative to non-
cancerous stromal cells. The 4 samples to the right of "No Dox" are from subcutaneous tumors that had
not received doxycycline. the 4 samples to the right of "+ Dox" are from subcutaneous tumors that had
received doxycycline.
Supplemental Figure 48. Analyzing the fraction of hairpin expressing cells under Kras knockdown. Cells
expressing the hairpin are Gfp+ because there is a Gfp cassette in front of the hairpin, while cells not
expressing the hairpin will be Gfp-. Cell line D had either a Kras (Kras- 1) or Luciferase (Luc- 1) hairpin
introduced. Subsequently, the cell line was transplanted subcutaneously into the mice. After 12 days when
the tumor had established, doxycycline was administered to the mice. After 6 days of dox treatment, the
percentage of Gfp+ cells in the bulk tumor was analyzed by FACs (fluorescent activated cell sorting). 4
mice were in the Lucferase hairpin group, while 5 mice were in the Kras hairpin group.
Supplemental Figure 49. Measuring the level of Kras knockdown in tumor cells expressing the hairpin
against Kras. Cell line D had either a Kras (Kras- 1) or Luciferase (Luc- 1) hairpin introduced. The cell line
was subsequently transplanted subcutaneously into nude mice. After 12 days of tumor growth, mice were
given dox for 6 days. Tumors were dissected and FACs (fluorescence activated cell sorting) sorted into
Gfp+ and Gfp- cells. The mRNA levels of Kras and ErkI (as a control) were measured in the Gfp+ and
Gfp- populations. Plotted on the y-axis is the relative difference in the indicated mRNA level when
comparing the Gfp+ and Gfp- populations. A negative percentage difference indicates that the mRNA
level is lower in the Gfp+ population. 4 tumors with the Kras hairpin and 4 tumors with the Luciferase
hairpin were analyzed. The error bars indicate standard deviation. ** indicates a statistically significant
difference from 0% with a p-value of <0.01.
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CHAPTER 2: Performing the RNAi Screens
Abstract
We used our regulatable RNAi system in mouse PDAC cell lines to test the importance
of 32 Kras effectors both in vitro and in vivo. Anywhere from 2 to 18 hairpins were designed
against each effector. We took two paths to test the various hairpins: a pooled screening
approach and an individual gene-by-gene approach. Through the pooled method, we identified
mTOR and Rictor, among other genes, as being important for the maintenance of PDAC The
individual gene-by-gene approach detected mTOR, Raptor, and as genes critical for PDAC
proliferation. We will perform additional studies for mTOR, Raptor, and Rictor to further assess
their relevance in PDAC.
Introduction
Many prior studies have performed high-throughput screens for genes that are involved in
cancer (Berns et al., 2004; Echeverri and Perrimon, 2006; Root et al., 2006). Cancer screens can
be separated into two types: cancer-promoting and cancer-inhibiting screens. Cancer-promoting
screens search for genes that, when either overexpressed or inhibited, promote tumor growth. In
contrast, cancer-inhibiting screens look for genes that, when either overexpressed or inhibited,
will reduce tumor growth. Over-expression studies are generally performed with plasmids
containing cDNAs driven by constitutive promoters. Inhibition studies are now often done by
RNAi technology.
Cancer-inhibition studies with RNAi or another inhibitory approach are the most
clinically and therapeutically relevant studies as they seek out targets that can eventually become
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therapeutic targets (Silva et al., 2004). As our eventual goal is to reduce the disease, we sought to
identify a strategy to identify potential targets. Inhibitory screens have been performed in cancer
using RNAi and small molecules. Smaller-scale screens and single-gene experiments have been
performed with dominant-negative mutants, which, when expressed, will disable or reduce the
activity of the gene being expressed. RNAi provided a facile and adaptable system to screen
various genes. While many screens have used RNAi strategies, not as many have used an
inducible RNAi system. By being able to control the activation of the hairpin through
administration of doxcycyline, knockdown can be achieved in an in vivo tumor after allowing
the tumor to form.
Many RNAi studies have been performed in cancer-inhibition studies. Two technical
strategies involve a well-by-well approach and a pooled strategy (Burgess et al., 2008; Meacham
et al., 2009; Scholl et al., 2009). The well-by-well approach allows for careful testing of each
gene in question, but is more labor and resource intensive. In contrast, the pooled strategy is a
high-throughput method, allowing for the testing of a larger library of genes. However, it is
significantly more challenging to get the pooled method to be functional as it is a new
technology. We decided to use both the well-by-well and the pooled strategy. In the case where
the pooled strategy technique was validated, we would expand our library of tested genes.
Recently, many RNAi screens have been performed for Kras synthetic lethal candidates
(Barbie et al., 2009; Luo et al., 2009; Sarthy et al., 2007; Scholl et al., 2009). These screens have
used various sized RNAi libraries to identify genes that are important in Kras-mutant cancer cells
but not in non-Kras mutant cells. Ideally this would identify genes that, when targeted, would
inhibit tumor growth without causing excessive toxicity. Some studies used non-Kras mutant
cancer cells as the comparator, while other studies used non-Kras mutant non-cancer cells. The
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ideal comparator is the healthy human tissue to which the drug (targeting the gene of interest)
will be exposed in patients. These synthetic lethal studies identified genes including Survivin,
Wilms Tumor 1, Tbkl, Plkl, Apc/c, the proteasome, Stk33, Syk, Ron, Integrin $6, and Snail2.
These genes are candidates for further study and as targets for small molecule drug inhibition.
Instead of performing a large-scale high-throughput screen, we selected 32 genes for a
focused screen. We selected a small pool of candidates because we needed to individually clone
hairpins into the inducible vector, which is a labor intensive process (TGMP, TRMN). To our
knowledge, there were no pre-made hairpin libraries in an inducible vector. Moreover, by having
fewer candidate genes, we could construct several hairpins targeting each gene. This allows us to
create effective hairpins that can achieve a substantial degree of knockdown.
We studied the canonical Kras effector pathways Mapk, Pi3k, and Ral, as they have been
implicated in a variety of cancers. Each of the effector pathways are also well-studied in their
own rights, as they regulate critical functions in cells and are often over-activated even in non-
Kras mutant cancers. In addition, they are interconnected by feedback-signaling pathways.
Moreover, antibodies, phospho-antibodies, and immuno-precipitation kits are available for these
pathwaysWe believed that looking at the most studied Ras effectors in a systematic fashion
would allow us to rule out potential candidates and identify promising leads.
We took two approaches to screening the Kras effectors: 1) a pooled hairpin screen 2) an
individual gene-by-gene assessment. A pooled hairpin screen is a time and cost effective
technique that allows for the screening of a library of hairpins for their effect on a PDAC cell
line. In short, hairpins that target genes critical for the maintenance and survival of the PDAC
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cell line will be depleted over time. By examining for hairpins that are depleted after dox-
treatment, we can identify genes that may be important for the survival of PDAC.
Results
In more detail, a library of hairpins contained in a dox-inducible vector was introduced
into various PDAC cell lines (Figure 50). To select a pure population of infected cells, the cells
are treated with puromycin, as the TGMP vector containing the hairpin is puromycin-selectable.
All the remaining cells will contain at least one copy of the hairpin-containing virus. Since we
did not titer down our virus stock such that only one virus entered each cell, some cells may
contain multiple hairpins. While there may be "passenger effects", these effects should average
out across the hairpins such that hairpins with deleterious effects will be depleted in aggregate. If
a hairpin actually promotes cell proliferation, we would observe an increase in the percent
representation of this hairpin. To serve as controls that have no effect on proliferation, hairpins
against Gfp, luciferase, and renilla luciferase were included. Since the overall population of
hairpins may be depleted or enriched, we included these control hairpins to determine the change
in representation expected from a neutral hairpin. The representation of the hairpins in the cell
population was determined by a PCR reaction followed by high-throughput sequencing, which
allows for rapid determination of the relative representation of each hairpin in a single
experiment. The PCR reaction will amplify the hairpin sequences in the population while
maintaining their relative representation. More precisely, we compared the library representation
of cell lines that received dox for 10 days with that of cell lines that had been untreated for 10
days. We chose to compare time-matched samples as opposed to simply using the original
untreated population because viral integration into certain portions of the genome could induce
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unwanted proliferative benefits or disadvantages. These integration-induced proliferation
changes are removed through normalizing against time-matched untreated samples.
To increase the cost-efficiency of this procedure, multiple samples can be pooled in a
single solexa lane. In more detail, for a given samples or population of cells, a unique barcoded
primer can be used to amplify the ahirpins. Consequently, up to 10 different samples, each with a
different barcoded primer, can be combined together in a high-throughput sequencing lane. With
increasing sample count, the number of sequencing reads for each hairpin decreases. From our
empirical testing, we find that 30 samples dilutes the number of reads excessively, while 10
samples allows for a more than sufficient number of reads. Barcoded primers reduces sequencing
costs and the labor required to prepare the samples.
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Figure 50. Schematic for the pooled and anchored pooled hairpin screen.
We performed the pooled hairpin screen not only in cell culture, but also in a
subcutaneous model. After the introduction of the hairpin library and subsequent puro-selection,
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the resulting cell population is transplanted into the backs of nude mice. After allowing the tumor
to grow for 6 days, dox is administered to one group, while the other group is left untreated.
After 10-15 days of treatment, tumors are harvested and solexa sequencing is performed. To
increase the efficiency of the process, we used bar-coded primers to amplify each tumor sample
in the in vitro and in vivo samples, and then combined all the resulting PCR products into one
solexa sequencing reaction. 10 different samples can be assessed in a single solexa run, thereby
reducing the cost and labor required.
To test the combined inhibition of two genes in a high-throughput fashion, we developed
an anchored, pooled hairpin screen. In this screening technique, we are able to test, in a single
assay, all two hairpin combinations that involve a given anchored hairpin. We first introduce the
dox-inducible, anchored hairpin in a neomycin-selectable cassette (Figure 50). Afterwards, we
select for a pure population of vector-containing cells bytreating the cells with neomycin.
Subsequently, we introduce the hairpin library and proceed as described above. The resulting cell
population, when given dox, will activate the anchored hairpin in all the cells and another hairpin
in different subsets of the cell population. Consequently, every cell will experience knockdown
of two different genes, with the exception of the few cells that coincidentally receive a hairpin
from the library that is the same as the anchored hairpin. After activating hairpin expression by
administering dox, we would not expect the anchored hairpin to be depleted, as all cells were
selected to contain this hairpin. However, the library of hairpins will be depleted according to the
indvidiualy toxicity of the hairpin, as well as its toxicity in combination with the anchored
hairpin. To separate out the effect of individual toxicity from that of synergistic toxicity, we can
compare the results of a pooled hairpin screen with its related anchored pooled hairpin screen.
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We performed the pooled and anchored pooled hairpin screen in different cell lines both
in vitro and in vivo (Figure 51). The hairpin library was introduced into PDAC cell lines A, B
and "normal" cell lines, iBMK, and 3T3 mouse fibroblasts. We tested the library in the normal
cell lines because we wanted to identify genes that are important in cancer cells but not in normal
cells. The cell lines were assessed in vitro and in vivo because the response in mice is likely to be
more representative than that in cell culture. On the other hand, in vitro studies are more rapid
and exhibit less assay-to-assay variability.
In cell line A, we introduced the mTOR hairpin in the TRMN vector to perform an
anchored pooled hairpin screen (A, R-mTOR-1). Cell lines A and A, R-mTOR-1 were assessed
both in vitro and in vivo. Cell lines B, iBMK, and 3T3 were evaluated only in vitro. In the in
vitro and in vivo assays, cells are split into a dox-treated and untreated group, where each group
is performed in triplicate and quadruplicate in vitro and in vivo, respectively.
in vitro in vivoCell Lie (in triplicates) (In quadruplicates)
A
A, shmTOR-1
Figure 51. Table indicating the pooled hairpin screens that were performed.
To get a sense of how the hairpin representation changes upon dox-treatment, we
analyzed the change in percent representation for each of the hairpins after dox-treatment (
Figure 52). To illustrate the meaning of "change in percent representation," if a hairpin is
represented at 0.5% of the pool (as expected if there were 200 equally represented hairpins) in
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the untreated group, and at 0.25% of the pool in the dox-treated group, then there would be a
negative 50% change in percent representation. There were a total of 1378 hairpin assays
analyzed across the 6 replicates with 230 hairpins in the hairpin library. Approximately half of
the 1378 hairpins showed an increase in representation, while the other half revealed a depletion
(Figure 54). Some hairpins increased their representation by a substantial degree, with some
showing a change greater than 400%.For a given hairpin, an increase in the percent
representation could arise because the other hairpins are being depleted, or it could arise because
the hairpin actualy promotes proliferation. The select group of hairpins that demonstrate a
notable increase in percent representation is likely to have proliferative benefits for the cell.
While these effects are not expected since these hairpins target Kras effectors, proliferation
benefits could arise from off-target effects of the hairpins. Despite the presence of these
proliferation-inducing hairpins, we should still be able to identify hairpins that are deleterious to
the cells and that are depleted.
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Figure 52. Overall change in hairpin representation upon doxycycline treatment. The hairpin
library contains 230 hairpins. Six different assays were performed with the library, and all the
resulting hairpin data is plotted in the figure. Dox was given for 7-10 days for each of the assays,
and the change in hairpin representation is indicated on the y-axis. More specifically, each bar on
the graph indicates the percentage change in the percentage representation for each hairpin. For
instance, if a hairpin comprised of 0.5% of the hairpin pool originally (as would be expected if
there were 200 hairpins and each is equally represented), and then, after dox-treatment, increased
to 1% of the hairpin pool, the change in percent representation is 100%.
We included positive control hairpins in our hairpin library to ensure that our pooled
screening system can identify deleterious hairpins (Figure 53). The positive control hairpins
include two hairpins targeting Kras, and one hairpin target each of Pcna (Proliferating cell
nuclear antigen), Rpa3 (Replication protein A 14 kDa subunit), and Rpl 15 (60S ribosomal
protein L15). Pcna, Rpa3, and Rpl15 are all proteins that are critical in the replication for any
cell, so we would expect that their knockdown would be deleterious to the cancer. The Kras
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hairpin should be depleted because Kras knockdown in these cell lines in vitro and in vivo have
been detrimental to tumor growth. As expected, these positive control hairpins were depleted in
the dox-treated groups, as compared to the time-matched untreated groups, by 25%, 27%, 23%,
70%, 59%, for Kras-1, Kras-2, Pcna-1, Rpa3-1, Rpl15-1, respectively. The differences in the
extent of depletion can be a function of the gene or of the degree of inhibition by the particular
hairpin. To conclude, we are able to detect depletion of these positive control hairpins,
suggesting that the pooled hairpin system is likely able to identify depleted hairpins.
The negative control hairpins include one hairpin against each of Gfp, Luciferase, and
Renilla Luciferase. The PDAC cell lines express Gfp, as the TGMP vector links Gfp expression
with hairpin expression. Inhibition of Gfp will not affect expression of the hairpin because at the
time of RNAi-based inhibition, the GFP gene transcript will already be separated from the
hairpin. Luciferase is also expressed in the PDAC cell lines, as it was introduced by a retroviral
(MSCV) vector. Renilla luciferase is not expressed in the PDAC cell lines. As illustrated, the
three negative control hairpins were not depleted. In fact, Gfp- 1, Luciferase- 1, and Renilla- 1
were enriched by 21%, 18%, and 33%, respectively. These hairpins may be enriched not because
of any positive proliferative effect, but because the large majority of the hairpins were depleted
as they targeted Kras effectors, resulting in enrichment of the remaining, neutral control hairpins.
In summary, across a large number of assays (30), positive control hairpins were depleted, and
negative control hairpins were enriched. Thus, we should be able to detect depletion of hairpins
that have an anti-proliferative effect. Moreover, we would expect a moderate enrichment of
hairpins that have no effect on proliferation.
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Figure 53. Looking at the change in percent representation for positive and negative control hairpins. The
results for positive and negative control hairpins across various assays are plotted on the figure indicated.
Positive control hairpins are expected to induce the depletion of cells: Kras-1, Kras-2, Pcna-1, Rpa3-1,
and Rpl 15-1. Negative control hairpins are not expected to have an effect on cell proliferation: Gfp-1,
Luciferase-1, Renilla-1. The normalized levels indicated on the y-axis are levels in dox-treated samples
relative to time-matched untreated samples. In total, 30 experiments including positive and negative
control hairpins were performed. Error bars indicate the standard error.
Another technical issue is to determine the reproducibility of the pooled hairpin screen.
We analyzed the change in percent representation for each of the hairpins across three replicates
in the dox-treated and untreated conditions (Figure 54). The plot for each of the replicates is
mostly overlapping when the order of the hairpins on the x-axis is allowed to change from
replicate to replicate. The hairpin profile/histogram from each replicate is plotted in red, blue, or
green. The turquoise coloring indicates the overlap of the three replicates. Both dox-treated and
untreated replicates show this strong overlap. In conclusion, the overall unordered hairpin
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Figure 54. Hairpin representation changes upon doxycycline treatment. Cell line D containing a hairpin
library was split into two groups, one exposed to dox for 10 days done in triplicate, the other left
untreated for 10 days triplicate. The experiment was done in triplicates. In the top left panel is the no dox
group where each of the replicates is represented in a different color: red, green, and blue. In the middle
left panel is the + dox group, also with each replicate represented in a different color. The colors are
partially transparent such that their overlap creates a composite color. When the x-axis is unordered, as
indicated in the three figures on the left, each hairpin can be in a different location on the x-axis for each
replicate. In the bottom left panel, the untreated samples (in triplicate) are indicated in red, while the dox-
treated samples (in triplicate) are indicated in green. The figures on the right are with ordered hairpins.
The top right figure contains three replicates (colors red, blue, and green) that are done in the no dox
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condition. The bottom right figure contains three replicates that are done in the dox-treated condition. The
order of the hairpins for the figures on the right are fixed. The hairpin order is sorted such that the
replicate in red will increase its percent representation as the hairpins move from left to right.
On the other hand, when comparing the hairpin representation plot in the dox-treated as
compared to the untreated group, we see a distinct shift (Figure 54). The dox-treated samples are
indicated in green, while the untreated group is indicated in red. The dox-treated samples show
more hairpins with higher percent representation, and fewer hairpins with low percent
representation. One interpretation is that many hairpins, including those originally present at low
percent representation, decrease in percent representation due to their anti-proliferative effect.
Consequently, many of the hairpins that were present at low percent representation will be
depleted. Another interpretation is that a large group of hairpins were enriched, thereby pushing
out and reduced the representation of the other hairpins. In conclusion, dox-treatment reduces the
diversity of hairpins and increases the representation of a group of hairpins. However, the group
of hairpins that is enriched changes from replicate to replicate.
To better understand the changes upon dox-treatment, the experiments were performed
with an ordered x-axis (Figure 54). An ordered x-axis is a regular x-axis where each point on the
axis corresponds to a particular hairpin. With an ordered x-axis, there is high variability from
replicate to replicate. As illustrated, the blue, green, and red replicates overlap very poorly.
Consequently, a particular hairpin does not show an obvious change in representation upon dox-
treatment. In conclusion, a high number of replicates will be needed to detect significant changes
in hairpin representation.
We tested the functionality of the anchored hairpin in the context of a pooled hairpin cell
line in vivo. Cell lines with an anchored hairpin against mTOR (mTOR-2 or mTOR-3) in the
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TRMN vector demonstrate knockdown of mTOR (Figure 55). After 9 days of dox treatment,
mTOR protein levels decreased 37% and 75% with the mTOR-2 and mTOR-3 hairpin,
respectively. This suggests that the TRMN vector is functional and that knockdown of the
"anchored gene" is achieved in the tumor. Moreover, we tested for the ability to detect a
phenotypic effect from knockdown of Kras in vivo. The TRMN vector, containing one of two
individual hairpins against Kras (Kras- 1, Kras-2), was tested in two PDAC cell lines (A, B). As a
negative control, we used cell line B containing a vector with no hairpin. After 14 days of dox-
treatment, we observe a reduction in tumor weight by 30% and 57% for cell line A with hairpins
Kras-1 and Kras-2, respectively. As for cell line B with hairpins Kras-1 and Kras-2, we see a
reduction in tumor weight of 59% and 68%, respectively. The empty vector revealed no
significant change in tumor weight after 14 days of dox-treatment. The TRMN vector, containing
Kras hairpins, can induce a substantial decrease in tumor weight. To summarize, the anchored
hairpin can achieve knockdown and tumor inhibition in vivo.
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Figure 55. Validating efficacy of the anchored pooled hairpin system. In the upper figure, the TRMN
vector containing a hairpin against mTOR (either R-mTOR-2 or R-mTOR-3), as well as the TGMP vector
containing the hairpin library, was introduced into cell line A. The resulting cells were split into two
groups, one receiving dox for 9 days (N=4), while the other was left untreated for 9 days (N=4).
Afterwards, mTOR levels in the tumors from the dox-treated group were measured and compared to those
from the untreated group. In the lower figure, cell lines A or B contained a hairpin against Kras (Kras-1,
Kras-2) in the TRMN vector, as indicated by R-Kras-1 or R-Kras-2, or no hairpin as written. The
resulting cell line was split into two groups, one received dox for 14 days, and the other was left untreated
for 14 days. The tumor weight of the dox-treated group was then measured and normalized to the weight
of the untreated group.
Using a hypothetical example, we illustrate the procedure used to identify hairpins that
are depleted upon dox-treatment (Figure 56). In this example, cell line a was examined in
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triplicate in dox-treated and untreated conditions. The hairpins in the pool are indicated in the
first column. After a certain number of days of either dox-treatment or no treatment, the relative
representation of each of the hairpins in the cell lines is indicated in the corresponding row. The
values are a normalized count of the corresponding hairpin in each replicate. The raw count for
each replicate is divided by the sum of of all the counts in that particular sequencing read. This
ensures that the value indicates the amount of that hairpin relative to the other hairpins in that
particular replicate. In the far right column is the percentage change in the mean hairpin count
when comparing the dox-treated samples to the time-matched untreated samples.
To designate a gene as one that, when inhibited, will hinder tumor growth, we required
that two or more hairpins targeting the gene be depleted by more than 50%.This scoring method
is often referred to as the "second best hairpin method." We require at least two hairpins to
demonstrate an effect because one hairpin may, by chance, exhibit off-target effects that are
responsible for its depletion In the toy example, there are two hairpins targeting gene A, both of
which are depleted by more than 50%.We would consider gene A a hit and likely important in
the maintenance of the cell line. Additional studies with gene A can be individually performed to
validate this finding. We use this method of scoring genes to analyze the data presented below.
Gene ~ ~ ~ ~ el Aine 315 3.a5.uof
Hairpin_ No dox ClLiea Dx % Change
GeneZ- 25.3 
_7. -94%
Gene A-2 128'26A4 4, -86%
Gene C-2 4273. 16 -76%
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Figure 56. Toy example of analyzing the results from the pooled hairpin screen. Cell line a is the
imaginary cell line used in this example. There are 6 hairpins illustrated in this example, although there
could be many more in the hairpin library being analyzed. As an example, GeneC-2 is the second hairpin
directed toward gene C. The numbers in the boxes color coded in blue -> red (low - > high values) are
normalized values that represent the amount of hairpin in that particular replicate. The value is the
number of reads by high-throughput sequencing for that particular hairpin, followed by normalizing
across the column (dividing by the sum of all the values in the column). The first 3 columns are of cell
line a in untreated conditions, while the next 3 columns are of it in dox-treated conditions. The last
column is the percentage change in the mean value as we move from the untreated to the dox-treated
samples.
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The results from the following pooled hairpin screens are depicted in Figure 57: cell lines
A, A-mTOR-1, B, 3T3, and iBMK in vitro, and A, A-mTOR-1 in vivo. We also performed an
anchored pooled hairpin screen in cell line A with a hairpin against mTOR (mTOR- 1) both in
vitro and in vivo. The first column indicates the genes, when inhibited, impedes tumor growth in
at least one cell line. The percentages in the digram indicate the extent of depletion of the second
best hairpin against the corresponding gene.
The percentages in the "-50% Cutoff' column in Figure 57 are the row sum of the
percentages from the diagram corresponding to the indicated gene. A higher percentage indicates
that the gene is likely important in multiple cell lines assessed. The genes listed in the table are
those with the largest summed percentages: Mek2, RalA, mTOR, Ikka, NfKb, Rictor, and p1106.
These genes are likely important for the survival or proliferation of cancer and non-cancerous
cells. It would be ideal to identify hairpins that are depleted in cancer lines but not normal lines,
but due to insufficient statistical power, we combined cancer and non-cancerous lines to identify
genes that are important in both cell types.
The "-25% Cutoff' column indicates percentages that are derived from a diagram that
requires that the second best hairpin only be depleted by 25%, as opposed to 50%.This provides
a less stringent cutoff and allows for the identification of hairpins that are only partially depleted
in the screen. These hairpins may be particularly interesting because, although their effect is
partial, they may consistently be depleted across different cell lines. The corresponding diagram
for the 25% cutoff would be larger than the one indicated in Figure 57. The summed percentages
are, as expected, larger than those using the -50% cutoff. There are also differences in the
ordering of some of the genes, in particular NfKb, ikka, p11 Oy, Akt3, Rictor, and p1106. To
validate these genes, they were subsequently analyzed in indivdual assays.
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Figure 57. Results of the various pooled hairpin screens. A pooled hairpin screen was performed in 1)
PDAC cell lines A and B in vitro 2) in PDAC cell line A in vivo 3) in normal cell lines, 3T3s and iBMKs
in vitro. Each assay is represented by a column. Genes that were a hit as defined by the second best
hairpin scoring method (described in Figure 56) are listed in the first column. Genes involved in the
Mapk, Pi3k, and Ral pathway are shaded in blue, red, and green, respectively. The percentage indicated in
the green-red color scale is the percentage depletion of the second best hairpin targeting that gene, when
comparing the dox-treated replicates to the untreated replicates. This calculation is explained in more
detail in Figure 56. In the sub-figure on the right, the percentage indicates the sum of all the percentages
in the row corresponding to that gene in the figure to the left. The percentages are indicated for the 50%
cutoff and also for a 25% cutoff. A 25% cutoff would indicate that according to the second best hairpin
criteria, in order for the gene to be included, the second best hairpin would only need to be depleted by at
least 25%. An anchored pooled hairpin screen was performed in vitro with cell line A and the anchor
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hairpin, mTOR-1 (indicated as A, mTOR-1). This same cell line was transplanted in vivo for a similar
analysis.
To validate the hits, we examined Mek2, Ikka, and Nfrb in cell line B, with multiple
hairpins against each gene (Figure 58). We tested RalA in cell lines A, B, and D. We achieved
significant knockdown of Mek2 and ikka, but did not see a consistent and significant change in
viability, suggesting that Mek2 and ikka are likely not critical for the proliferation and survival
of PDAC cell lines. As for Nfxb, we were unable to achieve substantial knockdown despite
testing over 15 independently designed hairpins. In the case of RalA, we achieved notable
knockdown of the protein and mRNA level in cell lines A and D, respectively. With regards to
the effect of RalA KD on viability, only hairpin number five had a significant effect, suggesting
likely off-target effects. In conclusion, Mek2, Ikka, and RalA are likely unimportant for the
maintenance of PDAC cell lines.
Figure 58. Validating hits from the pooled hairpin screen. Mek2, Ikka, and NfKb were tested in cell line
B. 5, 6, and 5 hairpins against Mek2, Ikka, and Nfrb were tested. After 5 days of dox-treatment, cells
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were compared to untreated cells. Viability and protein differences relative to untreated cells are indicated
in red and blue bars respectively. Protein assays were done in single, while viability assays were done in
triplicate and the mean value was used. RalA was tested in cell lines A, B, and D. In cell lines A and B,
viability and protein were measured, while in cell line D, mRNA and viability were assessed.
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In addition to the pooled hairpin screen, another approach we took to identify Kras
effectors is to individually test each gene. We performed the pooled hairpin screen and the
individual gene-by-gene approach in parallel in the situation that the pooled approach was not
technically feasible. As an overview of the gene-by-gene approach, we examined the effect that
the hairpins have on mRNA, protein, and viability from a population perspective (Figure 59). For
each of the 32 Kras effectors to be tested, multiple hairpins were synthesized and tested. In total,
228 hairpins, which targeted 32 genes, for an average of 7.1 hairpins per gene, were tested. 199
hairpins targeting 25 genes were assessed for mRNA levels. The relative levels for mRNA
indicate the mRNA level after 5-10 days of dox treatment, as compared to time-matched
untreated samples. The majority of the hairpins reduce levels of the target mRNA, as expected,
as indicated by a relative level below 100%. Some hairpins have the unexpected effect of slightly
increasing mRNA levels, thereby resulting in a relative level above 100%. In these situations, it
is likely that stochastic fluctuations explain the increase in mRNA level, as opposed to an actual
increase in the target mRNA. Approximately 70% of the 199 hairpins reduce mRNA levels of
their target gene by more than 50%.Overall, we observe a uniform distribution with regard to the
degree of mRNA knockdown. In other words, the probability of achieving x% of knockdown is
equal for x within the range 0 to 100%.This is a reasonable distribution without other
information with regards to hairpin design and efficacy.
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Figure 59. Overview of individual gene knockdown assays. In total, 228 hairpins against 32 genes were
tested. 199 hairpins against 25 genes were tested for mRNA. mRNA levels were measured after dox-
treatment for 5-10 days and normalized to the untreated cell line. 21 hairpins were tested against 7 genes
for protein. Protein levels were assessed after 5-7 days of dox-treatment and normalized to the untreated
cell line. 138 hairpins were tested against 28 genes for viability. Viability was assessed after 3 days of
dox-treatment and normalized to the untreated cell line. The plots depict the effect of the various hairpins
on mRNA, protein, and viability. Hairpins are sorted on the x-axis based on the extent of the effect they
have on mRNA, protein, and viability.
21 hairpins targeting 7 genes were examined for protein levels. Fewer hairpins were
assessed for protein levels as quantitative western blots are more cost and labor intensive. The
relative levels for protein are similar to that of mRNA except for samples that have been treated
with dox for 5-7 days. The cut-off between hairpins that achieve knockdown versus those that do
not is more clear-cut when looking at protein levels. 16 hairpins show a knockdown of 40% or
greater, while the other 5 hairpins achieve a knockdown of 15% or less.
138 hairpins targeting 28 genes were assessed for viability. The relative levels for
viability indicate the change in viability after 5 days of dox treatment (normalized to the
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untreated samples). The viability plot shows a notably different pattern than the mRNA and
protein graphs. The majority of hairpins do not have a significant effect on viability, while a
small sub-set reduce viability by 30% or more. While the ability of hairpins to knockdown their
target mRNA or protein follows a relatively uniform distribution, the effect on viability is
different, as certain hairpins will not reduce viability even if they are able to substantially
knockdown the target gene.
Of the 32 genes tested by the individual gene-by-gene approach, only mTOR, Raptor,
and Rictor, was shown to be important with multiple hairpins and across multiple PDAC cell
lines. 3-5 hairpins were tested against each of the 32 genes. The hairpins were tested for their
ability to knockdown the protein levels of the target gene. If more than 75% knockdown by
protein level could not be achieved, additional hairpins were synthesized and tested. Once 10
hairpins had been tested, we would move on to the next gene even when greater than 75%
knockdown had not been achieved. For the hairpins that achieved some degree of knockdown
(greater than 25% by protein level), we examined their effect on viability. We performed the
majority of our testing in cell lines A and B. For a gene to be considered important, two
independent hairpins would need to demonstrate a significant effect on protein and viability in
both lines A and B. The only genes that satisfied these criteria are mTOR, Raptor, and Rictor. Of
these three, only mTOR was identified as being one of the top 10 genes from the pooled hairpin
screen. This suggests that the pooled method may not be able to identify all the effective hairpins
in a pool, which is often the situation in high-throughput screens. In the next chapter, we discuss
further work on the mTOR, Raptor, and Rictor genes.
Discussion
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We established a pooled hairpin screening system that allows us to test various genes in
vitro and in subcutaneous transplant systems. To obtain sufficient power to detect hairpin
depletion, additional replicates can be performed. 20 replicates can be performed and analyzed in
a single high-throughput sequencing lane, allowing for low cost and labor analysis. In addition,
we demonstrate that an anchored pooled hairpin screen can be successfully performed where the
anchored hairpin achieves knockdown and inhibits tumor growth in vivo. To our knowledge, no
prior study has performed combinatorial knockdown in a screening format. This technology can
easily be adapted for larger hairpin libraries both in cancer and in non-cancer studies.
The hairpin-by-hairpin assessment of the various Kras effectors demonstrated that the
hairpin algorithm generally gives rise to hairpins that are uniformly distributed with regards to
knockdown potential. This distribution of knockdown is expected without any additional
information assuming that no particular amount of knockdown is favored. The uniform
distribution also suggests that if a sufficient number of hairpins are tested, effective hairpins that
achieve substantial knockdown are likely to be identified. In contrast to the degree of protein
knockdown, the majority of hairpins do not have a significant effect on viability. This shows that
many hairpins, despite their ability to achieve substantial knockdown, do not have a significant
effect on viability. In summary, the hairpin design algorithm gives rise to effective hairpins.
We discovered that, surprisingly, the large majority of the Kras effectors did not have an
effect on PDAC cell line viability. From the pooled hairpin screen, of the top 10 gene candidates,
only Kras, mTOR, and Rictor became validated targets after further study. The other candidates,
Mek2, RalA, NfKb, ikka, p11 Oy, Akt3, and p1106 could not be validated in individual hairpin
studies. For some genes, hairpins could not be designed that allowed for substantial knockdown
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of the target gene. For other genes, despite substantial knockdown, no significant change in cell
viability was observed.
From the individual gene-by-gene testing, we found only mTOR, Raptor, and Rictor to
be important genes. For the majority of genes, substantial knockdown (arbitrarily defined as
greater than 65% knockdown) could be achieved, but no consistent change in cell viability across
hairpins and cell lines was observed. For a minority of genes, substantial knockdown could not
be achieved. In all the studies, only three replicates were performed, and thus the extent of
statistical power is limited. In general, it was surprising to find a majority of the genes not be
important considering that they are components of the canonical Kras effector pathways. The
majority of these genes have been demonstrated to be critical for the survival and proliferation of
cancer. We found that mTOR, Raptor, and Rictor are important in Kras-mutant PDACs.
While there are many benefits to testing a select group of genes, one of the downsides is
that the tested genes are already known to be involved in cancer. One risk of testing genes well-
studied genes is that often the genes are already known to be involved in cancer. Consequently,
any finding may not be as exciting as one from a library screen that turns up a previously
unheard of gene. Nevertheless, we hope to demonstrate the importance of mTOR, Raptor, and
Rictor in a careful and systematic fashion that has yet to be performed in PDAC.
Materials and Methods
Many of the experimental procedures are explained in detail in Chapter 1.
Quantitative Western Blotting
The procedure for quantitative western blotting is described in Chapter 1 The non-
phospho antibodies used are: mTOR (CST-(Cell Signaling Technologies)-2983), Raptor (CST-
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2280), Rictor (CST-2140), LC3a/b (CST-4108), Egfr (CST-4267S), CC3 (CST-9661), Mekl/2
(CST-4695), Akt (CST-4685), Raptor (CST-2280), Rictor (CST-2140), 4e-BP1 (CST-9644), S6p
(CST-2217), S6k (CST-2708). The phospho-antibodies used are: p-Akt [Ser 473] (CST-4058), p-
Akt [Thr 308] (CST-2965), p-Erkl/2 [Thr 202/Tyr 204] (CST-4377), p-Mekl/2 [Ser 217/211]
(CST-9154), p-Egfr [Tyr 1068] (CST-3777), p-S6k [Thr 389] (CST-9234), p-S6k [Thr 421/Ser
424] (CST-9204S), p-S6p [Ser 240/244] (CST-5364), p-S6p [Ser 235/236] (CST-4858), p-4eBP1
[Ser 65] (CST-945 1), p-4eBP1 [Thr 37/46] (CST-2855), p-4eBP1 [Thr 70] (CST-9455), p-
mTOR [Ser 2448] (CST-5536).
High-throughput sequencing
The miR30 hairpins were contained in a dox-inducible vector, TGMP (Tet-responsive-
element - Gfp - Mir3O - Puromycin). Vectors containing different hairpins were combined
together to form a pool of hairpins. For each experimental condition, PCR primers with different
barcodes were used to amplify the resulting pool of hairpins. 20 different barcodes were made,
each differing from one another by one or two nucleotides. The barcodes were 19-mer primers
that contained EcoRI and XhoI cloning sites, and the PCR mixture is: 12.5 pL of 2x Failsafe
Buffer B (Epicentre), 0.5 pM of the 5' loop primer, 0.5 pM of the 3' loop primer, 500pg of the
DNA template, This allowed for a single high-throughput sequencing reaction to analyze the
hairpin population of up to 20 treatment conditions. Subsequently, the standard Illumina sample
preparation protocol was used to obtain processed samples for sequencing. The illumina
GenomeAnalyzer v2 was used to sequence the resulting sample. This above described procedure
was used for both in vitro and in vivo samples.
Hairpin design
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Hairpins were designed by Scott Lowe's Lab (Cold Spring Harbor Laboratory) using a
proprietary algorithm. Hairpins were produced by ordering a 97-mer single-strand
oligonucleotide from Invitrogen and performing subsequent PCR to create the double-strand
hairpin. Multiple hairpins (3-25) were tested for each target gene of interest.
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CHAPTER 3: mTOR as a Target
Abstract
We demonstrate that knockdown of mTOR, Raptor, or Rictor, inhibits PDAC
proliferation in vitro and in vivo. These experiments were performed with numerous hairpins
across multiple cell lines. The effect of mTOR knockdown on viability in vitro and in vivo was
not as substantial as that from Kras knockdown. In vitro inhibition of PDAC proliferation was
most apparent from mTOR knockdown, followed by Raptor knockdown, and finally by Rictor
knockdown. In contrast, the in vivo effect of mTOR knockdown, Raptor knockdown, and Rictor
knockdown, are relatively comparable. Both mTOR and Raptor inhibition induced expected
changes in signaling downstream of mTORC 1, including substantial downregulation of p-S6k
and partial downregulation of p-4e-BP 1. As for mTORC2 signaling, Raptor knockdown induced
substantial upregulation of p-Akt(Serine 473), which is likely a mTORC l-mediated feedback-
induced upregulation. mTOR knockdown induced no significant change in p-Akt(Serine 473)
levels, suggesting that mTOR knockdown inhibited mTORC2 and prevented the feedback-
upregulation of p-Akt(Serine 473). We looked for a small molecule compound to combine with
mTOR knockdown to enhance the effect on viability. AZD6244, a Mekl/2 inhibitor, was the
only one of several drugs tested to demonstrate a substantial synthetic lethality effect, with the
comparator normal cell lines being immortalized baby mouse kidney cells and mouse 3T3
fibroblasts. Combining AZD6244 and mTOR or Raptor knockdown enhanced the deleterious
effects on cell viability in an additive fashion. In summary, mTOR, Raptor, and Rictor are
important targets in mouse PDAC cell lines in vitro and in vivo.
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Introduction
mTOR is a well-studied gene and validated cancer target that resides in the Pi3k pathway
(Ma et al., 2005). Mutations in cancer drive overactive mTOR signaling. Inhibition of mTOR
diminishes cancer proliferation. More recently, mTOR has been implicated in the epithelial-to-
mesenchymal transition and in metastasis. Everolimus, an mTOR inhibitor, has been approved
for various cancers: renal cell carcinoma, tuberous sclerosis, and pancreatic neuroendocrine
tumors (Raymond et al., 2004). Temsirolimus, another mTOR inhibitor, has been approved for
renal cell carcinoma and mantle cell lymphoma (Zhao et al., 2012). These mTOR inhibitors and
others have been through many clinical trials for various cancer indications. Unfortunately, the
overwhelming majority of the trials have shown negative results. Four phase 1I trials involving
mTOR inhibitors have been performed in PDAC. Two of the trials involved combination
therapies: one with an Egfr inhibitor and the other with chemotherapy. Unfortunately, none of
the trials showed positive or promising results. It is unclear whether the mTOR inhibitor is
ineffective because mTOR is a poor target or because insufficient mTOR inhibition was
achieved at the tumor site. We hope to better establish whether mTOR is an important target in
mouse models of PDAC.
mTOR signals downstream by forming two complexes, mTORC 1 and mTORC2 (Figure
60). mTORC 1 also contains Raptor among other proteins, while mTORC2 contains Rictor.
mTORC 1 regulates cell growth and proliferation primarily through phosphorylation of S6k and
4eBP1 (Gibbons et al., 2009). Both S6kl and 4eBP1 directly regulate protein translation (Park et
al., 2002). mTORC2 phosphorylates Akt on the Serine 473 site, which further activates Akt (in
addition to the phosphorylation at the Threonine 308 site) (Foster and Fingar, 2010; Zoncu et al.,
2011). Studies have shown that inhibition of mTORC1 by rapalogs leads to rapid and substantial
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inhibition of p-S6kl, but only transient and partial inhibition of p-4eBP 1 (Raymond et al., 2004).
Moreover, upon rapalog-treatment, mTORC2 activity is upregulated and p-Akt(Ser473) is
elevated. In contrast, inhibition of both mTORCl and mTORC2 by ATP-competitive inhibitors
have allowed for sustained inhibition of both mTORCl targets and p-Akt(Ser473) (Carracedo et
al., 2008). By analyzing phosphorylation downstream of mTORCl and mTORC2, we can better
understand the effects of mTOR inhibition in PDAC.
mTORC1 mTORC2
S4731 T3081
Figure 60. mTOR Signaling via the mTORCl and mTORC2 Complexes. The mTORCl complex consists
of mTOR, Raptor, Pras40, and mLST8/GpL. The mTORC2 complex consists of mTOR, Rictor, Protor,
mSin1, and mLST8/GpL. mTORC1 phosphorylates S6k and 4e-BPl. Phosphorylated S6k goes on to
phosphorylate S6. mTORC2 phosphorylates Akt at the Serine 473 site. Pdkl is responsible for
phosphorylation of Akt at the Threonine 308 site.
Studies are beginning to dissect the importance of mTORC 1 as compared to mTORC2 in
mTOR signaling (Carracedo et al., 2008). Until recently, drugs that targeted mTORCl but not
mTORC2 were available. Development of ATP-competitive mTOR inhibitors has allowed for
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the inhibition of both mTORC1 and mTORC2. However, no drug exists that inhibits mTORC2
only. Consequently, the most feasible approach to dissect the functions of mTORC 1 and
mTORC2 is to use RNAi. Hairpins against Raptor and Rictor would inhibit mTORC 1 and
mTORC2, respectively.
Many drugs have been developed targeting the Kras effector pathways Mapk and Pi3k.
In conjunction to our hairpin studies, we used small molecule inhibitors to probe for important
pathways in Kras-mutant PDAC. While hairpins allow for the targeting of any gene, once an
important gene is identified, additional work will be necessary to develop a therapeutic
compound to inhibit the gene. On the other hand, small molecules are more practical as they are
potential therapeutic compounds.
The most commonly targeted genes in the Mapk pathway include the Rafs and Meks.
GDC-0879, created by Genentech, targets Braf, while AZD-6244, created by Astrazeneca, target
Mek1 and Mek2. As for the Pi3k pathway, the most commonly targeted genes are Pi3k, Akt, and
mTOR. Wortmannin, a laboratory test compound without suitable characteristics to be a clinical
trial candidate, and ZSTK474, developed by Zenyaku Kogyo, target Pi3k. NVP-BEZ235, created
by Novartis, targets both Pi3k and mTOR, while MK-2206, created by Merck, targets Akt1/2/3.
AZD-8055, developed by Astrazeneca, targets both mTORCl and mTORC2. Everolimus,
created by Novartis, targets mTORC1.
Many of these compounds are being tested in clinical trials for cancer. When testing a
drug, most effort is placed in obtaining approval and in expanding indications. We plan to focus
on identifying compounds that are effective in PDAC, so we will systematically test the above
mentioned compounds in a variety of PDAC lines. In contrast, drug development studies focus
292
on one compound and test it a variety of cancer indications even when the pre-clinical results are
weak, as indication expansion is a profitable strategy.
Defining drug sensitivity is a challenge, as any drug, when given at sufficiently high
concentrations, will induce cell death. Rules of thumb suggest that a low nanomolar IC5 0 in vitro
is considered an effective drug. Theoretically, an effective drug is one that can inhibit the tumor
in vivo. Consequently, the concentration at which the drug can reach in the in vivo tumor should
be the concentration tested in vitro to determine its effect. However, it is difficult to obtain the
concentration of the drug in vivo, as the drug is often not yet approved for clinical trials. Even if
it were approved, obtaining biopsies on the patient tumor presents risks especially for solid
tumors of essential organs. Another approach to assessing drug sensitivity is to test the drug on
both cancer cells and normal cells and look for a synthetic lethal effect. This would give some
information as to the toxicity of the drug. In summary, determining sensitivity to a drug is not
necessarily a straight-forward assay.
Results
mTOR showed the strongest effect in the individual well-by-well assay and was also
identified as one of the top genes in the pool-based assay. mTOR knockdown in vitro was
performed with 7 independently designed hairpins across 6 cell lines (Figure 61). We tested
multiple hairpins because each individual hairpin may have off-target effects. The likelihood of
multiple hairpins having a deleterious effect due to off-target effects is much lower. Multiple cell
lines were assessed, as an individual cell line may have idiosyncratic sensitivies that are not
found in other PDAC lines. mTOR hairpins 1, 2, 3, 4, 5, 6, and 7, encased in the TGMP vector,
were tested in PDAC cell lines A, B, C, D. Hairpins 6 and 7 were also tested in the TRMPVIN
vector, designated in the figure as 6' and 7v. 4 hairpins were tested in line A, 5 in line B, 3 in line
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C, and 6 in line D. Viability was assessed after 5 days of dox treatment, while protein was tested
after 5 to 7 days of dox. Viability and protein levels were normalized to time-matched untreated
samples. Viability was reduced by 10-90%, while protein levels were reduced by 40-90%.In
comparison, Kras KD in vitro reduced viability by 35-70%, while protein levels were reduced by
75-90%.Because of the different levels of protein knockdown, it is difficult to conclude whether
Kras or mTOR knockdown results in a larger effect on cell viability. To summarize, the mTOR
hairpins were able to achieve protein knockdown and have an effect on viability across multiple
cell lines.
mTOR Knockdown in vitro
Cell A B C
Line , 1 r - _11
1 4 3 2 4 1 6 7v 6 2 3 1 2 1 2v
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Figure 61. Knockdown of mTOR in PDAC cell lines. Various hairpins against mTOR (1, 2, 3, 4, 5, 6),
placed in the TGMP vector, were tested in PDAC cell lines (A, B, C, and D) and normal cell lines
(iBMK, 3T3). Hairpin 6 and 7 were also placed in a slightly different vector, TRMPVIN. The effect on
cell viability and mTOR protein levels were measured after 3 and 5 days of dox-treatment, respectively,
and normalized to untreated cells. Each pair of blue and red bars corresponds to a particular hairpin. The
error bars indicate the standard error.
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Since the viability effect of the mTOR hairpins could be due to off-target effects, we
sought to correlate the extent of protein knockdown with the effect on viability (Figure 61). Each
pair of protein and viability bars is a single cell-hairpin combination being tested. As expected,
the general pattern is that hairpins that show a greater degree of protein knockdown also show a
larger effect on viability. For each of the viability or protein assays, multiple replicates were
performed to enhance the statistical strength of the conclusion. In summary, we believe that the
effect of mTOR knockdown is on-target, as the greater the extent of the protein knockdown, the
larger the effect on cell viability.
To determine whether mTOR is important in vivo, we transplanted mTOR hairpin-containing
cells subcutaneously into nude mice (Figure 62). Two hairpins against mTOR (mTOR- 1 and
mTOR-2) were tested in two lines (A and B). After 12 days of dox-treatment, mTOR protein
levels were reduced by 72%, 70%, and 69% in the cell lines A, mTOR-1; A, mTOR-2; and B,
mTOR-2 (normalized to time-matched untreated samples). The tumor weights were reduced by
45%, 55%, and 38%, respectively. These experments were done in high replicate, with at least 12
tumors in each treatment group. The tumor weight reduction from mTOR KD is not as dramatic
as that from Kras KD. On the other hand, KD of mTOR protein levels is detectable, unlike that
of Kras levels. mTOR KD is likely detectable because cells experiencing mTOR knockdown are
not immediately dying off.
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Figure 62. Knockdown of mTOR in vivo. Two hairpins against mTOR (1, 2) were tested in PDAC cell
line B, while shmTOR-2 was tested in lines A and B. The resulting cell lines were transplanted into the
backs of nude mice. After administering dox for 12 days, the resulting tumor weight and mTOR protein
levels are indicated relative to time-matched untreated tumors. Each data point represents an individual
tumor. In the figure on the right, cell lines A and B containing the mTOR-2 hairpin were transplanted into
the backs of nude mice. In vivo bioluminescence imaging was performed to determine the size of the
tumor prior to splitting the mice into two groups. One group was given dox, while the other was left
untreated. After 7 and 8 days, bioluminescence levels were measured once again. Bioluminescence levels
are normalized to the levels at day 0.
Another approach that we took to analyze the effect of mTOR hairpins on tumor size is
by bioluminescence imaging (Figure 63). After 7 or 8 days of dox-treatment, the
bioluminescence levels of A, mTOR-2 or B, mTOR-2 are notably less than that of the untreated
group. In contrast to the bioluminescence studies for Kras, the tumors experiencing mTOR
knockdown continue to increase their bioluminescence levels. This suggests that mTOR
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knockdown does not induce tumor regression, but rather only slows down tumor growth. To
summarize, mTOR is important in vivo for the maintenance of PDAC, although not as important
as Kras.
A, mTOR-2 B, mTOR-2
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Figure 63. Bioluminescence imaging of mTOR knockdown in vivo. Cell lines A and B, containing a
hairpin against mTOR (shmTOR-2), were transplanted subcutaneously into the backs of nude mice.
Tumors were allowed to grow for 12 days. Subsequently, mice were split into two groups, one receiving
dox, and the other was left untreated. Bioluminescence levels of A, shmTOR-2 was measured 7 days
afterwards, while that of B, shmTOR-2 was assessed 8 days afterwards.
For mTOR to be a good therapeutic target, it should not only be necessary for the tumor,
but also not be necessary for normal cells. This phenomenon is known as synthetic lethality. By
being unessential to normal cells, mTOR inhibition is less likely to give rise to undesired side
effects. We also tested the synthetic lethality potential of Kras.
The effects of Kras and mTOR KD were examined in PDAC cell lines A, B, and C and
in the normal cell lines iBMK and 3T3 (Figure 64). The viability of the cancer and normal cell
lines were assesed after 5 days of dox-treatmentBoth Kras and mTOR KD had a more
deleterious effect on the viability of cancer cells than on that of the normal cells. For mTOR KD,
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the cancer cell lines show a reduction in viability of 60-85%, while the normal lines show a
decrease of only 20-35%.As for Kras KD, the cancer cells lines show a reduction of 25-55%,
while normal lines show a reduction of 0-5%.
The difference in the effect on viability between cancer and normal cells is not explained
by a difference in the amount of mRNA knockdown. The mTOR and Kras mRNA is reduced by
45-65% and by 55-65% across on the cell lines. Moreover, the mRNA levels are not reduced
moreso in the cancer lines than in the normal lines. PCNA was used as a positive control, as it is
required for the replication of any cell. We would expect knockdown of PCNA to reduce the
viability of all the cell lines. Knockdown of PCNA reduced viability of the cell lines by 75-
95%.There was no difference in viability among the cancer lines as compared to the normal
lines. The hairpin against PCNA is effective, as the mRNA levels were reduced significantly by
75-90%.In summary, mTOR and Kras are likely good therapeutic targets in that they are
important for cancer cells but not for normal cells.
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Figure 64. Assessing synthetic lethality of mTOR and Kras knockdown in PDAC and normal cell lines.
Hairpins against mTOR, Kras, PCNA, were assessed in PDAC cell lines A, B, C and the normal cell lines
iBMK and 3T3. The effect of the hairpin on viability after 5 days of dox-treatment (normalized to
untreated samples) is indicated in purple for the PDAC lines and orange for the normal lines. In the figure
on the right, the effect of the hairpins on mRNA levels after 3 days of dox-treatment (relative to
untreated) is illustrated.
After establishing mTOR as a suitable therapeutic target, we studied the biochemical
effect of mTOR KD by examining the signaling downstream of mTOR (Figure 65). We surveyed
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the following signaling molecules: p-S6k (Thr389), p-S6 (Ser235/236), p-4eBP1 (Thr37/46), p-
Akt (Ser473). p-S6 (Ser235/236), p-S6k (Thr389), and p-4eBPl (Thr37/46) are targets of
mTORC 1, while p-Akt (Ser473) is a target of mTORC2 (Figure 66). Moreover, p-S6
(Ser235/236) is a target of p-S6k (Thr389). mTOR KD was performed across 3 different cell
lines using 5 different hairpins. After 1 day of dox treatment, mTOR levels were reduced by a
little more than 50%.Consequently, we would expect some change in the levels of downstream
signaling molecules. We observe a reduction in levels of p-S6k(Th389) and p-S6(S235/236) by a
little less than 50% on average. In contrast, levels of p-4eBPl (T37/46) and p-Akt (S473) did not
change.
I Day of Dox
p-S~k p-S6 p-4eBPI p-Akt
0 mTOR (Th389) (S2351236) (Th37146) (S473) oA, 2
A, 3
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Figure 65. The effect of mTOR knockdown on mTOR signaling in vitro. Six mTOR hairpins (1, 2, 3, 4, 5,
6) were tested across various PDAC cell lines (A, B, C, and D). In the top figure, dox was administered to
the cell lines for 1 day. The y-axis indicates the change in the level of the protein as compared to samples
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that were untreated for 1 day. Levels of mTOR protein and mTOR downstream signaling molecules were
assessed. The bottom figure is similar to the top figure with the exception that cell lines were treated for 3
days.
mTORCI1 mTORC2
S473 T308
Pi
Figure 66. Phospho-signaling Downstream of mTOR. mTOR forms two complexes with other proteins:
mTORC 1 and mTORC2. mTORC 1 phosphorylates S6k and 4e-BP 1. S6k phosphorylates S6. mTORC2
phosphorylates Akt at Serine 473. Pdk1 phosphorylates Akt at Threonine 308.
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After 3 days of dox-treatment, mTOR knockdown increases and reaches over 50%.The
reduction in p-S6k(Th389) and p-S6(S235/236) become more dramatic and reach over 75% on
average. Levels of p-4eBP1 (T37/46) are decreased on average by 50%. Levels of p-Akt (S473)
remain unaltered. Each of these genes shows enhanced KD over time, as the amount of KD after
3 days is notably greater than that after 1 day. In summary, knockdown of mTOR results in
substantial downregulation of mTORC 1 targets p-S6k and p-S6, but not as much of the
mTORC 1 target p-4eBP 1. This is in line with previous studies in which mTORC 1 inhibitors
have demonstrated that p-S6k and p-S6 levels are dramatically reduced, while p-4eBP1 levels are
only transiently and partially inhibited.
As for mTORC2 inhibition, p-Akt (S473) levels remain unchanged even after 3 days of
dox-treatment. This is surprising considering that mTOR signals through both mTORCI and
mTORC2. We would expect mTOR inhibition to affect mTORC2 and reduce p-Akt (S473)
levels. However, upon further analysis, there is likely an effect, as raptor KD induces
upregulation of p-Akt (S473) levels (described further below). Consequently, mTOR KD is
likely inhibiting mTORC2 and preventing p-Akt (S473) from being upregulated upon
inactivating of mTORC 1. In conclusion, upon knockdown of mTOR, we see inhibition of
downstream mTORC 1 molecules and likely also of downstream mTORC2 molecules.
We extended our analysis of signaling changes to mTOR knockdown to an in vivo setting
(Figure 67). Two mTOR hairpins (shmTOR-2, shmTOR-4) were analyzed in PDAC cell line A.
One mTOR hairpin (shmTOR-2) was analyzed in cell line B. After transplantation, the tumors
were allowed to grow for 12 days. Afterwards, dox was administered for 12 days. After 12 days
of dox-treatment, mTOR and its downstream signaling molecules demonstrated reduced levels.
In particular, mTOR protein levels were decreased by 50-75%.p-4eBP 1 (Th37/46) levels
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decreased by about 50%.P-Akt (S473) levels decreased by 15-25%.Similar to the in vitro studies,
p-4eBP1 (Th37/46) demonstrates a reduction of approximately 50%.This suggests that the in
vitro studies are representative and that mTOR inhibtion does not completely inhibitly p-4eBP 1
signaling even after 12 days of dox-treatment. P-Akt (S473) shows results that are in contrast to
that in vitro. While the in vitro study shows no change in signal, the in vivo study demonstrates a
slight reduction. This difference may be because prolonged dox-treament (12 days in vivo as
compared to 5 days in vitro) allows for more substantial inhibition of mTORC2. Another
possibility is that the feedback-induced upregulation of p-Akt (S473) has subdued by 12 days
post-dox-treatment. To summarize, in the more physiologically representative in vivo setting,
both mTORC 1 and mTORC2 signals are least partially inhibited.
12 Days of Dox
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mTOR p-4eBP1 p-Akt
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Figure 67. Analyzing the signaling effects of mTOR knockdown in vivo. PDAC cell lines A and B
containing a hairpin against mTOR (mTOR-2 or mTOR-4) were transplanted subcutaneously into nude
mice. After allowing for engraftment and tumor expansion, doxycycline was administered to one group of
mice. After 12 days of treatment, the tumors were harvested and analyzed by quantitative western
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blotting. Protein levels of mTOR, p-4eBP1, and p-Akt(S473) were determined and compared to tumors
that were allowed to grow in the absence of doxycycline for 12 days.
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To examine the differences between mTOR knockdown and mTOR drug inhibition, we
looked at the downstream signaling effects of AZD8055 treatment. AZD8055 was given at
various concentrations (0, 1, 10, 1OOnM, luM 1OuM) on different PDAC cell lines (A, B, C, and
E) (Figure 68). We examined the levels of various mTORCl targets: p-4eBP1(Th37/46), p-
4eBP1(S65), p-S6K(Th421/S424), p-S6(S235/236), p-S6(S240/244), p-Pras40(Th246)),
mTORC2 targets: p-Akt(S473), and potential feedback-induced activation of p-Egfr(Ty1068). In
cell line A, p-mTOR was also assessed to ensure that AZD8055 was inhibiting the target. p-
mTOR, the mTORC 1 targets, and the mTORC2 targets all demonstrated progressively increased
inhibition with increasing concentrations of AZD8055. This suggests that AZD8055 is
successfully inhibiting mTOR and inducing the desired downstream effects. As for p-Egfr and p-
Erk, the changes in protein levels are inconsistent across cell lines and do not follow a
concentration-dependent gradient. There are not consistent changes in Egfr and Mapk feedback
signaling upon administration of AZD8055. In summary, AZD8055 induces the expected and
desired changes in the mTORC 1 and mTORC2 downstream signaling molecules.
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Figure 68. The effect of AZD8055 on various downstream signaling pathways. PDAC cell lines A, B, C,
and E were treated with AZD8055, a small molecule inhibitor of mTOR, at various concentrations (0, 1,
10, 1OOnM, luM, 1OuM) for 3 days. The cell line was then analyzed for the indicated protein levels by
quantitative western blot. The y-axis indicates the change in the protein level as we move from the
untreated to the dox-treated group cell line. To illustrate the diagram, there are 5 bars associated with each
color. For example, the five bars in blue, moving from left to right indicate the effect of 1, 10, 1 OOnM,
luM, and lOuM of AZD8055 treatment on cell line A. Red, orange, and green, indicate the same
experiment but for cell lines B, C, and E, respectively.
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mTOR functions through forming two multi-subunit complexes: mTORC1, which
contains Raptor, and the other complex, mTORC2, which contains Rictor. To determine whether
the necessity of mTOR is due to its function through mTORC 1 or that through mTORC2, we
knocked down Raptor and Rictor, separately. Multiple raptor hairpins (shRaptor-1, shRaptor-2,
shRaptor-3, shRaptor-4, shRaptor-5) were introduced into PDAC lines A, B, C, D (Figure 69).
The change in the viability and protein levels was assessed after 3 days of dox-treatment. Raptor
knockdown results in a reduction in viability by 10-70%.Protein levels were reduced by 40-
100%.On average, the three hairpins induced a reduction in viability for line A, B, and C of 67%,
40%, and 57%, respectively. In addition, the variability in the effect on viability among hairpins
within a cell line is low, suggesting that Raptor is an important target. In conclusion, mTORC1 is
important for the maintenance of PDAC cell lines.
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Figure 69. The Effect of Raptor Knockdown in vitro. Five hairpins against raptor (1, 2, 3, 4, and 5) were
introduced into four PDAC cell lines (A, B, C, and D). The figure indicates the change in cell viability
and Raptor protein levels after 5 days of dox-treatment. Viability and protein are indicated relative to
samples that are left untreated for 5 days. Error bars indicate the standard error.
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To examine whether mTORC 1 is also important in a more physiological setting, we
examined Raptor knockdown in subcutaneous transplants (Figure 70). We studied 3 Raptor
hairpins (Raptor- 1, Raptor-2, Raptor-4) in PDAC line A and Raptor-4 in line B. We examined
the change in tumor weight after 11 to 17 days of dox-treatment. Tumor weight was reduced by
25-60%.We also studied the effect of Raptor knockdown in cell line A containing shRaptor-4.
Raptor protein level was reduced by 75%.In summary, mTORC1 is an important component of
mTOR signaling in PDAC, as knockdown of raptor in vivo has a deleterious effect on tumor
growth.
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Figure 70. The Effect of Raptor Knockdown in vivo. Raptor hairpins (1, 2, 4) were introduced into mouse
PDAC lines A, B. The indicated cell line-hairpin combination is transplanted subcutaneously into nude
mice. After allowing the tumor to grow for 12 days, dox is administered for the indicated number of days,
"Days on Dox". Time-matched untreated tumors are indicated in the columns with "0" for "Days on
Dox". In the figure on the left, normalized tumor weights are indicated. Tumor weights are normalized by
dividing the tumor weights by a value such that the average tumor weight of untreated tumors is equal to
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1 in each group. In the figure to the right, normalized Raptor protein levels are indicated. The normalized
values are determined in the same fashion as are the tumor weights.
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To understand the effect of Raptor KD, we looked at downstream protein signaling
changes both in vitro and in vivo (Figure 71). In vitro, dox was administered for 3 days and
protein levels were compared to samples that were untreated for 3 days. We observe
downregulation of Raptor by 50-85%, of p-S6k(T389) by 100%, and of p-4eBP1(T37/46) by 50-
80%.Similar to previous studies that have studied inhibition of mTORC1 by rapalogs, p-
S6k(T389) experienced notably more inhibition than p-4eBP1(T37/46). P-Akt(S473) was
actually upregulated by 55-130%.This is consistent with prior studies with rapalogs where
rapalog-treatment causes feedback-induced upregulation of P-Akt(S473).
The signaling effects of Raptor KD was also assessed in vivo (Figure 71). Dox was
administered for 12 days, and the resulting samples were compared to those that were left
untreated for 12 days. We observe downregulation of Raptor by 20-60%, of p-4eBPl(T37/46) by
25-55%.P-Akt(S473) actually shows upregulation by 25-50%. These results are in the same
general direction as our findings in vitro. In summary, both in vitro and in vivo, we observe
substantial downregulation of the mTORC1 target p-S6k(T3 89), partial downregulation of p-
4eBP 1 (Th37/46), and upregulation of p-Akt(S473).
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Figure 71. The effect of Raptor knockdown on downstream protein signaling. Three Raptor hairpins (1, 2,
4) were introduced into PDAC cell line A. One hairpin (4) was introduced into line B. The above figure
shows the results from in vitro studies. Dox was administered for 3 days, and the resulting change in the
protein level of the signaling molecule is indicated relative to cells that were untreated for 3 days. Three
cell line-hairpin combinations (A, shRaptor-2; A, shRaptor-4; B, shRaptor-4) were injected
subcutaneously into nude mice. After allowing them to grow for 12 days, the mice were either given dox
for 12 days or left untreated for 12 days. The levels of the protein signaling molecules in the dox-treated
group were assessed and normalized relative to the untreated group.
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After establishing that Raptor plays an important role in mTOR signaling, we examined
the importance of the mTORC2 complex by knocking down Rictor. In in vitro studies, 7
different hairpins against Rictor were tested across 4 different cell lines (A, B, C, and D) (Figure
72). The extent of Rictor KD ranged from 40 to 99%.The effect on viability spanned 0 to 40%
(in comparison, Raptor KD reduces viability by 10 to 70%).While the rictor hairpins achieved
substantial knockdown, the effect on viability was less than that by Raptor KD, though still
significant.
Two Rictor hairpins were tested in cell line A in vivo. One harpin reduced the tumor
weight by 30%, while the other reduced weight by 20% (in comparison, Raptor KD reduced
tumor weight by 25 to 60%).Similar to the findings in vitro, Rictor KD reduces tumor weight by
a relatively small but significant amount. Rictor KD has less of an effect on viability in vitro and
tumor growth in vivo than does Raptor KD. This finding is in line with the fact that most
inhibitors being developed against mTORC 1, as opposed to mTORC2. There are far more
studies on Raptor and cancer than there are on Rictor, suggesting the potential relative
importance of Raptor over Rictor.
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Figure 72. Effect of Rictor knockdown in vitro and in vivo. 7 different hairpins against Rictor (1, 2, 3, 4,
5, 6, 7) were introduced into PDAC cell lines (A, B, C, or D). The hairpins are encased in the TGMP-
vector except for those with *, indicating that the TRMN vector was used. A, shRictor-4 and A, shRictor-
5 were transplanted subcutaneously into nude mice. Changes in viability and protein levels are indicated
after dox-treatment (relative to untreated samples). Dox was administered for 5 days in vitro and for 14 or
16 days in vivo, respectively. Error bars represent standard errors.
To more directly compare the effects of mTOR, Raptor, and Rictor KD, we have
summarized the previously described results in Figure 73. On average, mTOR, Raptor, and
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Rictor, achieve substantial and similar degrees of protein KD of 70%, 80%, and 70%,
respectively. Their effects on viability are different with mTOR, Raptor, and Rictor KD reducing
viability by 55%, 40%, and 5%, respectively. As mentioned above, mTOR KD has the most
substantial effect, followed by Raptor KD and finally by Rictor KD. Since the extent of protein
KD can affect the change in viability, we sought to normalize the effect on viability by the
degree of knockdown. This would allow us to obtain a better measure of the importance of each
gene. The "normalized viability" is determined by dividing the change in viability by that in
protein level and then multiplying by negative one. In other words, the "normalized viability" is
the presumed effect on viability if 100% knockdown was achieved, assuming a linear
relationship between the extent of knockdown and the effect on viability. For example, if the KD
induces a 40% reduction in viability and a 50% reduction in the target protein, then the
normalized viability effect would be -40%/-50% * -1 = -80%, or a 80% reduction. The
normalized viability for mTOR, Raptor, and Rictor, are, on average across all the performed
experiments, 75%, 55%, and 10%.To summarize, even after normalizing for the degree of KD, in
vitro experiments suggest that mTOR is the most important target, followed by Raptor and
finally by Rictor.
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Figure 73. Comparing the effects of mTOR, Raptor, and Rictor knockdown in vitro. On the figure to the
left, the data presented previously is summarized so that the effect of mTOR, Raptor, and Rictor can be
easily compared. Each data point indicates an experiment with a particular cell line and hairpin. The y-
axis indicates the change in either protein or viability levels after some period of dox treatment, relative to
time-matched, untreated samples. Protein is determined by quantitative western blotting for the levels of
mTOR, Raptor, or Rictor. Viability is determined by the Cell-Titer-Glo assay. The averages are indicated
by a longer horizontal line, flanked by shorter standard error bars. The figure on the right further
condenses the data to show the effect on "normalized viability". Normalized viability is the effect on
viability after taking into considering the extent of protein knockdown. The "normalized viability" is
determined by dividing the change in viability by that in the protein level and then multiplying by
negative one. In other words, it is the presumed effect on viability if 100% knockdown was achieved,
assuming a linear relationship between the degree of knockdown and the effect on viability. For example,
if the viability effect is -40% and that of protein is -50%, then the normalized viability effect would be -
40%/-50% * -1 = -80%.
We also compared the effects of mTOR, Raptor, and Rictor inhibition in vivo. All of the
prior in vivo experiments are aggregated in Figure 74. mTOR, Raptor, and Rictor inhibition
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result in a tumor weight reduction of 35%, 25%, and 25%, on average, when compared to time-
matched untreated tumors. A decrease in tumor weight does not suggest that the tumor is smaller
in size than it was prior to dox-treatment. Rather, the tumor weight, when compared to time-
matched untreated tumors, is lesser in weight. In comparison to the in vitro effects by mTOR,
Raptor, and Rictor, which reduce viability by 55%, 40%, and 5% (these are the actual changes in
viability, as opposed to the "normalized viability"), the in vivo effect is less significant for
mTOR and Raptor, but more dramatic for Rictor. This suggests that mTOR and Raptor may not
be as effective targets in human clinical trials as they are in vitro. Rictor may actually be a
promising target in vivo. As for comparing the relative effect of mTOR, Raptor, and Rictor KD
in vivo, additional replicates will be necessary to increase the statistical power. At first glance, it
appears that mTOR KD may have a slightly larger effect in vivo than Raptor or Rictor KD.
However, the effects of inhibiting each of the three genes are comparable. In summary, mTOR,
Raptor, and Rictor, all have statistically significant effects on tumor weight in vivo and are
promising candidates for therapeutic development.
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Figure 74. Comparing the effects of mTOR, Raptor, and Rictor knockdown in vivo. Previous work on in
vivo studies of mTOR, Raptor, and Rictor are summarized here. Each data point represents a tumor. To
normalize the tumor weights, the mTOR tumors are each divided by the number such that the average
weight of the untreated tumors is equal to one. The Raptor tumors are normalized in the same manner, as
are the Rictor tumors. The dotted red line indicates the average tumor weight.
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In addition to analyzing the effect of KD of mTOR and of other Kras effectors, we used
small molecules to probe the importance of the MAPK and P13K signaling pathways in PDAC.
The following drugs that we assessed are indicated along with their associated targets: GDC-
0879 (Braf), AZD-6244 (Mek), ZSTK474 (Pi3k), Wortmannin (Pi3k), MK-2206 (Akt), BEZ-235
(Pi3k/mTOR), Everolimus (mTOR), AZD8055 (mTOR) (Figure 75). These drugs were
developed by the following companies: Genentech, Astrazeneca, Zenyaku Kogyo, Merck, and
Novartis. All the drugs described are currently being pursued in clinical trials for cancer
indications, with the exception of Wortmannin. All of the drugs have not yet been approved and
are currently in clinical trials, with the exception of Wortmannin, which failed in clinical trials
and is now a laboratory test compound, and Everolimus, which has already been approved for
renal cell carcinoma and is currently in trials for other cancer indications.
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Figure 75. Diagram of the Small Molecule Inhibitors and Their Targets. The small molecules that we
tested are indicated in the above figure, along with the company responsible for the small molecule. The
targets of the small molecules are in the Mapk and Pi3k pathways.
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It is challenging to define whether a cell line is sensitive to a particular drug, as any drug,
given at a sufficient high enough concentration, will reduce the viability of the cell line.
Consequently, the ideal definition of sensitivity is whether the drug, at concentrations that can be
reached in the human tumor, is toxic to the tumor. Unfortunately, it is difficult to determe the
concentration a drug can achieve at the tumor site. If the drug is not yet approved for clinical
trials, it cannot be administered to patients. If it can be administered to patients, it is difficult to
determine its concentration due to the risk to the patient of obtaining a biopsy. This is
particularly true for non-skin solid tumors where tumor accessibility is limited.
To approximate whether a PDAC cell line is sensitive to a particular drug, we
determined the IC50 and compared it to the IC 5os, from prior literature, for cell lines deemed to be
sensitive to that drug (Figure 77). Studies of a drug often determine its IC50 for a range of
cancerous and non-cancerous cell lines (Figure 76). A semi-aribtrary cut-off can be drawn to
separate out the sensitive lines (lower IC 50) from the non-sensitive lines (higher IC50). If, in our
testing of the drug, we find an IC50 that is less than the cut-off, we would deem that cell line
sensitive to the drug. Another approach that we took to identify promising drugs is to look for
synthetic lethality. An ideal drug is one that inhibits cancer cells but not the surrounding,
neighboring healthy tissue. More specifically, we would calculate the IC50 for PDAC cells and
non-cancerous cells (iBMKs and 3T3s) and look for lower IC5os in the PDAC lines as compared
to the non-cancerous cells.
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Figure 76. Illustration of How Sensitive Cell Lines are Defined. This graph is adapted from Hoeflich,
2009. The IC50 for the Braf inhibitor, GDC-0879, is depicted for a variety of melanoma, colon, and
NSCLC cancer cell lines. A semi-arbitrarily placed red line separates cell lines deemed sensitive (IC 50
lower than 8.5pM) from those deemed resistant (IC50 greater than 8.5pM).
We tested the following drugs: Everolimus (mTORC1), AZD8055 (mTORC1/2), NVP-
BEZ235 (p1 10, mTOR), ZSTK474 (p1 10, mTOR), MK2206 (Akt), AZD6244 (Mek) across a
spectrum of PDAC lines (A, B, C, D, E, F) and normal lines (iBMK, 3T3) (Figure 77). For
everolimus, four PDAC lines showed an ICso notably higher than that for sensitive lines, while
two PDAC lines showed IC50s significantly lower than that for sensitive lines. In summary, it is
difficult to draw a conclusion for everolimus because some PDAC lines are sensitive, while
others are not. As for AZD8055, all five PDAC lines showed IC 5os notably lower than that
defined by sensitive cells. Therefore, PDAC lines are likely sensitive to AZD8055, making it a
promising therapeutic agent. Additional studies will be necessary to determine whether non-
cancerous lines are less sensitive to AZD8055 than are cancer lines. As for BEZ235, all 6 PDAC
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lines and 2 non-cancerous lines (iBMK, 3T3) show substantially lower IC 5os than that deemed by
sensitive cells. While PDAC cells are sensitive to BEZ235, unfortunately non-cancerous cells are
also highly sensitive. Consequently, BEZ235 may not be an ideal therapeutic, as it is likely to
have toxic side effects.
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Figure 77. Synthetic Lethality of a Variety of Small Molecule Drugs. Various drugs (Everolimus,
AZD8055, BEZ235, Z5TK474, M1K2206, and AZD6244) were tested across a spectrum of PDAC cell
lines (A, B, C, D, E, and F) and normal lines (iBMK and 3T3). IC50S of cancer and normal cell lines are
indicated in purple and orange column bars, respectively. Prior literature suggests that the sensitive cell
lines are those with IC50s less than that indicated by the yellow columns.
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For ZSTK474, we find that two PDAC and two non-cancerous lines (iBMK, 3T3) both
show significantly lower IC 5os than that claimed by sensitive cells. ZSTK474 targets the same
genes as does BEZ235 and shows similarly toxic effects against non-canceorus cells. MK2206
also has a toxic profile in that the IC50 for both PDAC and non-cancerous lines are significantly
lower than that deemed by sensitive cells. AZD6244, on the other hand, is promising as it
demonstrates IC 5 os lower than the sensitive line cut-off for 6 PDAC lines and IC5 os significantly
higher than the cut-off for the two non-cancerous lines. This data suggests that AZD6244 has
potential for being an effective therapeutic drug without limiting side effects.
As individual drugs have not had sustained success in solid cancer therapy, combination
therapy is a more promising approach. To determine whether a combination of two drugs is
synergistic, we used two separate measures of synergy, Bliss Independence and Loewe
Additivity (Figure 78). Bliss independence tests whether the combination of drugs reduces
viability more than one would expect assuming that each drug acts independently. For instance,
if drug A kills 10% of the cells and drug B kills 30% of the cells, then the combination of the two
should kill 1 - (1-0.1) * (1-0.3) = 37% of the cells, if drugs A and B acted independently. If the
combination kills more than 37% of the cells, the bliss score is less than 1 and the combination is
considered synergistic.
Loewe additivity tests whether the combination of two drugs does more than if the two
drugs were the same drug. This measure of synergy addresses an insufficiency in the Bliss test in
that if Drug B were the exact same drug as Drug A, a bliss independence calculation would give
rise to a false positive. In other words, loewe additivity helps better analyze drug combinations
that act on the same target or same pathway, as these combinations may give rise to a false
positive signal when using Bliss Independence as a measure. As an example, a combination of
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drugs acting in the same pathway, would give rise to a loewe score that suggests independence.
Assuming that drugs A and B are actually the same drug (therefore they act in the same pathway)
and that their IC5os are 4pM, then the combination of 3pM of A and 1pM of B will kill 50% of
the cells, as their IC 50s are 4ptM. Consequently, when put into the loewe equation, we compute
(3/4) + (1/4) = 1. A loewe additivity score of one indicates independence, while one less than one
indicates synergy. The weakness to the loewe additivity methiod is that two independently (by
bliss independence) acting drugs could give a false positive. To detect these false positives, the
bliss independence method can be used in conjunction with loewe additivity. A drug
combination that indicates synergy by both bliss independence and loewe additivity measures is
more likely to be truly synergistic.
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Figure 78. Calculating synergy by Bliss and Loewe between two drugs. The method by which to
determine the bliss score is indicated on the left, while the method to determine loewe additivity is
indicated on the right. Each drug is administered for 3 days and cell viability is assessed afterwards. For
bliss independence, if drug A kills 10% of the cells, and drug B kills 30% of the cells, then assuming
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independence, we would expect the combination of drug A and B to kill 37% of the cells. If the
combination kills more than 37% of the cells, the bliss score will be less than one and the combination
would be considered synergistic. For loewe additivity, an IC50 curve is first performed for drugs A and B.
This allows us to determine the concentration of drug required to achieve a y %reduction in cell viability.
Subsequently, the drugs are given in combination at the IC50, and the resulting percent reduction (x %) in
viability is determined. Looking back at the individual drug curves, the concentration of drug A and B
required to individually achieve a x% reduction in viability is noted. The concentrations of A and B in the
combination therapy, and the concentrations of A and B individually, to achieve a x% reduction in
viability, is recorded in the Loewe score equation.
Since individual drug assays demonstrated that AZD6244 was an independently effective
drug and that BEZ235 was effective although toxic, we combined them to assess for synergy and
synthetic lethality (Figure 79). Moreover, previous studies have shown that the combination of
BEZ235 (p110, mTOR inhibitor) and AZD6244 (Mekl/2 inhibitor) is synergistic in a geneticaly
engineered mouse model of cancer that contained mutations in Kras and p53, the same genetic
lesions as in our PDAC model. Based on these previous studies and additional experiments,
pharmaceutical companies are now testing MK2206 (Aktl/2/3 inhibitor) in combination with
AZD6244 (Mekl/2 inhibitor) in cancer. We assessed for synergy, by bliss independence,
between BEZ235 and AZD6244 and between MK2206 and AZD6244 in PDAC and normal cell
lines. The combination of AZD6244 and BEZ235 had bliss scores in three PDAC lines of 0.64,
0.21, and 1.43. In two out of three PDAC lines, the combination is synergistic, as the bliss scores
were notably less than one. In the normal cell lines 3T3 and iBMK, the bliss scores are 1 and 0.8,
both reasonably close to 1, suggesting a lack of significant synergy. As illustrated, the
combination of AZD6244 and BEZ235 is generally more synergistic in PDAC lines than in
normal lines. As for the combination of AZD6244 and MK2206, the difference in synergy
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between PDAC (0.50 and 0.40) and normal lines (0.74 and 0.27) is less apparent. In summary,
combining BEZ235 and AZD6244 may be a good strategy but will require further analysis of
additional PDAC lines to solidify the claim of synergy.
Figure 79. Synergy assessment of AZD6244 and BEZ235 or MK2206. Synergies between the
combination of AZD6244 (inhibits Mekl/2) and BEZ235 (inhibits p110, mTOR) and between AZD6244
(inhibits Mekl/2) and MK2206 (Akt 1/2/3) were assessed by bliss score across various PDAC cell lines
(A, B, D, indicated by blue bars) and normal cell lines (3T3, iBMK, indicated by green bars). Scores less
than 1 indicate a synergistic interaction.
Another approach we took is to combine the most promising drug, AZD6244, with RNAi
inhibition of the most effective targets, mTOR and Raptor (Figure 80). AZD6244 was given at
3ptM for 3 days, while hairpin knockdown was activated for 5 days. AZD6244 was administered
2 days after dox-administration, thereby allowing completion of the study after 3 days of
AZD6244 treatment. We studied two different mTOR hairpins across 3 PDAC lines, and two
different Raptor hairpins in 2 PDAC lines. AZD6244 treatment reduced viability by 23% to 49%.
mTOR knockdown reduced viability by 39 to 68%. Raptor knockdown reduced viability by 50%
to 60%. Each of the therapeutic options alone significantly reduces viability. A combination may
further reduce viability. We assumed a bliss independence model where AZD6244 and the
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hairpin (shmTOR or shRaptor) would act independently. We computed the expected effect of
combined AZD6244 and hairpin treatment on cell viability, and compared the effect to the actual
reduction in viability upon combination therapy. The actual reduction in viability was only
marginally greater than that expected assuming bliss independence, suggesting a lack of synergy.
Nevertheless, the combination of AZD6244 and hairpin had a significantly greater effect on
viability than either agent alone. In conclusion, combining Mekl/2 inhibition with mTOR or
Raptor inhibition may be a suitable therapeutic strategy despite the lack of apparent synergy.
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Figure 80. Combining AZD6244 treatment with RNAi inhibition of the mTOR pathway. The percent
change in cell viability (y-axis) was determined after the various treatments and normalized to untreated
cells: a) AZD6244 was given for 3 days at 3uM b) mTOR, Raptor, and Rictor hairpins were activated for
5 days by dox treatment c) AZD6244 was combined with hairpin knockdown by administering AZD6244
on day 3 of dox-treatment, allowing for combination therapy where the drug is given for 3 days and the
hairpin is activated for 5 days. On the x-axis, we have indicated the respective hairpin and cell line. To
illustrate the nomenclature, "A, 2" within the mTOR group indicates that the mTOR-2 hairpin was put
into cell line A. The effect on viability by a drug or hairpin individually is indicated in blue and red,
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respectively. By assuming independence between the drug and hairpin, the expected effect on viability
when combining a drug and hairpin is indicated in green (mathematical independence, calculated in the
same fashion as bliss independence). When the drug and hairpin are combined and the actual effect on
viability is measured, the effect is indicated by the purple bar.
Discussion
We show that mTOR, Raptor, and Rictor, are important for PDAC in vitro and in vivo.
While previous studies have suggested the importance of each of these genes in cancer, we
identified these genes through a systematic assessment of Kras effectors. Moreover, most of the
prior literature used rapalogs, as opposed to hairpins, to assess the importance of Raptor and
mTORC 1. Rapalogs have various unintended off-target effects, as they also inhibit Pi3k and
other genes, albeit at lower IC5os. More generally, small molecules will inhibit proteins that have
a binding region that is structurally similar to that in the target gene. In contrast, hairpins have
off-target effects that can be taken into consideration by using multiple independent hairpins
targeting a particular gene. Hairpins will inhibit genes with mRNA sequences that are similar to
that targeted by the hairpin. Consequently, when multiple hairpins, targeting different regions of
a gene, are tested, it is unlikely that each one of them will have the same off-target effect. We
used multiple hairpins against mTOR, Raptor, and Rictor, and in multiple PDAC cell lines to
conclusively demonstrate their importance in PDAC.
With regards to the effect on downstream signaling, we obtained some interesting
findings. Upon mTOR knockdown, we would expect to observe downregulation of both
mTORC1 targets, p-S6k, and p-4eBP1, and mTORC2 target, p-Akt(Ser473). We see substantial
inhibition p-S6k and partial inhibition of p-4eBP1. This is in line with prior work with rapalogs
demonstrating that p-S6k is inhibited substantially and for a prolonged period of time, while p-
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4eBP 1 is only partially and temporarily inhibited. We may expect, from mTOR inhibition, more
prolonged and substantial inhibition of p-4eBP1 because mTORC2 has been claimed, in some
studies, to be responsible for the eventual upregulation of p-4eBP 1. However, we find that
mTOR inhibition or Raptor inhibition both inhibit p-4eBPI by, on average, 50% after 3 days of
dox-treatment. It appears that the additional effect on mTORC2 by mTOR KD does not enhance
inhibition of p-4eBP 1. Although one may initially expect p-Akt(S473) to be downregulated due
to the inhibition of mTORC2, there is feedback-induced upregulation of p-Akt(S473) due to the
inhibition of mTORC 1. The fact that p-Akt(S473) levels remained unchanged suggest that
mTOR KD resulted in inhibition of mTORC2, as otherwise, the inhibition of mTORC 1 would
have induced upregulation of p-Akt(S473). As further support, Raptor KD induces upregulation
of p-Akt(S473) by, on average, 80%.
KD of Raptor in vitro induces substantial inhibition of p-S6k, partial inhibition of p-
4eBP 1, and notable upregulation of p-Akt(S473). These results are in line with that observed
upon mTORC 1 inhibition by rapalogs. This provides additional confidence to our findings.
Moreover, it suggests that the signaling changes observed in the studies using rapalogs are not
due to off-target effects of the drugs. In vivo KD showed partial inhibition of p-4eBPI and
upregulation of p-Akt(S473). These are also the expected changes based on the in vitro
experiments and prior literature. In summary, mTOR and Raptor KD give rise to changes in
phospho-signaling that can be understood with prior work on this pathway.
In conjunction with using hairpins to assess various Kras effector pathways, we used
small molecules targeting the Mapk and Pi3k pathways. We found that AZD6244, an inhibitor of
Mekl and Mek2, demonstrated a lower IC50 for PDAC lines as compared to normal cell lines,
suggesting that it may be an effective therapy with limited toxicity. As hairpin inhibition of
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mTOR or Raptor is effective in PDAC lines, we sought to combine AZD6244 with inhibition of
mTOR or Raptor. The combinations gave rise to additive, but not synergistic benefits. Additive
benefits are helpful so long as the side effects are tolerable. Our study is the first to our
knowledge to combine drug treatment with hairpin-mediated knockdown of another gene. This
technique can be used to identify additional genes to combine with drug treatment. In summary,
inhibition of Mekl/2 can be effectively combined with inhibition of mTOR or Raptor.
Combining AZD6244, an inhibitor of Mekl/2, with NVP-BEZ235, an inhibitor of
Pi3k/mTOR, showed a synergistic effect in cancer cells but not normal cells. Synergistic benefits
are beneficial especially when the toxicities are not equally synergistic. Even when the toxicities
are equally synergistic, the combination may be beneficial for patients who are capable and
willing to endure more substantial side effects. The AZD6244 and BEZ235 combination is
potentially an effective therapeutic strategy. Pharmaceutical companies are combining AZD6244
with another inhibitor targeting the Pi3k pathway, MK2206, an Akt inhibitor. More generally,
combining Mapk and Pi3k inhibition may be an effective strategy. Considering the prevalence of
Mapk and Pi3k inhibitors in development, testing various combinations may be practical and
rapid.
Materials and Methods
Many of the experimental procedures are described in detail in Chapters 1 and 2.
Cell viability assay for drug studies in vitro
Cells were plated in a 96-well plate and grown in standard cell culture media (DMEM)
inside a standard cell culture incubator (37 'C) For the mouse-derived PDAC cell lines A, B, C,
D, E, and their sub-clones, 500 cells were plated. For 3T3s, 1000 cells were plated. As for
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iBMKs, 500 cells were plated. Cells were split into a treatment and non-treatment group. The
drug is administered at a final concentration of lug/mL in cell culture media over a period of 3
days. 1000 cells of any cell line is plated and allowed to proliferate for 24 hours prior to
commencing drug treatment. The drug powder received from the manufacturer is initially
dissolved in DMSO. DMSO is mixed with cell culture media in a volume ratio of 1:20,000.
When combining two drugs in vitro, each drug is given at double its usual concentration such
that the final volume of DMSO is maintained at 1:20,000.
Combining drug treatment with hairpin knockdown
Hairpin knockdown is induced for 5 days, while drug treatment is performed for 3 days.
The viability effect from hairpin knockdown does not generally become apparent in only 3 days,
so 5 days is given. Hairpin knockdown is initiated two days in advance of the drug treatment
such that when the phenotypic effect from the knockdown is being observed, the drug is also
exerting its effect.
Calculating IC 50
The drug of interest is given at various concentrations (0, 1 nM, 1 OnM, 1 OOnM, 1p M,
10ptM) for 3 days. The viability of the remaining cells is determined by cell titer glo (Promega)
and is compared to untreated cells. The viability is plotted against the drug concentration and a
standard best-fit drug dose curve is plotted using Graphpad (Prism). The concentration of drug at
which viability is reduced by 50%, according to the best-fit curve, is noted as the drug's IC5 0 .
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Appendix
We tested AZD8055 (mTOR inhibitor) at the IC50 because, at this concentration, the drug
is having an effect on viability, but not an overwhelming effect (Supplemental Figure 81). As
illustrated previously, administering AZD8055 at increasing concentrations results in the
expected changes in downstream mTOR signaling. It is unclear whether these signaling changes
are observed when AZD8055 is administered at a more reasonable concentration such as the
IC50 . The IC5os for the PDAC cell lines A, C, E, and F were 46nM, 18nM, InM, and InM. While
the IC50 was determined after 3 days of dox-treatment, this signaling assay was performed after
only 1 or 3 hours of dox-treatment. We did not want any feedback or secondary signaling from
dying cells to affect the levels of our measured signaling proteins. We assessed mTORC 1 and
mTORC2 downstream targets (p-S 6 (S2 3 5/236), p-4eBP1(Th37/46), and p-Akt(S473)), as well as
feedback signaling molecules p-Egfr(Ty1068) and p-Erkl/2. Cell lines A and C demonstrated a
notable decrease in mTORC1 and mTORC2 signaling, while lines E and F showed an increase in
p-Akt signaling with no obvious change in p-S6 and p-4eBP1 signaling. The difference between
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the cell lines likely arises because lines A and C were given notably higher concentrations of
AZD8055 than lines E and F. At the lower concentration of nM, AZD8055 may only partially
inhibit mTOR, resulting in the feedback-induced upregulation of p-Akt(S473). In contrast, at the
higher concentration of 18nM or 46nM, more complete inhibition of mTORC 1 and mTORC2 is
achieved. Lastly, there appears to be a slight compensatory upregulation of p-Erkl/2 in the cell
lines examined. In summary, at higher but not lower concentrations, AZD8055 achieves
inhibition of the mTORCl and mTORC2 downstream signaling molecules.
We examined the effect of prolonged treatment (3 days) with AZD8055 (mTOR
inhibitor) or Everolimus (mTORC 1 inhibitor) at the IC50 on downstream phospho-singaling
(Supplemental Figure 82). We wanted to determine the effect of drug treatment after an extended
period of time (3 days). The drugs were administered to the cell lines A and B at their respective
IC50s for 3 days, at which point we would expect 50% of the cells to be remaining. Phospho-
signaling protein levels were assessed at the end of 3 days. The only consistent change in
downstream phospho-signaling is downreguation of p-S6k and p-Egfr. In line with previous
studies, Everolimus achieves notably more inhibition of p-S6k than of p-4eBP1. In contrast, an
earlier described experiment demonstrated that administration of AZD8055 inhibits both p-S6k
and p-4eBPl. However, in that experiment, AZD8055 was given at higher concentrations, while
in this experiment the IC50 concentration was used.
Besides the BEZ235 and AZD6244 combination, we examined various other drugs
combinations and assessed for synergy by bliss independence and loewe additivity
(Supplemental Figure 83). We tested various drug combinations (AZD6244 and Everolimus,
AZD6244 and Wortmannin, AZD6244 and BEZ235, AZD6244 and GDC0879, Wortmannin and
Everolimus, GDC0879 and Everolimus, GDC0879 and Wortmannin, and GDC0879 and
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BEZ235) at different drug concentrations in cell line D. Of the various drug combinations tested,
AZD6244 and BEZ235 was the only combination that showed synergy in both bliss and loewe
measurements and across a range of drug concentrations. Although it may appear that the
GDC0879 and Everolimus combination gives rise to synergy at various different concentrations,
the combinations used GDC0879 at 1OuM, a concentration at which off-target effects are likely
to occur. To conclude, the synergy demonstrated by BEZ235 and AZD6244 spans across various
drug concentrations in cell line D.
Since AZD6244 was the only compound which we tested that demonstrated synthetic
lethality, we assessed its effect on downstream phospho-signaling in PDAC lines A and B
(Supplemental Figure 84). AZD6244 was given at the IC50 for 3 days and the resulting effect on
various phospho-proteins was measured and normalized relative to untreated cells. AZD6244
induced significant (>300%) upregulation of p-Mek and p-Akt(S473). Since AZD6244 targets
Mekl/2 and there are feedback mechanisms in the Mapk signaling pathway, AZD6244 can result
in feedback upregulation of the components higher up in the Mapk pathway. This increased
signaling results in the observed increase in p-Mek. As for p-Akt(S473), there is cross-talk
between the Mapk and Pi3k pathways that is disrupted upon AZD6244 treatment, resulting in the
increase in p-Akt(S473). With regards to the other signaling molecules analyzed (p-S6k, p-Egfr,
p-4eBP 1, p-Erk, and cPARP), we do not see an obvious increase or decrease in protein levels.
To look for potential synergies between small molecule mTOR inhibition and
knockdown of a target gene, we combined AZD8055 with short hairpin mediated knockdown of
Mek2 or Egfr (Supplemental Figure 85). We selected Mek2 and Egfr because they have been
shown to be upregulated in the presence of mTOR inhibitors. For various PDAC lines (A, B, D)
containing different Mek (Mek- 1, Mek-2) or Egfr (Egfr- 1, Egfr-2) hairpins, the IC50 was
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determined in the absence and presence of dox. IC 50 s and viability were assessed over a period of
3 days, while dox was administered over a period of 5 days. To determine the IC 50 in the
presence of dox, dox was administered 2 days prior to the initiation of the viability assays. If the
hairpins were synergistic with drug treatment, we would expect a decrease in IC50 in the presence
of hairpin-induced knockdown. Moreover, if the hairpins also had a deleterious effect on
viability, then the combination of hairpin and drug treatment would be particularly effective.
Unfortunately, in none of the cell line-hairpin combinations tested did knockdown induce a
decrease in the IC50 of AZD8055. In addition, the hairpins do not have a significant effect on
viability by themselves. In conclusion, the combination of knockdown of Mek or Egfr and
AZD8055 treatment is not a suitable therapeutic strategy.
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Supplemental Figure 81. The effect of AZD8055 at the IC50 concentration on various downstream
signaling molecules. The IC50 of cell lines A, C, E, and F were determined to be 46nM, 18nM, lnM, and
InM. The cell lines were treated at their respective IC5os for 1 or 3 hours. Afterwards, cells were analyzed
by quantitative western blot. The y-axis indicates the percentage change in protein level as we move from
the untreated to the treated sample. Each color represents a cell line. The first bar in each color represents
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the change in the designated protein after 1 hour of treatment, while the second bar represents the change
after 3 hours of treatment, both relative to the untreated, matched cell line.
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Supplemental Figure 82. The effect of small molecule inhibition of mTOR on downstream signaling.
AZD8055 and Everolimus were given to PDAC cell lines A and B at their respective IC50s for three
days. The IC50 was determined by treating the cells with the drug compound for 3 days. The change in
levels of the indicated signaling molecules after 3 days of dox was determined by quantitative western
blotting. Blue bars indicate cell lines treated with AZD8055, while green bars indicate those treated with
Everolimus. The first and second bars represent cell lines A and B, respectively.
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Supplemental Figure 83. Calculating synergy between drugs via the Bliss and Loewe methods. The two
drugs combined are indicated in the columns "Drug A" and "Drug B". The concentration of the two drugs
used is indicated in the corresponding row. The resulting bliss score and loewe additivity is indicated in
the column termed "Bliss" and "Loewe". The scoring chart is indicated on the right and color coded
accordingly. Scores less than 1 indicate synergy as suggested in the previous figure.
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Supplemental Figure 84. Examining the effect of AZD6244 (Mekl/2) treatment on downstream phospho-
signaling. AZD6244 was given to two cell lines (A and B) at their respective IC50 for 3 days. The change
in phospho-signaling levels was determined relative to cells not treated with the drug.
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Supplemental Figure 85. Testing for synergy between Mek2 or Egfr knockdown and AZD8055. The IC50
for each cell line-hairpin combination is indicated by the blue bar. PDAC cell lines (A, B, D) were tested
with Mek2 (Mek2-1, and Mek2-2) and Egfr (Egfr-1, Egfr-2) hairpins. To describe the nomenclature, "B,
1" above Mek indicates that the Mek2-1 hairpin is placed in cell line B. The IC50 is determined after 3
days of treatment with various concentrations of AZD8055. The IC50s correspond to the primary y-axis.
To calculate the IC50 in the context of Mek2 or Egfr knockdown, cells containing a hairpin were given
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dox for 2 days before being given AZD8055 for 3 more days to determine the IC50. The resulting IC50 is
indicated in red. The effect of knockdown on viability is indicated by the green bars and corresponds to
the secondary y-axis indicated in green. The viability assessment was performed after 5 days of dox-
treatment.
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CONCLUSION
Below we describe some next-step experiments that could be performed. Generally
speaking, additional work can be performed to expand our understanding of mTOR, Raptor, and
Rictor. In addition, the pooled-hairpin screening technology, in particular the anchored
technology, can be made more robust to allow for larger-scale testing. At the end of this section,
we discuss the PDAC field more broadly and potential future directions.
We have performed a focused-screen of Kras effectors in PDAC cancers and found
mTOR, Raptor, and Rictor, to be important targets. In vitro, mTOR, Raptor, and Rictor KD
reduce viability by 55%, 45%, and 5%, respectively. After normalizing for the extent of
knockdown (i.e. Raptor hairpins, on average, induce notably more KD than do mTOR and Rictor
hairpins), mTOR, Raptor, and Rictor KD reduce viability by 75%, 55%, and 10%. These
numbers suggest the theoretical decrease in viability if the proteins were knocked down 100%,
assuming a linear relationship between protein knockdown and a reduction in viability. In vivo in
subcutanoues transplant models, mTOR, Raptor, and Rictor reduce tumor weight by 35%, 25%,
and 25%.Additional experiments with more hairpins and cell lines could be performed to further
solidify our conclusion.
Although we were able to design effective hairpins against mTOR, Raptor, and Rictor,
dozens of hairpins were painstakingly tested to identify those that achieve substantial
knockdown. For other genes, we were unable to identify hairpins that could obtain significant
knockdown. Even with advanced hairpin design algorithms, constructing effective hairpins is an
extremely laborious process. Advancements in hairpin design technology will allow studies like
this one to be performed more rapidly.
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To further validate our findings for mTOR, Raptor, and Rictor, studies can be performed
in human cell lines or in an GEMM with either a floxed allele or inducible hairpin will provide
more confidence as to whether these resutls will translate to the clinic. More generally speaking,
IT is particularly important to develop better pre-clinical models of PDAC because many drugs
show positive results in pre-clinical studies, but are not effect in human trials. Human clinical
trials go through three phases (1, 2, and 3). Cancer therapies rarely fail in phase 1 trials, as
therapies are not tested for efficacy in phase 1 but rather for safety. More importantly, a small
number of patients are tested in phase 1 trials. Consequently, there is insignificant power to
detect the presence or absence of benefit. In contrast, phase 2 trials generally have dozens of
patients and consequently look for a trend of drug efficacy. Many cancer drugs fail in phase 2
trials as they lack efficacy. Some drugs will make it to phase 3 trials as they show either a trend
of benefit or a statistically significant benefit. However, in the phase 3 trial with increased
patient number and statistical power, the drugs are often found to be ineffective. In conclusion,
better pre-clinical models of PDAC can reduce the number of drugs that enter clinical trials and
end up failing. More specifically, drug failure rates in phase 2 and phase 3 trials can be reduced.
A potentially better pre-clinical model of PDAC could involve a GEMM with the
genotype: LSL-Kras G12D, p53 , Rosa26 rTA/+.Lenti-virus containing Cre driven by a
constitutive promoter (i.e. PGK, phospho-glucokinase) and a dox-inducible hairpin (i.e a hairpin
preceded by a tet-responsive element) can be used to infect the pancreas. Infected pancreatic
cells would express Cre and begin expressing KrasG12D and lose both copies of p53.
Consequently, PanINs would develop and eventually become PDACs. All cells that give rise to
the tumor would have the lenti-virus integrated in the genome, including the dox-inducible
hairpin. Consequently, upon the administration of dox, rtTA will be activated in all the cells.
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However, only in the tumor cells, which contain the hairpin, will knockdown be experienced. An
autochthonous model is more likely to give rise to representative responses to target gene
inhibition. Since the development and histology of autochthonous PDACs is more realistic than
xenograft models, we would expect that the former's response to therapies to be more
representative of that of the human disease. Hopefully such a system would allow us to identify
more effective therapies for human PDAC.
One challenge of developing such a GEMM is being able to effectively deliver virus to
the pancreas of the mice. We have had difficulty in infecting the pancreas. Injection of lenti-virus
into the pancreas of mice often does not give rise to tumor formation. In the cases where tumors
formed, the tumors did not look like pancreatic tumors by histology but rather like tumors that
originated from other tissue types. This suggests that the lenti-virus had infected a different
tissue of origin, i.e the neighboring liver or spleen, giving rise to a different type of cancer. To
focus tumor formation to the pancreas, a pancreas-specific promoter can be placed in front of the
Cre that is located in the lenti-virus. Consequently, if tissue types besides the pancreas are
infected, Cre is not expressed, and the oncogenes and tumor suppressors are not activated.
Technological adjustments such as this should allow for the successful development of such a
GEMM of PDAC.
We also demonstrate that mTOR knockdown is synthetic lethal in that PDAC lines are
notably more sensitive than normal lines (iBMK, 3T3s). This suggests that the inhibition of
mTOR will induce more damage to the tumor than neighboring tissue, suggesting that toxicity
may be limited. Additional studies can be performed to assess the synthetic lethality of Raptor
and Rictor hairpins. Performing synthetic lethality screens in humans will be more revealing in
part because human lines are likely more representative of the human disease than are mouse
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lines, as human lines originate from human PDACs. In addition, there are more immortailzed
normal human cell than immortalized normal mouse lines. Immortailzed lines can proliferate
indefinitely in culture and allow for a facile system to test genes. Unfortunately, for mouse cell
lines, there are a limited number of immortalied but non-tumorigenic (unable to form tumors
when injected subcutaneously into nude mice). By having a greater number of cell lines, we can
develop greater confidence to the syntehtic lethal nature of particular genes.
With regards to the signaling effects of mTOR, Raptor, and Rictor inhibition, no work
was performed on Rictor inhibition. Experiments could be performed for Rictor and the results
could be compared to that for mTOR and Raptor. Moreover, additional studies for mTOR,
Raptor, and Rictor could be performed in human PDAC lines to test for a species-specific
difference in signaling effects downstream of mTOR. By understanding the signaling, we may be
able to better understand the inadequacies of mTOR, Raptor, and Rictor inhibition.
In conjunction to hairpin studies, we have tested some of the prevalent Mapk and Pi3k
inhibitors on PDAC. We found that a Mekl/2 inhibitor, AZD6244, is potent against PDAC lines
but not against normal lines, showing its potential as a PDAC therapeutic. The combination of
AZD6244 with mTOR or Raptor KD was additive in that the combination reduced viability more
than each treatment alone. In addition, the combination of AZD6244 and NVP-BEZ235, an
inhibitor of Pi3k and mTOR, is synergistic on PDAC cell lines but not on normal cell lines. This
suggests that this combination may be efficaicious and have reasonable toxicity.
We have successfully inhibited a gene (mTOR, Raptor) with a hairpin in vitro, while
simultaneously administering a small molecule (AZD6244) drug. We can continue to use this
system to test additional combinations of hairpins and drugs. We are unaware of previous work
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that has combined a hairpin and a drug. With a dox-inducible system, we can precisely control
when the hairpin is activated and synchronize it with the administration of the drug. This system
allows us to test combinations previously untestable. This system is advantageous to simply
combining two drugs because drugs are only available against a handful of targets. On the other
hand, hairpins can be designed against any gene, theoretically, although in practice some genes
are notoriously difficult to inhibit (i.e. p53 requried testing all possible hairpins titled across the
genome to identify a few potent hairpins). In addition, cancer therapies are often multi-inhibitor,
as single target inhibition is rarely effective for complex soild tumors that have functional
mtuations in many different pathways. This system allows us to take an existing, effective
therapy, and combine it with hairpin inhibition of any gene of interest. On a related note, dual
hairpin inhibition is challenging because it is difficult to find two vectors that can achieve
significant inhibition of the genes of interest. However, it has been done before on a case-by-case
basis, although never established as a robust system.
We can also extend the drug and hairpin combination to a more high-throughput
strategy. With the pooled-hairpin screening system established, we can combine drug inhibition
with a pooled-hairpin screen. This would allow testing of the drug in combination with the
inhibition of a variety of genes in the pool. This approach give can not only give rise to
interesting combinations to examine, but if the hairpin's target gene or its pathway has inhibitors
available, it may lead to a practical, potentailly effective therapeutic combination.
We have developed an approach to test combinations of genes in a high-throughput
fashion, with an anchored, pooled hairpin screen. Being able to rapidly assess combinations of
genes is important as it is becoming apparent that single-target inhibition is generally insufficient
for treating complex cancers. To our knowledge, no previous study has performed an anchored,
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pooled hairpin screen. By having an anchor gene, all cells in the pool exhibit KD of that
particular gene. In addition, various subsets of cells in the pool also experience KD of another
gene selected from the pool of hairpins. This allows us to test, in a single well of an assay, all
pairwise combinations of gene X and Y, where X is fixed and Y is selected at random from the
hairpin library.
Prior studies have performed combinatorial screens but with chemical drug compounds.
However, the studies have not used a pooled approach. One drug is given to all the cells, while a
different second drug is given depending on the well. Consequently, in a 384-well plate, 384
combinations of drugs can be tested, with one common anchor drug across all the wells. When
compared to the pooled hairpin screening approaches, there are two notable weaknesses. First,
the pooled-hairpin approach allows for the testing of all 384 or more combinations in a single
well, as opposed to needing 384 or more individual wells. Second, the pooled-hairpin approach
enables the inhibition of genes for which no inhibitors are available.
Additional work will be necessary to develop the pooled hairpin approach into a standard
screening approach. One yet unmentioned advantage is the ability to group many assays in a
single deep-sequence lane. This allows for additional resource and labor efficiency. A potential
next step is to use an mTOR hairpin as an anchor and screen for genes that, when combined with
mTOR inhibition, are additive or synergistic in their effect on viability. Multiple hairpins against
mTOR can be used and the assay can be performed across various PDAC cell lines. One method
to rapidly identify potentially synergistic targets is to compare the results of an anchored pooled
hairpin screen with that of an unanchored pooled hairpin screen, where the same pool of hairpins
is used in both scenarios. If a hairpin is depleted in the anchored pooled screen significantly
more so than it is depleted in the unanchored pooled screen, it would suggest that the hairpin is
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synergistic with the anchored hairpin. Consequently, combining inhibition of the hairpin's target
and the anchored harpin's target may be a promising therapeutic strategy.
The field of PDAC research will likely pursue studies that are similar in structure to past
studies, where important gene targets are sought after, and novel inhibitors are tested. With the
advancement of molecualr biology techniques, larger panels of PDAC lines can be tested, and
more expansive libraries of drug compounds can be used. Developments in mouse modeling
techniques will allow more realistic models of PDAC to be developed at decreasing cost and
increasing efficiency. Testing of compunds in autochthonous mouse models is likely to become
more prevalent. Hopefully, they will be representative of the human condition, in which case,
they will likely become a mainstay of pharamceutical drug development.
For a truly effective therapy of PDAC, early diagnosis will likely be necessary. While
there is much effort placed upon identifying treatments for late-staged, advanced, or metastatic
PDAC, late-stage therapies are unlikely to significantly prolong survival of PDAC patients. Most
cancers that afflict the world population are soild, non-hereditary, and multi-gene cancers. For
such cancers, no treatment has substantially extended the lifespan of a significant fraction of
patietns. On the other hand, any solid tumor, if diagnosed early enough, can be surgically
resected, and the patient can be cured. More effort should be placed in identifying biomarkers of
early disease. These biomarkers can be mRNA or proteins in the blood stream. Ideally, they are
easily detectable with low risk, cost, and effort. More complex imaging modalities such as
ultrasound, CT, or MRI imaging in conjunction with conjugated fluorescent reporters are less
likely candidates as they are generally costly and labor-intensive. Unfortunately, biomarker
studies, relative to target identification studies, are less capable of entering high-impact journals.
If this perspective can be changed to one with increased value placed on biomarker
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identification, additional effort by academic and pharamceutical labs may allow for increased
development of biomarkers for PDAC and cancer more generally.
In conclusion, there is much that still needs to be done to extend the 6 month survival of
patients who have been diagnosed with metastatic PDAC. Although it may be difficult to extend
survival for a meaningful length of time, continued efforts should be made. In conjunction, more
energy should be put in developing biomarkers that can allow for early diagnosis and treatment
of PDAC.
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